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THESIS SUMMARY 
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Background: Age-related macular degeneration (ARMD) is a major cause of irreversible 
visual loss in the elderly and a significant threat to their quality of life.  Although low vision 
services often improve the functional outcomes of individuals with macular disease, it 
remains unclear whether or not they have any impact on quality of life.  The principal aim of 
this study was to determine the effect of a hospital-based low vision clinic on the quality of 
life of individuals with ARMD. 
 
Methods: Forty patients with ARMD attended the low vision clinic at Milton Keynes 
University Hospital.  Quality of life was measured with the vision-specific Low Vision Quality 
of Life (LVQOL) questionnaire and the general health EuroQol (EQ-5D-5L) questionnaire. 
Measures were completed at baseline (time zero, T0), and at three- (T3) and six-month (T6) 
follow-up visits. 
 
Results: The near visual acuity of individuals attending the low vision clinic for the first time 
improved significantly between visits T0 and T3 (p=0.005), reflecting the practiced use of 
their newly-dispensed low vision aids. As expected, there was no significant change in near 
acuity over this time period for existing patients.  For both new and existing patients, a 
significant increase in LVQOL score was evident between visits T0 and T3, with a further 
significant improvement between T3 and T6.  Similarly, there was a significant decrease in 
EQ-5D-5L questionnaire scores between visits T0 and T6. 
 
Conclusions: The higher LVQOL scores obtained at the end of the study period (T6) 
provide evidence that low vision services at Milton Keynes University Hospital served to 
improve patient quality of life.  The reduction in EQ-5D-5L scores over the same time period 
suggests that low vision services also provide for an improvement in general health-related 
quality of life. 
 
Impact: The findings support the cause of low vision services to improve not only the vision 
and functional outcomes of individuals with macular disease but also their quality of life. 
Moreover, the findings suggest that a more efficient allocation of resources at low vision 
clinics may be possible through the standardisation of patient follow-up frequency. 
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Figure 3.20 Plot of total Low Vision Quality of Life (LVQOL) score (/125) against total 
EuroQol five-dimension, five-level (EQ-5D-5L) general health-related quality of life score 
(/25) at the (a) initial (T0), (b) three-month (T3) and (c) six-month (T6) visits. ................ 105 
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Figure 3.22 Total Low Vision Quality of Life (LVQOL) score (left) and total EuroQol five-
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1 INTRODUCTION 
1.1 Low Vision  
1.1.1 Definition and prevalence 
Visual impairment is a major world health issue that is an economic burden and reduces 
quality of life (QoL).  Monitoring prevalence data on visual impairment allows for research 
and planning of policies to prevent and eliminate treatable causes (Pascolini and Mariotti, 
2012; Bourne et al. 2013; Stevens et al. 2013).   
The global prevalence of blindness and low vision is 39 million and 246 million respectively, 
and which collectively form the magnitude of ‘visual impairment’ (Pascolini and Mariotti, 
2012).  These data form part of the World Health Organisation (WHO) Prevention of 
Blindness and Deafness Programme where the authors carried out a systematic review of 
data for 2010 from 39 countries across 6 WHO regions.  Blindness was defined as a 
presenting visual acuity (VA) in the better eye of less than 3/60, and moderate and severe 
visual impairment (MSVI, also referred to as ‘low vision’) as VA in the better eye less than 
6/18 but at least 3/60.   
This analysis was expanded by Bourne et al. (2013) and Stevens et al. (2013) in systematic 
reviews of additional published and unpublished data from 1980 to 2012, from 227 studies 
in 84 countries, using the same definitions of blindness and MSVI.  The authors estimated 
that in 2010, 65% of 32.4 million blind people, and 76% of 191 million people with MSVI had 
a preventable or treatable cause. 
Their data are interesting because, as with Pascolini and Mariotti (2012), it highlights the 
unequal distribution of visual impairment across the world.  These studies do not present 
UK specific data.  Figures from the Royal National Institute of Blind People (RNIB; Access 
Economics, 2009) estimated that in 2008, the collective level of low vision comprising data 
for blindness (VA of <6/60 in the better-seeing eye) and partial sight (VA of <6/12 to 6/60 in 
the better-seeing eye), was approximately 2 million (3.25 % of the UK population).   
The objective definitions based on visual acuity for low vision used by the WHO and RNIB 
are different from that of the Low Vision Services Consensus Group (LVSCG, 1999), who 
defined a person with low vision as: 
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‘One who has an impairment of visual function for whom full remediation is not 
possible by conventional spectacles, contact lenses or medical intervention and 
which causes restriction in that person’s everyday life.’   
The above definition also includes people who do not necessarily meet the WHO / RNIB 
criteria, but for whom low vision impacts on their daily life.  This involves a more subjective 
assessment of low vision that would be difficult to apply across different nations in different 
regions of the world due to different living standards; however this approach is useful as it 
includes the debilitating effect of blindness and low vision on people’s lives. 
Even small levels of visual impairment could have a significant impact on QoL (Loughman 
et al. 2011).  A visual acuity of ‘just below’ driving standard would result in a loss of license 
and potential loss of independence, whereas more substantial impairment could impact 
upon a person’s ability to perform everyday functional tasks such as reading, shopping, and 
watching television (The College of Optometrists and The Royal College of 
Ophthalmologists (CO-RCO), 2013). 
The effects of low vision and consequential reduced functioning are well documented and 
include reduced social interaction (Loughman et al. 2011), a reduction in psychological 
wellbeing (McManus and Lord, 2012), and an increased prevalence of depression (Ryan, 
2014), particularly in the elderly population (Evans et al. 2007).  Tabrett and Latham (2009) 
reported on the levels of depression in visually impaired patients being comparable to those 
of patients with other chronic conditions (e.g. stroke, cancer and diabetes). 
In the UK, the Department of Health aims to minimise preventable / treatable causes of 
blindness and low vision and provide support to manage untreatable causes through 
various methods including low vision services (LVS) and registration. 
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Registration 
Visually impaired patients in the UK who meet the appropriate criteria1 are certified as ‘sight 
impaired’ (SI), or ‘severely sight impaired’ (SSI), by a consultant ophthalmologist.   
A Certificate of Vision Impairment (CVI) is used to register with the patient’s local authority.  
The benefit of registration for the patient is easier access to a range of practical and financial 
support, although access to low vision services and social services rehabilitation can still 
be obtained by those who do not meet registration criteria.   
Epidemiological statistics on certification are not an accurate representation of the actual 
number of people in the UK living with visual impairment severe enough to impact upon 
their daily life (Access Economics, 2009).  This is estimated to be almost 2 million (about 1 
person in 30), a greater number than the 360,000 obtained from SI and SSI registration 
figures (Access Economics, 2009).  
A large number of patients will be affected by low vision, even though their acuity levels and 
visual field are not below the stated thresholds for registration.  For these patients, provision 
of low vision (and rehabilitation services) can be as important to QoL as for those who are 
registered. 
 
1.1.2 Minimizing the impact of low vision 
The economic impact of low vision in the UK is substantial.  An RNIB report estimated the 
combined direct and indirect health care costs in 2008 from SI and SSI in UK adults to be 
£22 billion, with the largest component cost from reduced QoL and premature mortality, 
reducing the stock of health capital by £14.53 billion (Access Economics, 2009).  These 
costs were predicted to increase by 21.4% to 2013 (Access Economics, 2009), with the 
                                                
1 Severely sight impaired: Group 1 – VA below 3/60; Group 2 – VA of 6/60 but below 3/60 with a 
very contracted field of vision; Group 3 – VA of 6/60 or above with a contracted field of vision, 
especially in the lower part of the field.  Sight impaired: VA 3/60 to 6/60 with full field; or up to 6/24 
with moderate contraction of the field, opacities in media or aphakia; or, 6/18 or even better if they 
have a gross defect, for example hemianopia, or if there is a marked contraction of the visual field.  
Adapted from the Certificate of Vision Impairment, Department of Health (2013). 
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demands on the UK economy set to rise further with a predicted large increase in the 
number of people affected by sight loss in the future.   
Using prevalence data for future projections, it has been estimated that there will be 
approximately 3.99 million people in the UK affected by low vision in the year 2050 (122% 
of 2008 estimations).  This is partly due to an ageing UK population (Access Economics, 
2009), with epidemiological studies consistently demonstrating the link between increased 
age, increased prevalence of eye disease and associated vision loss (Bunce and Wormald, 
2008; Evans and Wormald, 1996). 
Data from the Office for National Statistics (ONS) show that the number of people in the UK 
population is rising steadily, with an associated increase in the population median age over 
time (ONS, 2012).  The continuing increase in the number and proportion of people over 65 
years of age has led to a prediction that this group will account for 23% of the total 
population in 2035, an increase from 17% in 2010 (ONS, 2012).  The fastest growing 
population group comprises those aged 85 and over (ONS, 2012).  This group also has the 
highest levels of sight loss, with one in three people affected (RNIB, 2013).   
Understanding the causes of low vision and the temporal trends for each cause are 
essential in both prevention and treatment.  Treatment should also include the provision of 
low vision services to enable people to live as independently as possible (LVSCG, 1999), 
thus reducing the economic burden on UK resources. 
 
1.1.3 Causes of low vision  
The causes of low vision can be extensive, originating from a range of congenital, hereditary 
and age-related eye conditions; or as a direct result of trauma (CO-RCO, 2013).  Low vision 
can also be associated with general health conditions such as stroke, obesity and diabetes, 
or related to learning disabilities (CO-RCO, 2013).  
Global causes of low vision 
Pascolini and Mariotti (2012) and Bourne et al. (2013) demonstrated that 54% of global 
blindness in 2010 resulted from two treatable causes, cataract and uncorrected refractive 
error.  In both studies, uncorrected refractive error was the largest cause of overall visual 
impairment inclusive of blindness (42%; Pascolini and Mariotti, 2012), and MSVI (51%; 
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Bourne et al. 2013) worldwide.  This highlights the significance that adequate provision of 
a simple refractive correction could have on the global health economy.  
The differences in the magnitude and causes of blindness and (MSVI) low vision between 
high and low-income regions are stark (Figure 1.1), further representing the significance of 
treatable causes (Bourne et al. 2013).   
In less developed (low-income) regions, blindness and MSVI are caused by a range of 
preventable / treatable and untreatable conditions.  In more developed nations, the 
improved medical care means that causes are predominantly untreatable.  Results over a 
20 year time period from 1990 to 2010 (Bourne et al. 2013) are consistent with other studies 
in demonstrating an increased global prevalence of untreatable causes, particularly age-
related macular degeneration (ARMD) in high-economy regions (Klaver et al. 1998; Taylor 
et al. 2005). 
 
Figure 1.1 The contrast in causes of (a) blindness and (b) moderate and severe visual impairment 
(MSVI) / low vision in 2010 between developed Western Europe, developing central Sub-Saharan 
Africa and Worldwide.  Adapted from Bourne et al. (2013). 
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Causes of low vision in the UK 
Access Economics (2009) reported on the leading causes of sight loss in UK adults (Table 
1.1), defining sight loss as SI or SSI in the better eye.  These figures include data from 
correctable causes of sight loss.  In the UK it is estimated that more than 50% of sight loss 
can be avoided on the basis of improvement in sight with the correct treatment, including 
correction of refraction error with a spectacle prescription (Access Economics, 2009).  When 
compared with global figures of 80% (Pascolini and Mariotti, 2012), although this UK figure 
is lower, the burden on the UK health economy from treatable causes is still unnecessarily 
large. 
Table 1.1 Leading causes of sight loss in UK adults, adapted from Access Economics (2009).  The 
percentage of affected adults with sight loss from all other causes (7.4%) was calculated as the 
remainder after each of the five leading causes had been subtracted from total sight loss causes of 
100%. SI – sight impaired, SSI – severely sight impaired (in the better eye). 
Cause of sight loss Percentage of adults in the UK affected 
Sight loss equivalent to partial sight (SI) or 
blindness (SSI) due to refractive error 
53.5% 
Age-related macular degeneration 16.7% 
Cataract 13.7% 
Other eye diseases 7.4% 
Glaucoma 5.3% 
Diabetic retinopathy 3.5% 
Bunce et al. (2010), reported on the main causes of blindness (broadly equivalent to SSI) 
and partial sight (broadly equivalent to SI) from certifications in 2007-2008 in England and 
Wales.  Table 1.2 shows that the principal cause of new certifications of both SI and SSI 
was the same – ‘degeneration macular and posterior pole’, which mainly comprises ARMD 
(Bunce et al. 2010).  This was followed to a much lesser extent by glaucoma and diabetic 
retinopathy / maculopathy for SSI certificates, and diabetic causes with a marginally higher 
percentage than glaucoma in the case of SI. 
Proportional comparison with historical data confirms these trends (Bunce and Wormald, 
2006 & 2008).  Although the exact numbers of patients with certifiable visual loss may not 
be available, epidemiological data through CVI’s is important to monitor trends in the causes 
of low vision, and therefore predict the numbers of people requiring support from low vision 
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services.  This is particularly relevant in the case of ARMD due to the resulting high numbers 
of certifications from this condition.   
Table 1.2 Causes of new blindness (SSI) and partial sight (SI) certifications, April 2007 to March 
2008, adapted from Bunce et al. 2010. 
Cause of certification Blindness Partial sight 
Degeneration macular and posterior pole 58.6% 57.2% 
Glaucoma 8.4% 7.4% 
Diabetic retinopathy / maculopathy 6.3% 7.6% 
Hereditary retinal disorders 5.5% 4.2% 
Optic atrophy 4.2% 2.9% 
Disorders of visual cortex 2.3% 2.9% 
Retinal vascular occlusion 1.8% 1.2% 
Cerebrovascular disease 1.5% 4.3% 
Progressive myopia 1.2% 1.3% 
Keratitis / corneal opacity and other disorders of 
cornea 
- 1.2% 
No information on main cause 2.7% 2.7% 
Other causes 7.5% 7.1% 
 
1.1.4 Macular disease 
The macula is responsible for central vision.  Macula disease is one of the main causes of 
irreversible visual impairment in the UK and affects all age groups, predominantly those 
over 60 years in the form of ARMD. 
Stargardt’s disease, a form of juvenile macular degeneration, is the most common form of 
inherited macular dystrophy (Kanski, 2003), with presentation by the second decade.  The 
most commonly affected daily living tasks were reported to be reading, driving and 
recognizing faces (Miedziak et al. 2000).  The authors made psychological comparisons 
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between patients with late onset Stargardt’s disease and those with ARMD.  Other, rarer 
juvenile macular degenerations include Juvenile Best Disease and Cone Dystrophy. 
 
1.1.5 Glaucoma 
Glaucoma is a progressive, age-related optic neuropathy known to cause retinal ganglion 
cell death (Sehi et al. 2009).  This leads to structural changes including loss of the 
neuroretinal rim of the optic nerve head and thinning of the retinal nerve fibre layer.  The 
resultant irreversible peripheral visual field defects (Greaney et al. 2002) lead to reduced 
levels of functional vision affecting mobility and driving, eventually resulting in ‘tunnel vision’.   
Intraocular pressure is the only modifiable risk factor for primary open angle glaucoma 
(Coleman and Miglior, 2008).  Reduction of intraocular pressure by medication or surgery 
remains the only approach known to be effective against visual loss (Steele and Spry, 
2009). 
Quality of life studies have reported on both the side effects of medication and the loss of 
visual function associated with glaucoma.  Nordmann et al. (2003) reported that reduced 
vision-related QoL was attributed to side effects from topical medication.  Nelson et al. 
(2003) highlighted the disability caused by bilateral loss of peripheral vision; tripping over, 
problems with mobility and bumping into objects.  Evans et al. (2009) concluded that 
although QoL was affected to a similar level in both glaucoma and ARMD, different problem 
areas were highlighted.  These were predominantly general and mental health for 
glaucoma, with physical function more restricted for those with ARMD.  The authors 
proposed that the retention of central vision in glaucoma may explain these findings, 
although they could not state concisely that QoL was worse in patients with one disease or 
the other.   
 
1.1.6 Diabetic retinopathy 
Diabetic retinopathy (DR) is a progressive and potentially sight-threatening eye disease.  It 
has been proposed that neurovascular changes in the retina preceding, although coexisting, 
with microvascular changes, are responsible for its multifactorial pathogenesis (Heng et al. 
2013).  Involvement of the foveal area by oedema and ischemia (diabetic maculopathy) is 
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the most common cause of visual impairment from diabetes (Bhagat et al. 2009) with 
established ischemia leading to untreatable central vision loss (Heng et al. 2013).   
Laser treatment for sight-threatening clinically significant macular oedema is now being 
superseded by anti-vascular endothelial growth factor (anti-VEGF) therapies such as 
ranibizumab (Lucentis), approved for use in the UK by the National Institute for Health and 
Clinical Excellence (NICE) in 2013.  The current treatment strategy for proliferative DR, 
panretinal photocoagulation, is destructive and after multiple treatments the resultant loss 
of visual field may preclude driving (Heng et al. 2013). 
Vision loss from DR, principally attributed to clinically significant macular oedema, is an 
economic burden as one of the leading causes of visual impairment and disability in the 
working age population of the UK (Access Economics, 2009).  The impact of diabetic related 
vision loss on QoL has been examined, and one study found that QoL reduction in patients 
with DR was similar to those with ARMD (Brown et al. 2002).  Overall, the evidence using 
various patient-reported outcome measures suggests that DR has a negative effect on both 
health and vision-related QoL (Fenwick et al. 2012); although the authors concluded that 
further research is required in this area.   
 
1.1.7 Hereditary retinal disorders  
Hereditary retinal disorders are a wide group of inherited conditions, with diagnosis 
confirmed by electrodiagnostic testing.   
The most common hereditary retinal disorder is retinitis pigmentosa (RP), a progressive 
rod-cone dystrophy characterised by nyclatopia, visual field loss and deterioration in visual 
acuity (Goodwin, 2008).  There is no cure for RP and no proven treatment that slows its 
progression.  Hahm et al. (2008) evaluated vision-related QoL and depression in patients 
with RP.  The authors concluded that those patients with depression had poorer vision-
related function scores, although these did not correlate to visual acuity levels. 
In a review of the causes of visual impairment registration in England and Wales, Bunce 
and Wormald (2008) found that hereditary retinal disorders accounted for 2.8% of blindness, 
and 2.0% of partial sight certifications across all age groups.  These disorders appear to 
have higher prevalence in areas of increased consanguinity (Liew et al. 2014), which may 
be reflected in a greater demand for low vision services in these areas.  Data for individual 
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age groups shows that the majority of those certified blind (66%) fall into the 16-64 year age 
group.  Liew et al. (2014) reported on the significance of an increase in blindness 
registrations for this ‘working age’ group in 2009-2010 compared with 1999-2000.  The 
authors suggest that this could reflect either improvement in certification or a true increase 
in incidence; however improved diagnostic techniques and research in this area will assist 
with accurate diagnoses, and CVI data.   
Research into inherited retinal diseases is progressing rapidly; with potential new gene 
therapy treatments being the main focus as responsible genes are isolated (McClements 
and MacLaren, 2013).  This is in the early stages and currently, due to irreversible visual 
loss, management of patients is focused around registration, low vision services and 
rehabilitation training.  These will be of particular importance for the working age group to 
enable patients to continue in employment where possible, reducing the burden on the UK 
economy. 
 
1.1.8 Rationale for the focus on age-related macular degeneration in this thesis 
Age-related macular degeneration is by far the leading cause of certifiable visual impairment 
in the UK accounting for 58.6% SSI and 57.2% SI new certificates from April 2007 to March 
2008 (Bunce et al. 2010).  However, these registers only give information on those newly 
registered within that time period (i.e. incidence of certification), not the true prevalence or 
incidence of the disease (Evans and Wormald, 1996). 
In an attempt to estimate this more accurately, Owen et al. (2003) established a pooled 
prevalence for ARMD related vision loss and applied these to the UK population.  The 
authors reported that in 2003 there were an estimated 214,000 people with ARMD related 
disease at vision levels suitable for registration, with this figure predicted to increase to 
239,000 by 2011.  However, they concluded that because only one of the six prevalence 
studies considered was in the UK, it was difficult to know exactly how many people in the 
UK were living with ARMD related irreversible vision loss. 
Predominantly, ARMD occurs in the elderly population, with increased prevalence 
associated with increasing age (Lim et al. 2012).  This has a large impact on QoL, and is 
associated with a higher prevalence of depression, falls and reduced independence in this 
age group.  Due to the fact that ARMD is largely untreatable, geographically accessible LVS 
are important in assisting patients to maintain their social and functional independence and 
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QoL.  At Milton Keynes University Hospital NHS Foundation Trust (MKUH), 72% of patients 
attending the low vision clinic have visual impairment related to ARMD.  It is therefore 
important to gain further insight on the impact of ARMD on QoL, and to evaluate LVS with 
this disease in mind.  Furthermore its economic burden will increase in the future because 
of the ageing UK population.   
To manage the impact of ARMD on patients and Hospital Eye Service (HES) resources 
requires an understanding of the fundamentals of the disease.  The following section 
reviews the anatomy of the macula and the physiology of ARMD and its progression. 
 
1.2 Age-Related Macular Degeneration (ARMD) 
1.2.1 Introduction 
Age-related macular degeneration is a progressive, degenerative disease (Lim et al. 2012).  
The disease occurs at the macula area of the retina, damaging central vision as it 
progresses.  Early stages are referred to as age-related maculopathy (ARM), and occur 
when changes to the macula are observed before the onset of loss of vision (Lim et al. 
2012).  ARM can progress to two more problematic late forms, atrophic (“dry”) and exudative 
(“wet”) – referred to as ARMD (Nowak, 2006).   
Late ARMD results in a loss of macula function causing reduction in high-resolution visual 
acuity and central vision loss (Chakravarthy et al. 2010a).  The consequence is a reduction 
in distance and near vision, along with a reduced ability to carry out tasks for daily living 
e.g. reading, driving and shopping (Loughman et al. 2011).  This results in a reduced QoL 
(Mitchell et al. 2008). 
Although the atrophic form of the disease is more prevalent, affecting more than 80% of 
people with intermediate and advanced ARMD (Nowak, 2006), it can also rapidly progress 
to exudative disease with significantly greater loss of vision.  These aspects of ARMD are 
discussed in detail below, following a description of the relevant macula anatomy in relation 
to function and progression of the disease. 
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1.2.2 Anatomy of the macula 
Introduction 
The macula is a 5-6 mm diameter area located centrally within the retina (Provis et al. 2005), 
with its centre, the fovea, lying 4.5 to 5 mm away from the optic nerve head (Figure 1.2).  
This area, although representing less than four percent of the total retinal area, permits 
high-resolution visual acuity, along with optimal spatial and colour vision (Fine et al. 2000; 
Loughman et al. 2011).  Macula health is of great importance; a small lesion in this area will 
have a significant impact on visual function (Provis et al. 2005). 
 
Figure 1.2 Ophthalmoscopic view of the macula (blue circle) and the fovea (yellow circle) in relation 
to the optic nerve head. 
 
The structure of the retina 
The human retina is an extremely complex and highly specialised structure comprising ten 
discrete layers of various cells (Figure 1.3), varying in thickness, density and type across 
the retina from its centre to periphery.   
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Figure 1.3 An overview of retinal neural circuitry.  Adapted from Hildebrand and Fielder (2011), and Kolb (2003). 
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The structure of the macula 
Adaptation of the macula region with its highly specialized neural circuitry results in high-
resolution visual acuity (Provis et al. 2005).  The cone-dominated cell structure of the 
macula within the central retina is different from the rod-dominated surrounding periphery, 
reflected in their different functions.  Three anatomically distinct regions comprise the 
macula: perifovea, parafovea and fovea (comprising the foveal slope and foveola; Figure 
1.4).  Provis et al. (2005) suggested that anatomical adaptations at the macula, and the fact 
that its unique topography allows for high level of visual processing, may also be significant 
in the pathogenesis of ARMD. 
 
Age-related changes within the retina and choroid 
Although ageing does not inevitably lead to ARMD, age-related changes within the retina 
are thought to be significant in its pathogenesis and occur in the choriocapillaris (CC), 
Bruch’s membrane (BrM), the retinal pigment epithelium (RPE), and the photoreceptors 
(PR; Ehrlich et al. 2008; Carneiro, 2011).   
The choriocapillaris, situated within the choroid, is a vascular network supplying oxygen and 
nutrients to Bruch’s membrane and all retinal layers within the macula region, ensuring that 
the outer retina (RPE and photoreceptors) can meet its high metabolic demands (Carneiro, 
2011).  With increasing age, there is a progressive reduction in choroidal thickness and 
choriocapillary density, along with decreased lumina of the choriocapillaries (Ramrattan et 
al. 1994).  These changes, in combination with a reduction in choroidal blood flow, give rise 
to the ‘vascular theory’ of ARMD proposed by Friedman (1997).  This theory suggests that 
an increased resistance in choroidal blood vessels and decreased choroidal perfusion may 
lead to RPE cell dysfunction (Ehrlich et al. 2008). 
Bruch’s membrane is a connective tissue separating the choriocapillaris from the RPE 
(Hildebrand and Fielder, 2011).  It regulates ionic and metabolic transport between these 
two layers (Carneiro, 2011), and provides nutrition to RPE cells (Ehrlich et al. 2008).  With 
age the thickness of Bruch’s membrane increases (Ramrattan et al. 1994) and its lipid 
content increases (Ehrlich et al. 2008).  These lead to a loss of fluid permeability and nutrient 
transport across the membrane, adversely affecting the availability of nutrients for normal 
outer retinal function (Ehrlich et al. 2008; Carneiro, 2011).   
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Figure 1.4 (a) the macula (blue circle), comprising the perifovea, the parafovea (green circle) and 
fovea (yellow circle); (b) the fovea (yellow circle), foveal avascular zone (red circle), foveola (white 
circle), umbo (white dot); (c) a close-up of the foveal avascular zone with (d) cross section of the 
fovea.  Adapted from Provis et al. (2005) and Kanski (2003). 
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In healthy eyes, a continuous monolayer of RPE cells separates the choriocapillaris from 
the photoreceptors, forming the outer blood retinal barrier which is essential for maintaining 
photoreceptor function (Ehrlich et al. 2008; Hildebrand and Fielder, 2011). 
The RPE also has highly specialised transport functions, essential for photoreceptor 
integrity and renewal (Bonilha, 2008).  The reduced ability of ageing RPE cells to remove 
debris, along with inadequate nutrition may predispose the formation of deposits in the RPE 
and Bruch’s membrane region (Taylor, 2012).  The accumulation of basal linear deposits in 
particular, is thought to precede the formation of drusen (Taylor, 2012), the first clinical sign 
of ARMD (Nivison-Smith et al. 2014). 
As a result of oxidative stress damaging mitochondria within RPE cells, it is hypothesised 
that cells undergo apoptosis and a reduction in number (Ehrlich et al. 2008).  Along with the 
onset of an inflammatory response resulting in choriocapillary atrophy these form the 
‘nonvascular theory’ of ARMD.  This theory together with the aforementioned ‘vascular 
theory’ may ultimately be responsible for ARMD development (Ehrlich et al. 2008).  There 
is as yet, no unified theory for the pathogenesis of ARMD in a highly active area of ongoing 
research. 
 
1.2.3  Early age-related macular degeneration (age-related maculopathy) 
A number of schemes exist for the classification of ARMD, both for clinical and research 
purposes (Lim et al. 2012).  Whilst there is still no universally accepted system (Williams et 
al. 2009), it is generally accepted that early ARMD is characterised by the presence of 
drusen and / or RPE abnormalities (Nowak, 2006; Lim et al. 2012). 
Drusen 
Considered to be the hallmark of ARMD, drusen are discrete deposits of the subretinal 
pigment epithelium (Sivaprasad et al. 2005).  These are located between the basal lamina 
of the RPE and the inner collagenous layer of Bruch’s membrane (Carneiro, 2011).  
Clinically, they are seen as circular, yellow dots (Williams et al. 2009) and can be classified 
based on their size and shape into ‘hard’ and ‘soft’ forms (Figure 1.5).   
Drusogenesis is a complex process and not fully understood (Nowak, 2006; Williams et al. 
2009).  The presence of RPE cell debris within the structure of drusen suggests that 
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inadequate transport between the RPE and Bruch’s membrane may be responsible, 
although current theories now implicate oxidative damage through the accumulation of 
lipoproteins in Bruch’s membrane (Nivison-Smith et al. 2014).  As the formation of drusen 
may be influenced by genetics and environmental factors in a selective, rather than a 
passive process, Ehrlich et al. (2008) hypothesise that this explains why not all elderly 
patients develop ARMD.  Additionally, although it is universally accepted that almost all 
patients with ARMD have drusen, it is not understood why only a proportion of patients with 
drusen go on to develop late ARMD, and therefore, whether drusen do indeed play a role 
in this progression (Williams et al. 2009). 
 
Figure 1.5 Schematic of the retinal location of hard and soft drusen, with characteristic features and 
implications for age-related macular degeneration risk.  Adapted from Nivison-Smith et al. (2014). 
PR – photoreceptors, RPE – retinal pigment epithelium, BrM – Bruch’s membrane, CC – 
choriocapillaris.  
 
RPE hyperpigmentation and hypopigmentation 
Morphological changes to the RPE observed in early ARMD are also characteristically seen 
in both late forms of the disease, with impairment of RPE cell function hypothesised to be 
a critical event in the development of late ARMD (Nowak, 2006; Nivison-Smith et al. 2014).   
In early stages of the disease, non-geographic atrophy of the RPE is characterized by 
hyper- and hypopigmentation (Nowak, 2006), and thinning of the neurosensory retina 
(Carneiro, 2011; Figure 1.6).  Hyperpigmentation is hypothesised to occur as a result of 
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RPE dysfunction (Bhutto and Lutty, 2012).  This is likely to indicate proliferation, clumping 
or migration of RPE cells (Nivison-Smith et al. 2014).  Hypopigmentation results from a 
decrease in RPE pigment (Nivison-Smith et al. 2014), and / or RPE atrophy (Bhutto and 
Lutty, 2012).   
 
Figure 1.6 A schematic for the possible sources of pigmentary changes (hypopigmentation, 
hyperpigmentation) in age-related macular degeneration.  PR – photoreceptors, BrM – Bruch’s 
membrane, CC – choriocapillaris. Adapted from Nivison-Smith et al. (2014).   
 
The impact of early ARMD  
Early age-related macular degeneration is often diagnosed incidentally at routine eye 
examination because patients are generally asymptomatic (Chakravarthy et al. 2010a).  In 
contrast to late stage ARMD, early changes are not associated with central vision loss (Lim 
et al. 2012; RCO, 2013) and are expected to have much less impact on visual acuity (and 
in turn, the patient’s QoL).  Lamoureux et al. (2011) assessed the impact of early versus 
late ARMD on vision-specific function and concluded that early ARMD had no impact on 
this measure, however they highlighted the need for education to prevent disease 
progression.  Bennion et al. (2012) reviewed literature from qualitative studies on the 
experience of living with ARMD, and observed that many patients with good vision still 
reported concerns regarding future visual impairment.   
Multiple studies have revealed that a proportion of patients with early changes will ultimately 
develop late ARMD (RCO, 2013).  Although the percentages of patients converting from 
early to late disease differs between study groups, the longer the disease duration, the 
greater the risk of progression (Mitchell et al. 2002; Klein et al. 2007). 
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With more effective treatments for neovascular ARMD now available, the identification of 
clinically significant early signs as markers for a high risk of progression to late ARMD is 
imperative in the prevention of visual loss (Chakravathy et al. 2010b).  Future developments 
in the understanding of ARMD pathogenesis and novel preventative treatments, along with 
additional clinical diagnostic techniques may help further quantify and reduce this risk. 
 
1.2.4 Atrophic (late) age-related macular degeneration 
In the absence of choroidal neovascularisation (CNV), geographic atrophy (GA) reflects the 
natural endpoint of the atrophic process of ARMD (Sunness, 1999).  Atrophy of the RPE, 
choriocapillaris and photoreceptors is responsible for a slow, progressive reduction of 
central vision (Chakravarthy et al. 2010a; Lim et al. 2012) resulting in moderate to severe 
vision loss.  At present, there is no available treatment for GA (Mata et al. 2013) and 
therefore, its prevalence will inevitably increase as the population ages. 
Pathogenesis and progression 
Although the precise mechanisms leading to GA development remain evasive (Mata et al. 
2013), multiple theories have been proposed for its pathogenesis.  Nowak (2006) described 
these as lipofuscin formation, drusogenesis and local inflammation.  An additional ‘vascular 
theory’ for its pathogenesis is that of choroidal vascular resistance proposed by Friedman 
(1997).   
Signs and symptoms 
GA appears as a distinct area of RPE and photoreceptor loss greater than 175 μm in 
diameter and atrophy of the choriocapillaris (Nivison-Smith et al. 2014).  This is observed 
clinically as a round / oval area with defined edges, paler in colour compared to the 
surrounding tissue, often with internal hypopigmentation (Nivison-Smith et al. 2014), and 
through which the choroid and its vessels may be seen more distinctly (Sunness, 1999; 
Figure 1.7). 
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Figure 1.7 Retinal photograph of geographic atrophy (GA) highlighting retinal pigment epithelium 
pigment changes and drusen.  The expanded view shows the region of geographic atrophy identified 
by fundus autofluorescence (FAF).  Adapted from Nivison-Smith et al. (2014). 
 
Primarily GA develops as small, focal areas of depigmentation (Chakravarthy et al. 2010a), 
and initial symptoms may be reported as an inability to read very small print (RCO, 2013).  
As the disease progresses, many small areas of atrophy may enlarge and coalesce, 
sometimes forming a horseshoe configuration, and then a ring, around the fovea until the 
onset of foveal atrophy at later stages (Sunness, 1999; Nivison-Smith et al. 2014).  Difficulty 
in reading print of increasing size occurs gradually over time. 
Permanent scotoma(s) will be present in areas of GA (Figure 1.8).  Although the patients 
measured visual acuity may appear to be good, the presence of multiple scotomas near to 
fixation cause greater visual impairment than predicted from acuity alone (Sunness, 1999).   
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Figure 1.8 The impact of a scotoma on patient vision of the normal image (left) with increasing 
severity from centre to right.  In those patients with good measured acuity, reading and recognising 
faces may be difficult if the word or face does not appear within the small central island of remaining 
vision, devoid of scotomas (Sunness, 1999).  Adapted from Phillips (2008). 
 
As GA cannot be treated it causes a slow, progressive reduction of vision resulting in severe 
visual impairment (Chakravarthy et al. 2010a).  Contrast sensitivity is often reduced and 
impairment in dim lighting can be significant (Sunness, 1999).  Although GA results in a 
slower deterioration and better preservation of VA than exudative ARMD (Fine et al. 2000), 
in more than half of patients it is bilateral causing significant problems with daily living tasks 
(Sunness, 1999).   
 
1.2.5 Exudative (late) age-related macular degeneration 
Late stage exudative ARMD occurs as a result of choroidal neovascularisation (Figure 1.9).  
Abnormal new blood vessels growing through to the neural retina can bleed or leak fluid 
causing a sudden loss of central vision (Nowak, 2006).  This rapidly progressing form of 
ARMD accounts for two thirds of late stage disease and 90% of ARMD related blindness 
(Chakravarthy et al. 2010b).   
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Figure 1.9 A schematic of the growth of choroidal neovascularisation (CNV) from the choriocapillaris 
(CC) through Bruch’s membrane (BrM) into the sub-retinal pigment epithelium (RPE, left) and the 
subretina (right).  PR is the photoreceptor layer.  Also shown are some of the associated 
complications - pigment epithelial detachment and haemorrhage. Adapted from Nivison-Smith et al. 
(2014) and Ehrlich et al. (2008). 
 
Pathogenesis  
Nowak (2006) reported on the two possible mechanisms leading to CNV – hypoxia and 
inflammation:   
1. Hypoxia – ischemia / hypoxia from reduced choroidal perfusion results in increased 
oxidative stress (Ehrlich et al. 2008), leading to the up-regulation of pro-angiogenic 
growth factors e.g. vascular endothelial growth factor (VEGF; Nowak, 2006). 
 
2. Inflammation – an inflammatory response is stimulated by damaged RPE cells, 
resulting in a release of pro-angiogenic factors (Nowak, 2006; Ehrlich et al. 2008). 
Signs and symptoms 
Compared with GA, vision loss in patients with exudative ARMD is rapid, with a sudden 
onset reduction in central vision taking the form of either a blind spot (scotoma) or distortion 
of straight lines (metamorphopsia), or both (Lim et al. 2012; Figure 1.10).  In cases where 
exudative disease is unilateral, it is possible that the diagnosis could be an incidental finding 
(Chakravarthy et al. 2010a). 
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Figure 1.10 Image depicting a patient's view of scotoma and metamorphopsia resulting from 
exudative ARMD.  Source: The Macula Society www.maculasociety.org 
 
If untreated, the prognosis for vision is poor.  Wong et al. (2008) published the first 
systematic review of visual acuity loss in untreated eyes with exudative ARMD.  The severity 
of vision loss was shown by the percentage of patients with VA less than 1.0 logMAR (base 
10 logarithm of the minimum angle of resolution) which increased from 19.7% at baseline 
to 75.7% at 3 years.  The lack of specific data on the ethnicity and countries of analysed 
populations makes it difficult to conclude whether this would apply to the UK population.  
With more effective treatments now available in the UK, diagnosis and referral for potential 
treatment should be made at the earliest opportunity (Chakravarthy et al. 2010). 
Exudative ARMD is characterised by the presence at the macula of subretinal or intraretinal 
fluid and / or haemorrhage (Lim et al. 2012), with or without peri-retinal fibrosis (RCO, 2013).  
If untreated, the disease follows a rapid progression resulting in a fibrous scar at the macula 
with an associated severe central loss of vision (Chakravarthy et al. 2010a).  Figure 1.11 
demonstrates this progression over a three year period (Lim et al. 2012).  
 
 42 
 
Figure 1.11 The progression of untreated exudative age-related macular degeneration over a three 
year period: (a) a choroidal new vessel beneath the sensory retina (within the dashed oval); (b) 
appearance on fluorescein angiography; (c) after three years an enlarged area of subretinal fibrosis 
(within the dashed oval) at the site of the previous new vessel with an area of surrounding atrophy 
(nasal to the macula).  At this stage the scotoma will have enlarged extensively resulting in severe 
visual disability.  Adapted from Lim et al. 2012. 
 
1.2.6 Treatment strategies for atrophic age-related macular degeneration 
Currently, unlike exudative ARMD, there is no available pharmacological treatment to treat 
or slow the progression of GA (Holz et al. 2014).  Mata et al. (2013) over a two year period, 
investigated the efficacy of oral fenretinide (N-(4-hydroxyphenyl)retamide) as a potential 
treatment aimed at reducing its progression.  This work was inconclusive and additional 
studies into fenretinide and other therapeutic agents are required before these become 
widely available. 
RPE transplantation aimed at the protection of photoreceptors has also been attempted 
(Sunness, 1999).  Schwartz et al. (2012) reported on the first transplant of human embryonic 
stem cells into one eye of a patient with GA.  The authors observed a seven letter (from 
20/500 to 20/320) improvement in VA over a three-month period.   
The surgical implantation of miniature telescopes for the treatment of end stage ARMD uses 
magnification from the telescope to project images from the damaged central retina onto 
parafoveal areas, thus reducing the impact of the scotoma (Macular Society, 2015).  
Hudson et al. (2006) reported on the one-year postoperative results from a clinical trial of 
217 patients with bilateral vision loss from GA and / or exudative forms of the disease who 
had undergone telescope implantation in one eye.  The authors reported that 53% eyes 
gained an improvement of ≥3 lines in best corrected distance and near VA, compared to 
10% of contralateral eyes.  Relating this to an improvement in scores from the 25 item 
National Eye Institute Visual Function Questionnaire (NEI-VFQ), Hudson et al. (2006) 
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concluded that this procedure improved QoL as well as VA, due to a reduction in the effect 
of the patient’s central scotoma.  Unfortunately, this procedure is not suitable for all patients 
with late stage ARMD and is currently only available privately in the UK (Macular Society, 
2015). 
Ultimately, without any approved therapeutic treatment, GA will present a significant burden 
on UK health and social care resources in the future due its untreatable nature and the 
ageing population.  The National Health Service (NHS) continues to rely heavily upon LVS 
as the only treatment option, and timely referral should be made to the service to ensure 
that patients can access help at an early stage of vision loss. 
 
1.2.7 Treatment strategies for exudative age-related macular degeneration 
The lack of significant clinical results with the use of laser photocoagulation and 
photodynamic therapy as treatments for exudative ARMD resulted in a decline in their use 
once significant developments in anti-VEGF therapeutics had been made (Chakravarthy et 
al. 2010a; Holz et al. 2014).   
In two landmarks trials using ranibizumab (Lucentis), the authors reported improvements in 
visual acuity, not just stabilisation as was previously the case with the first approved anti-
VEGF pegantib (Macugen; Lim et al. 2012; Holz et al. 2014).  The most recent anti-VEGF 
agent to be introduced at MKUH is aflibercept (VEGF Trap-Eye).  It is hypothesised that this 
drug will have a greater period of action (Holz et al. 2014).  Trials comparing monthly 
ranibizumab with aflibercept at longer re-treatment intervals (three initial monthly doses 
followed by dosing every two months) showed similar efficacy in VA improvement and 
safety, with the advantage of a reduced injection and monitoring regime (Heier et al. 2012). 
Although anti-VEGF therapeutics have been demonstrated to be successful in reducing 
vision loss in patients with exudative ARMD, the intense (often monthly) long term treatment 
and monitoring regime places a burden on patients, carers, and economic resources 
(Chakravarthy et al. 2010a).  As injections are often initiated after significant retinal damage 
has occurred (Melville et al. 2013), the requirement for LVS is ongoing because treatments 
do not cure the problem completely, just stabilise it.  Treatments may result in useful 
parafoveal vision, but many patients report frustration at not being able to effectively use 
this remaining vision – this is where low vision aids (LVAs) become important. 
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1.2.8 Preventative strategies for age-related macular degeneration 
Along with developments in novel treatment strategies for ARMD, there has been ongoing 
research into the prevention of disease and reduction of its progression, of which evaluation 
of risk factors plays a major role (Chakravarthy et al. 2010b).  Apart from increasing age 
which showed a strong association with ARMD in all observed studies, Chakravarthy et al. 
(2010b) highlighted the significance of cigarette smoking, previous history of cataract 
surgery and a family history of ARMD with risk of disease development and progression.  
Other factors showing a moderate association with ARMD risk were found to be higher body 
mass index, a history of cardiovascular disease, and hypertension.  The authors 
recommended that patients be advised on self-identification of early visual changes that 
may be amenable to treatment, along with lifestyle changes, particularly stopping smoking. 
Dietary nutrient supplementation is another area of research currently undergoing close 
evaluation, and is particularly aimed at disease prevention and limitation of progression to 
advanced stages (Loughman et al. 2011; Holz et al. 2014).  The Age-Related Eye Disease 
Study (AREDS) a multicentre double-masked clinical study reported in 2001, that daily 
supplementation with high doses of vitamins C and E, beta-carotene and zinc reduced the 
progression to late stage ARMD by 25% over a 5 year study period (AREDS, 2001).  The 
AREDS 2 Research Group more recently reported that the addition of lutein and zeaxanthin, 
and / or omega-3 to the AREDS formulation was not significant (AREDS 2, 2013).   
 
1.3 Low Vision Treatment Strategies 
1.3.1 Introduction to low vision services 
Low vision services aim to improve the ability to function independently in daily life for those 
who suffer from low vision.  The LVSCG (1999) defined this service as: 
‘A rehabilitative or habilitative process which provides a range of services for people 
with low vision to enable them to make use of their eyesight to achieve maximum 
potential’.  
Anybody with low vision, anywhere in the UK, should be able to access LVS at any stage 
following diagnosis, regardless of their registration status and level of VA (CO-RCO, 2013).  
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Other important considerations include the patient’s social situation, emotional and 
psychological requirements, and any relevant educational or occupational issues (LVSCG, 
1999).  Flexible and timely access to LVS is imperative, with timely intervention found to be 
an important factor in rehabilitation outcomes (CO-RCO, 2013).   
The service within the UK generally involves a process of rehabilitation that aims to minimise 
the impact of vision loss, promoting independence and autonomy in daily living.  A range of 
low and high-intensity intervention strategies encompassing various sectors (healthcare, 
social services and voluntary services) and professionals often exists (CO-RCO, 2013; 
Ryan, 2014), delivered in a variety of different models (Binns et al. 2012).   
Together, professionals from multidisciplinary teams aim to provide the elements of support 
to address the social, financial, practical and psychological needs of the visually impaired 
patient via any (or all) of the following (Ryan et al. 2009): 
 Low vision assessment – either based within the HES or, other centres that are 
contracted to social services providing an assessment of visual function, LVAs and 
other equipment.  
 Rehabilitation services – local authority funded services, delivered by charities or 
other contracted organisations, providing information and support to enable patients 
to understand their eye condition and regain confidence and independence through 
training in essential skills. 
 Education services – Special Educational Needs Co-ordinators within schools, 
specialist teachers for the visually impaired, educational psychologists, rehabilitation 
and social workers.    
 Employment services – finding and remaining in work through the Access to Work 
scheme (providing adaptations to the place of work and / or equipment, advice on 
travel to and from work and support workers). 
 Voluntary organisations - national and local organisations including disease specific 
groups, providing wide ranging emotional and practical support, information and 
advice to patients and their carers / families. 
Integration of the above services is important, with effective communication and flexibility 
between providers essential to enable effective access to services.  There may also be links 
with other broader teams e.g. falls prevention services and GPs, together with those 
working specifically in eye health (CO-RCO, 2013).   
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Low vision aid (LVA) assessment and rehabilitation will be considered here in more detail, 
although the effectiveness of multidisciplinary models including other aspects of LVS will be 
considered later.   
 
1.3.2 Low vision assessment 
A low vision assessment follows a generalised routine, but is adapted for each patient to 
asses vision and discus individual needs.  This is followed by the provision of practical 
support and bespoke advice to help achieve specific visual goals whilst working within the 
limitations of the disease.   
A low vision aid (LVA) can be any piece of equipment, including optical (Figure 1.12), 
electronic, or non-optical (Figure 1.13), to enhance visual performance in those with low 
vision (LVSCG, 1999).  Improvement of functional vision by provision of LVAs is of particular 
importance, and can lead to enhanced QoL and independence for visually impaired patients 
(Scott et al. 1999; Gallagher and Jackson, 2012). 
 
 
Figure 1.12 Image depicting a variety of optical low vision aids regularly issued by the Low Vision 
Clinic, Milton Keynes University Hospital.  Use of the double-ended clamp allows hands-free viewing.   
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Figure 1.13 A number of non-optical low vision aids demonstrated to patient’s attending the Low 
Vision Clinic, Milton Keynes University Hospital.   
 
The protocol followed by optometrists working in the low vision clinic at MKUH for a new 
patient undergoing low vision aid assessment can be found in Appendix 1. 
 
1.3.3 Rehabilitation services  
The LVSCG (1999) made the recommendation that following diagnosis a patient should 
receive immediate support and information, whilst LVS provision should begin within six 
weeks.  Eye Clinic Liaison Officers (ECLOs) based within HES clinics are often the first 
professionals to provide this initial support, and the patient may be able to access their 
services on the day of diagnosis.   
The ECLO service exists to provide diagnosed patients (regardless of registration status) 
with the information and support that they require to understand their eye condition and the 
impact this will have on their lives and on those closest to them (CO-RCO, 2013).  This may 
involve referral to employment, educational, rehabilitation and other services.  It is often the 
ECLO who provides the link between the ophthalmologist and the local authority by 
ensuring that referral is made for assessment by the sensory impairment team (Johnson et 
al. 2015).  In the case of newly certified patients, ECLOs assist with CVI completion.   
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Not all hospital eye clinics within the UK have an ECLO (Slade and Ledwidge, 2013) and to 
date there is a lack of unbiased independent study on their effectiveness.  In their absence 
however, referral of a patient for rehabilitation services may be delayed (Johnson et al. 
2015).  Within community optometric practice, those patients who are not registered but for 
whom social services input would be beneficial can be referred using the Low Vision Leaflet. 
Assessment by the sensory impairment team at social services is a legal right for those with 
low vision because they fall within the classification of ‘disabled’ under the NHS and 
Community Care Act (1990; Ryan et al. 2009).  Adequate funding should exist for social 
services, or those contracted to them, to provide support and advice in any (or all) of the 
following areas:  
1. Emotional support – to work with the patient (and carers) to ensure that they 
understand the eye condition and its impact on vision and daily living.  To listen and 
to address emotional needs through other support networks as required. 
2. Certification – assistance with completion of the CVI form and information regarding 
the registration process. 
3. Orientation and mobility - training and the provision of aids to ensure that the patient 
can manage to complete local routes independently (if desired). 
4. Daily living skills – advice and training in making drinks, cooking, communication 
(using the telephone, writing).  Providing appropriate specialist equipment and 
training in its use. 
5. Modification of the patient’s environment – provision of advice and equipment for 
adapting the living and working environment.  For example, assessment of and 
advice on the correct lighting and colour contrast to help navigation within the home. 
6. Financial support – information on welfare benefits and other financial support that 
the patient may be entitled to (including help with the application process). 
7. Information on relevant local and national (including voluntary) organisations, 
support groups and services. 
8. Rehabilitative techniques – further training in the use of LVAs, eccentric viewing and 
steady eye strategy to enable skills to be utilised in the home and other 
environments. 
There is considerable overlap between clinicians providing LV assessments, ECLOs and 
rehabilitation workers.  This integration and communication with other healthcare, 
educational and employment teams is essential in promoting flexible access to multiple 
rehabilitative services for patients (CO-RCO, 2013). 
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1.3.4 Current model of low vision service delivery in the UK 
In the UK, all patients who require LVS should have prompt access via a number of different 
routes (CO-RCO, 2013).  These may include referral from an ophthalmologist, GP, 
community optometrist, ECLO, social worker, rehabilitation worker or other (CO-RCO, 
2013).  Ryan (2014) reviewed the evolution of LVS over the past 50 years and the changes 
that have occurred within services towards the multidisciplinary approach often seen today.  
At present, there is no standard model for the delivery of low vision services within the UK 
(CO-RCO, 2013).  
Traditional hospital based services with LV assessments provided by optometrists or other 
trained professionals (orthoptists, nurses and more recently occupational therapists, Ryan, 
2014), often with strong associations to social services (Binns et al. 2012), are still 
commonplace.  One example of such a system can be found in Milton Keynes 
(Buckinghamshire) whereby LV assessments are carried out by optometrists working within 
the hospital LV clinic.  From here, patients can be referred, on completion of a Referral of 
Vision Impairment (RVI), for home / telephone assessment by the Sensory Advice Resource 
Centre (SARC).  SARC is funded by the local authority through a contract with BID Services 
(a charity) who provide assessments, rehabilitation advice and specialist equipment for 
patients aged over 18 years with visual and / or hearing impairment. 
Through SARC patients can also be referred into the hospital LV clinic.  The part-time ECLO 
at MKUH also works for SARC, therefore very close links and efficient communication 
between services is possible.  In the neighbouring county of Bedfordshire, a different model 
of LVS provision exists.  LV assessments are not carried out within the hospital setting but 
provided by Sight Concern Bedfordshire, a voluntary society working in partnership with the 
sensory impairment team who are hosted by the local authority. 
In other areas of the UK LV assessments are provided by community optometrists, with 
primary care LVS increasing in prevalence since the late 1990s due to the rising numbers 
of people with visual impairment (Ryan, 2014). In 2011, The Local Optical Committee 
Support Unit (LOCSU) issued the ‘Adult Community Optical Low Vision Community Service 
Pathway’ (LOCSU, 2013).  This pathway was designed to offer cost-effective LV 
assessment in a primary care setting.  Provision is via accredited community optometrists 
and dispensing opticians who have access to rehabilitation workers / other locally 
commissioned services.  Patients are able to access the scheme via a number of routes 
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including self-referral, with the LV assessment taking place at the community optometric 
practice or the patient’s home (LOCSU, 2013).  Currently however, not all areas in the UK 
employ the scheme and to date there is no published research to evaluate how effective 
this system is. 
One example of a scheme provided by community optometrists that has demonstrated 
effective results in improved access to LVS is Low Vision Service Wales (LVSW; Ryan, 
2014).  This government-funded service was set up in 1994 and uses accredited community 
optometrists in the provision of LV assessment, with links to social services and other 
organisations.  One year after its implementation, Ryan et al. (2010) reported a significant 
reduction in both waiting times for LV assessment and journey time to the service, with 
Court et al. (2011) reporting the outcomes for patients to be as effective as the traditional 
hospital based service.  A recent audit of LVSW has highlighted the areas within Wales 
where accreditation of more optometrists is required to meet the demand for LVS (John, 
2014).  This is one example of why there is a need for periodic audit of LVS and its users 
to ensure cost-effective and quality service provision across the UK (CO-RCO, 2013).   
Ryan et al. (2010) suggested that LVSW can provide an efficient model going forward for 
expansion of LVS into community optometric practice, thus relieving the burden on hospital 
based services.  This reasoning is also fundamentally the basis of the instigation of the 
Community Optical Adult Low Vision Service pathway by LOCSU (2013).  Currently it is not 
known whether these models are likely to be more effective than traditional methods of LVS 
delivery in the long term. 
 
1.3.5 Future delivery of low vision services 
Access Economics (2009) predicted a doubling of the number of people in the UK (to almost 
4 million) who will suffer from sight loss that impacts upon their daily lives by 2050.  
Regardless of any future developments in improved treatments for the causes of low vision, 
there is predicted to be a consequential rise in the number of people requiring LVS in the 
future due to the ageing population (Ryan, 2014), particularly from age-related diseases 
such as ARMD (Owen et al. 2003).   
A novel approach to the provision of eye care services in the UK will be required to meet 
this increasing demand (Lightstone, 2012).  The UK Vision Strategy, a component of 
VISION 2020, was founded in 2008 to respond to this challenge (Lightstone, 2012).  The 
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strategy is a collaboration between many different cross-sector groups, with the focus of 
improving eye care in the UK (UKVSAG, 2013).  An updated framework for 2013 to 2018 
(UKVSAG, 2013) sets out three main outcomes: 
1. Everyone in the UK looks after their eyes and their sight – aims to raise awareness 
of eye health and an understanding of the prevention, detection and impact of sight 
loss amongst the public and health professionals. 
2. Everyone with an eye condition receives timely treatment and, if permanent sight 
loss occurs, early and appropriate services and support are available and 
accessible to all – aims to improve integration and effectiveness of eye health 
treatments and sight loss support services to ensure that patients receive improved 
treatment outcomes, and timely emotional and rehabilitation support. 
3. A society in which people with sight loss can fully participate – aims to improve 
awareness and acceptance of sight loss, whilst promoting independence and 
equality for patients.   
The UK Vision Strategy (UKVSAG, 2013) compiled a framework for LVS known as the ‘Adult 
UK sight loss pathway’ which was developed around the ten most important outcomes that 
services should deliver for the benefit of patients.  A map of the systems required to deliver 
the processes / outcomes, and how these are integrated is shown in Figure 1.14. 
Additional guidelines for those commissioning low vision services published by The College 
of Optometrists and The Royal College of Ophthalmologists (CO-RCO, 2013; see also 
Section 1.3.1) mirror those produced by the UK Vision Strategy.  Their report highlights the 
requirement for dedicated funding to be made available for future service provision.  The 
continuous process of evaluation of LVS is therefore essential to ensure ongoing and 
improved access to quality services for future generations where there will be an even 
greater demand on resources (CO-RCO, 2013).   
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Figure 1.14 The Adult UK sight loss pathway – a framework for low vision services which provides 
essential integration of different delivery services (e.g. community optometrists, hospital eye 
services, social services; Lightstone, 2012).  This map helps all delivery partners to understand their 
role, and understand the role of others in these processes and delivering outcomes.  Adapted from 
The UK Vision Strategy (UKVSAG, 2013).   
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1.4 Evaluation of Low Vision Services 
1.4.1 Introduction 
Access Economics (2009) reported the estimated economic cost of sight loss in the UK to 
be £22.0 billion in 2008.  This comprised £2.14 billion of direct healthcare costs (e.g. hospital 
recurrent expenditure, residential and community care services, etc.) and £4.34 billion of 
indirect costs (such as informal care costs, lower employment, and devices and 
modifications).  The largest proportion of cost comes from the burden of disease (£15.51 
billion) as a result of years lost due to morbidity and premature death.   
Access Economics (2009) grouped the costs of delivering LVS within indirect costs, 
including costs associated with LVAs, adaptations to the home and mobility devices.  These 
costs, estimated to be £336.5 million in 2008, take into account the average cost of devices 
multiplied by the prevalence of moderate and severe sight loss in the UK (Access 
Economics, 2009).  Wolffsohn and Cochrane (2000) suggest that the cost of providing LVS 
may be relatively small compared to the economic consequences of visual impairment, 
however the authors do not state a currency value for these.   
There is still a need for real evidence to evaluate the cost-effectiveness of such services 
(Binns et al. 2012; Ryan, 2014).  It is not known whether the true cost of visual impairment 
would be greater without the input of LVS, and therefore whether the cost of provision of 
LVS provides benefits which in turn reduce other indirect costs such as years of life lost due 
to morbidity.   
This is difficult to evaluate as the effects of LVS are measured in terms such as improvement 
in QoL, psychosocial status (Binns et al. 2012), and other such intangible benefits which 
are difficult to assess economically.  Nonetheless, it is reasonable to assume that an 
increased QoL would result in lower cost to UK society through increased independence 
and reduced burden on health and social care services.  Additionally, a visually impaired 
patient’s dependence on carers / family for support could result in a loss of income for the 
carer (Wolffsohn and Cochrane, 2000).  This results in an increased burden on UK 
resources through the provision of carers allowance and other benefits, along with loss of 
income tax payments from the carer.   
Quantification and evaluation of the outcome of low vision rehabilitation is essential to 
enable continued funding to be provided for LVS (Raasch et al. 1997; Wolffsohn and 
Cochrane, 2000).  Evaluation data will also educate clinicians working in community 
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optometric practice as to which patients are most likely benefit from LVS, ultimately ensuring 
that referrals to these services are made correctly. 
 
1.4.2 Quality of life  
Previously, the impact of a treatment in health care was assessed using mainly objective 
measures.  With the move towards a greater emphasis on the patient’s subjective 
perception of treatment outcomes, this is no longer the case (Parrish, 1996).  It was 
recognised that although patients were advised that a specific intervention (e.g. medication) 
had improved a specific bio-indicator (e.g. cholesterol level), the real importance for the 
patient was how that treatment outcome had affected their well-being and ability to function 
independently – in effect by assessment of its impact on their QoL (Parrish, 1996).  This 
assumption ignores the impact of cholesterol reduction on coronary heart disease and how 
this could increase life expectancy, something the patient would not be considering in their 
evaluation of quality of day-to-day life. 
As a result of the increased recognition of the importance of patient reported outcomes, 
QoL has been increasingly used as an outcome measure in clinical trials to evaluate new 
treatment interventions (Mitchell et al. 2008).  This has been applied to a wide range of 
systemic diseases (Parrish, 1996), and is one technique utilised and reported upon in the 
evaluation of LVS as a measure of the effectiveness of low vision rehabilitation (de Boer et 
al. 2006).   
The WHO defined QoL as ‘an individual’s perception of their position in life in the context of 
the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns’ (Wolffsohn and Karas, 2004).  A wide ranging concept 
encompassing interactions between physical and mental health, independence, and social 
wellbeing (Parrish, 1996), QoL cannot therefore be defined simply by the absence of 
disease / infirmity (Ellwein et al. 1995).  Bradley (2001), in reviewing the association 
between health status and QoL in patients with diabetes, expands on this with the 
observation that although a person who feels that they have poor health or wellbeing may 
also believe that they have an impaired QoL, this may not be the case.  Outcomes which 
measure QoL therefore have the potential to be both informative and misleading (Mitchell 
et al. 2005) due to the complex nature of the concept being measured. 
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The importance of measuring QoL to inform decisions on treatment strategies and policy 
planning in healthcare was reviewed by Guyatt et al. (1993).  The authors report on the two 
different approaches to achieve this –measurement of the generic health-related QoL, and / 
or QoL as measured in specific disease states. 
 
1.4.3 Quantification of quality of life  
Subjective QoL questionnaires utilise psychometric information to quantify the impact on 
the patient of the generic and / or specific disease state (Parrish, 1996).  The assessment 
of general health-related QoL can be used to obtain measurements of the health of 
populations, provide information for policy making decisions, and detect informative 
changes as a result of treatments in clinical trials (Guyatt et al. 1993).  Alternatively, 
questionnaires can be used to target specific disease states to allow evaluation of the 
effects of treatments in a particular area of the body (Guyatt et al. 1993), along with 
assessment of treatment programs for wider-ranging diseases such as cancer and mental 
health (Parrish, 1996).   
Questionnaire design is a complex process and a number of factors need to be considered 
to ensure that the questionnaire measures what it intends to, that it does so reliably, and 
that it can be used effectively with the population studied.  This is achieved through three 
psychometric properties:   
 Validity – whether or not the questionnaire measures what it is supposed to (Guyatt 
et al. 1993).  Included in this are the need for clinically relevant and understandable 
questions (content / face validity), the ability to discriminate between groups e.g. 
those with the disease compared to those without (construct validity), and how well 
the questionnaire compares with an existing well established and widely used 
questionnaire (criterion validity; Donovan et al. 1993).  
 Reliability – the repeatability or consistency of the measure.  Includes the 
relationship between items in the questionnaire (internal consistency), and the 
between and within observer variability (reproducibility).  Demonstration that the 
questionnaire measures the same outcomes in the same person over time (stability) 
is also important (Donovan et al. 1993). 
 Responsiveness – that the questionnaire is responsive to changes (e.g. in QoL) 
occurring as a result of treatment (Donovan et al. 1993), even if changes are minor 
(Guyatt et al. 1993).   
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Also of importance is the suitability of the questionnaire for application in clinical practice.  
It should be quick and easy to use and avoid overburdening the patient by use of the 
appropriate number of items.  The selection of items is therefore critical to the psychometric 
properties of the questionnaire, as discussed by Wolffsohn and Cochrane (2000).  The 
format of questions should also be considered as open-ended questions, although this can 
lead to a greater variation in scores (Wolffsohn and Cochrane, 2000).  Scores should also 
correlate easily to interpretable differences in QoL (interpretability; Guyatt et al. 1993; de 
Boer et al. 2004), to accurately report any clinical significance of treatment. 
Consideration must be given to the appropriate implementation method: in-person (self or 
interviewer-administered), by post or by telephone (de Boer et al. 2004; Wolffsohn and 
Karas, 2004).  It is imperative to choose a pre-tested method so as not to bias the results 
and invalidate its psychometric properties (de Boer et al. 2004).  This could be particularly 
relevant in the case of low vision patients who may not be able to read the questionnaire 
easily (Wolffsohn et al. 2000).   
Mangione et al. (1992), in their development of the ’Activities of Daily Vision Scale’ (ADVS) 
questionnaire for cataract patients, found no difference in results between in-person and 
telephone implementation.  Similar results were observed by Wolffsohn et al. (2000) in their 
study of different implementation methods of the Low Vision Quality of Life (LVQOL) 
questionnaire.  The authors reported that postal, telephone and in-person administration 
demonstrated similar validity and reliability.  Although a reduced QoL score from postal 
implementation was reported, Wolffsohn et al. (2000) concluded that using this method the 
questionnaire was no less likely to be completed or to suffer bias from assistance with 
completion where patients could not self-complete. 
Evaluative questionnaires measure changes in QoL over a period of time for one patient.  
This is in comparison to discriminative methods which assess the QoL differences between 
different patients at one point in time (Guyatt et al. 1993).  Only the former is relevant in this 
thesis and therefore all discussion of questionnaires to follow refers to evaluative types.  
The ability of the questionnaire to quantify accurately QoL changes over time is also 
dependent upon the interval between the first (baseline) and subsequent measures.  This 
interval will not be the same for every disease state due to variable rates of disease 
progression.  Wolffsohn and Karas (2004) discuss this with regards to low vision patients 
who may initially show a reduced QoL that is then artificially increased if QoL is re-measured 
too soon after low vision rehabilitation. 
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1.4.4 Use of quality of life questionnaires to evaluate low vision services 
Rationale for measuring quality of life within low vision services 
Although clinical measurements such as visual acuity and visual field assessment allow an 
objective assessment of the visual status to be made, they do not reflect the subjective 
impact of this disease on the patient (Margolis et al. 2002).  Visual impairment from an 
untreatable eye disease has been shown to impact negatively on health-related QoL 
(Loughman et al. 2011) and daily functioning through carrying out activities of daily living 
(Binns et al. 2012).  It is important for the clinician to be able to assess this from the patient’s 
perspective and make an onward referral to rehabilitation services at the earliest opportunity 
if necessary. 
Many studies have analysed the outcomes of LVS through either assessment of patient’s 
valuation of the services, the use of the prescribed LVAs, or through measurement of 
reading speed.  It is only more recently that studies have used vision-specific QoL 
measurements to provide quantitative outcomes (de Boer et al. 2006).  Those involved in 
the forward planning and prioritisation of LVS are better informed to make decisions when 
they have quantifiable evidence of the benefits of services e.g. improved QoL.  Any 
improvement in QoL would be a positive reflection of LVS in both financial and subjective 
terms.  Although this would be difficult to measure, it would certainly be useful in support of 
the continuing need for LVS (Wolffsohn and Cochrane, 2000).   
The application of questionnaires to evaluate low vision services 
Nilsson and Nilsson (1986) assessed the effect of a full range of rehabilitation techniques 
through multiple training sessions provided by a number of different professionals.  Patients 
with ARMD were given specific training in eccentric fixation and in the optimum use of LVAs.  
The authors observed that the numbers of patients able to read television titles and 
newspaper text increased significantly from 6.7% to 57.5% and 0.8% to 92.5%, respectively, 
following training.  A mention was made also to a ‘dramatic improvement in an individual’s 
situation of life’, which could be taken to imply QoL.   
McIlwaine et al. (1991) investigated the cost-effectiveness of LVS by evaluating the extent 
of prescribed LVA use and patient satisfaction, rather than QoL.  The authors suggested 
that a more extensive approach to LVS provision similar to that described by Nilsson and 
Nilsson (1986) should be considered.  As their service did not routinely provide a follow-up 
appointment McIlwaine et al. (1991) concluded that based on the 29 patients who requested 
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follow-up or further training via their responses to the questionnaire, additional follow-up 
appointments would improve the effectiveness of the service provided. 
Leat et al. (1994) observed that variability between studies using different criteria to 
measure LVS outcomes made comparisons difficult.  The authors designed a questionnaire 
that aimed to assess more widely the perceived benefits / success of LVS for the patient in 
performing a number of specific daily tasks (e.g. reading newspaper headlines, bank 
statements and letters).  In their conclusions, they discussed the importance of evaluating 
the success of LVS by multiple outcomes and not just one definition (e.g. whether the patient 
can achieve the ability to read).  This emphasis on comprehensive and multiple outcomes 
such as optimum functioning and gaining more independence could be considered as QoL 
outcomes, although Leat et al. (1994) do not specifically refer to this terminology. 
One disadvantage of some of the early QoL questionnaires is that they were developed for 
patients who were not suffering from permanent visual impairment but from eye conditions 
with the potential to be treated.  These included the ‘Catquest’ questionnaire (Lundström et 
al. 1997), which focussed specifically on the effect of cataracts on subjective QoL by 
administration of the questionnaire before and after cataract surgery.  Wolffsohn and 
Cochrane (2000) observed the limitations of such instruments and others, including those 
from Parrish (1996), and Lowe and Drasdo (1992) that were designed to assess QoL in 
patients with glaucoma and retinitis pigmentosa, respectively.  Questionnaires that focus on 
a single cause of visual impairment may have reduced validity if applied to a low vision 
population where multiple causes of impairment exist. 
To use an appropriate questionnaire designed specifically for patients with low vision is 
therefore essential when an accurate evaluation of the outcome of LVS is required.  To 
highlight this Wolffsohn and Cochrane (2000) referred to a study by Scott et al. (1999), 
which used three questionnaires to assess QoL at one week prior to and three months 
following low vision rehabilitation.  These were: the Medical Outcomes Study 36-Item Short 
Form (SF-36) for assessment of general health-related QoL; the Visual Function-14 (VF-
14) designed to assess vision-dependent activities known to be affected by cataract; and 
the 51 item Field Test Version of the NEI-VFQ. 
Scott et al. (1999) observed that 98.7% of 156 patients in the study reported a beneficial 
impact upon functional status from attendance at LVS, with significant improvements in the 
VF-14 scores.  However, the SF-36 scores did not support this trend, showing no significant 
change post rehabilitation and leading to the conclusion that the SF-36 was less sensitive 
to QoL differences than the vision-specific instruments.  Also, as these three questionnaires 
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were not designed specifically for patients with low vision, the authors hypothesised that 
some of the daily activities assessed with the VF-14 in particular may not be expected to 
improve as a result of LVS.  It could therefore be hypothesised that the use of such 
questionnaires could affect the validity of results, and it is justifiable to say that 
questionnaires that have not been well validated for use within low vision populations should 
not be used when trying to evaluate LVS. 
Wolffsohn and Cochrane (2000) attempted to overcome this problem.  Their LVQOL 
questionnaire was initially based on the accumulation of questions from 16 previous studies, 
with all duplicates removed before questions were assessed for relevance, coverage and 
face validity.  The resulting 74 items were trialled on 150 patients suffering from a range of 
conditions causing visual impairment, and were ultimately reduced in number to 25 
questions that were found to meet specific criteria: greatest reliability, internal consistency, 
not redundant and with good relevance.  The final version of the 25 question LVQOL 
questionnaire was then posted to 515 low vision patients prior to their appointment, and an 
age and gender matched control group completed the questionnaire during attendance at 
a routine eye examination appointment.  A low vision appointment included optometric 
assessment plus input from a wider rehabilitative team (as required).  One month following 
the clinic visit, a post-rehabilitation LVQOL questionnaire was posted to the patients who 
had submitted an initial questionnaire.   
Wolffsohn and Cochrane (2000) demonstrated that their questionnaire was able to 
discriminate between the control population with ‘normal’ vision and those with visual 
impairment, with an average LVQOL score of approximately 40 units lower in those with 
visual impairment.  Furthermore, QoL scores increased by an average of 6.7 points 
(equivalent to 17%) in those with low vision following rehabilitation, in comparison to 0.8 
points on the control group.  This demonstrated that LVS resulted in improved QoL for 
patients with visual impairment, and correlated well with findings from Scott et al. (1999).  
Wolffsohn and Cochrane (2000) also highlighted the observation that those who received 
additional multidisciplinary rehabilitation showed a greater improvement in QoL compared 
with those who did not.  This led to the conclusion that the multidisciplinary approach to LVS 
may be important in QoL improvement, and fits well with the findings of Nilsson and Nilsson 
(1986) and the recommendations of McIIwaine et al. (1991).   
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Quality of Life and comparisons between models of LVS provision 
Vision-related QoL outcomes have also been used as a way of making comparisons 
between different models of LVS provision.  Reeves et al. (2004) compared the outcome of 
three different models of low vision rehabilitation over a 12 month period.  The authors 
compared standard hospital based optometric LVS (at the Manchester Royal Hospital), with 
enhanced services (involving standard LVS together with up to three home visits to advise 
on training and provide alternative LVAs as needed).  The third group of patients received 
standard LVS plus up to three home visits from an Age Concern community care worker to 
discuss daily and other activities. 
Questionnaires used in the study were the SF-36 and the ‘Vision-Quality of Life Core 
Measure’ (VCM1; Frost et al. 1998).  Although designed primarily for use in patients with 
cataracts (Wolffsohn and Cochrane, 2000), the VCM1 questionnaire does investigate 
factors such as anger, depression and loneliness in more detail than other more functional 
based questionnaires (e.g. LVQOL).  Reeves et al. (2004) hypothesised that those patients 
receiving additional home visits and LVA training would demonstrate higher QoL scores 
and be more able to continue with daily tasks compared to those who attended the hospital 
clinic only.  However, results showed that this was not the case and there was no significant 
difference in QoL improvement between the three groups, concluding that evidence of 
effectiveness was required before adopting enhanced (multidisciplinary) LVS. 
In a non-randomized trial, de Boer et al. (2006) agreed with these findings when reporting 
on QoL outcomes at baseline and at one year follow-up for patients with varying causes of 
visual impairment referred to either optometric or multidisciplinary LVS (type dependent 
upon the patients geographical location).  The authors reported no significant difference in 
QoL outcomes between the two types of rehabilitation using the VCM1 and LVQOL 
questionnaires, except one finding showing less deterioration in mobility for those attending 
optometric LVS.  However, 27% of patients were lost to follow-up and de Boer et al. (2006) 
discussed the use of a control group in future studies where comparison is made between 
patients receiving LVS and placebo.  It remains an open question as to whether it is ethical 
to withhold LVS rehabilitation treatment from patients that require it.   
Pearce et al. (2011) used one approach to overcome this.  In a study of 96 patients within 
the LV clinic at Moorfields Eye Hospital London, patients randomised to an intervention 
group received a further review appointment whilst those in a control group did not.  The 
authors found through Mass of Activity Inventory (MAI) questionnaire scores that although 
self-reported improvement in daily tasks increased significantly following the initial LV 
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assessment, the additional follow-up visit where additional LVA training was administered 
resulted in no further improvement.  Although the LVSCG (1999) highlighted that it is the 
duty of the person supplying the LVAs to ensure that the patient receives training in their 
optimal use, there is mixed evidence as to whether patients benefit from further / additional 
LVA training beyond that provided initially (Binns et al. 2012; CO-RCO, 2013). 
Binns et al. (2012) in a systematic review of LVS discussed a number of different models 
and concluded that what is defined as a ‘multidisciplinary’ approach in one area may vary 
widely from that provided in another.  Therefore, it is difficult to make comparisons between 
standard (hospital or community based) and multidisciplinary models of LVS provision, 
particularly where studies are based in different geographical areas.  What is theoretically 
more important for clinicians working in any area of the UK is that there is a process by 
which they can gain an increased understanding of a patient’s needs at or prior to LV 
assessment, which will help decide whether referral to social services or other rehabilitation 
centres is required.  This is where another benefit of QoL questionnaires may be 
recognised. 
 
1.4.5 Evaluation of quality of life in patients with age-related macular degeneration 
A review by Finger et al. (2008) evaluated a number of QoL questionnaires that may be 
used specifically with patients suffering from ARMD.  They concluded that out of the six 
questionnaires assessed, the 25 item NEI-VFQ was found to be the most extensively used 
and the best validated.  The authors also suggested that future studies should aim to use a 
standard questionnaire when measuring vision-related QoL to allow for international 
comparison.  Although they do not define what this particular standard should be, they do 
state that the 25 item NEI-VFQ should be included.   
However, an earlier analysis of the 25 item NEI-VFQ carried out by Langelaan et al. (2007) 
recommended deleting some items.  However, their study consisted of 129 adult visually 
impaired patients, where only 9.4% suffered from macular disease.  It may be argued that: 
(1) on the basis of one study the 25 item NEI-VFQ cannot be completely discounted due to 
its previous wide usage amongst ARMD patients (Finger et al. 2008); and (2) it is very 
difficult to review literature which concentrates specifically on QoL questionnaires for ARMD 
patients, when often the questionnaires themselves can be used with a wide variety of eye 
conditions. 
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One more recent development which could help overcome this latter problem is the Macular 
Disease-dependent Quality of Life (MacDQoL) questionnaire.  Finger et al. (2008) observed 
that this may allow a more in-depth approach in the measurement of vision-related QoL 
specific to macular disease patients.  Mitchell et al. (2008) concluded that this 22 item 
questionnaire demonstrated good psychometric properties and allows for an individualised 
assessment of the impact of macular disease on QoL that goes beyond that of ‘visual 
function’ questionnaires.  Although this is potentially of great benefit, Finger et al. (2008) 
stated that this particular questionnaire needs evaluation on a larger scale and therefore it 
could be argued that for the current study a questionnaire that is already well validated for 
use with ARMD patients (such as the LVQOL) would be better.  Indeed, van Nispen et al. 
(2009a) questioned the exclusion of the LVQOL from the review by Finger et al. (2008) and 
highlighted its qualities as a measure of QoL. 
 
1.4.6 Rationale for using the Low Vision Quality of Life Questionnaire in the current study 
The 25 item, four dimension (distance vision; mobility and lighting; adjustment, reading and 
fine work; and activities of daily living) LVQOL questionnaire was chosen for this study as it 
has shown to be a reliable, fast method to measure vision-specific QoL (Wolffsohn and 
Cochrane, 2000). Moreover, it is free to use, which is of importance when considering its 
use in NHS LV Clinics.  Covering the functional, psychological and social dimensions of 
QoL, the questionnaire has seven response categories ranging from ‘5’ (having no vision-
related difficulty with the specific item) to ‘1’ (having a great difficulty).  The options ‘0’ (item 
could no longer be carried out due to the level of vision) and ‘N/A’ (the item was not relevant 
in that patient’s daily life) were also included, with ‘N/A’ given an average score to prevent 
the bias towards a lower QoL overall (Wolffsohn and Cochrane, 2000).   
Wolffsohn and Cochrane (2000) reported the LVQOL questionnaire to be a consistent, 
reliable and sensitive measure of the QoL in patients with irreversible visual impairment.  
This was also the conclusion of de Boer et al. (2004), who at that time rated the LVQOL 
amongst the two best questionnaires (out of 31 evaluated) to use with visually impaired 
patients.  However, de Boer et al. (2004) did make reference to the lack of evidence for the 
construct validity and responsiveness of the LVQOL questionnaire.  Further work to re-
evaluate the questionnaire using an item response theory model (van Nispen et al. 2007) 
concluded that some questionnaire items should be removed - this will be considered in 
more detail in Section 4.2.2. 
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De Boer et al. (2006) concluded that there was no significant difference in LVQOL scores 
between patients attending either optometric or multidisciplinary LVS at one year follow-up.  
The current study will include patients attending optometric and / or multidisciplinary low-
vision services, as these are often run in parallel in the UK.  To offer optometric low vision 
without other multidisciplinary (rehabilitation) services to a particular cohort may be 
considered unethical. 
 
1.4.7 Rationale for using the EuroQol five-dimension five-level questionnaire in the current 
study 
There should be consideration of a patient’s co-morbidities during LV assessment.  The 
higher prevalence of multiple chronic health-related conditions in the elderly (e.g. stroke, 
diabetes and cancer) was reported by van Nispen et al. (2009b) to lead to reduced QoL 
through deterioration of physical, social and psychological functioning.  Due to the increased 
prevalence of visual impairment with age, it is also more likely that a significant percentage 
of elderly patients with low vision will suffer from co-morbidity (Brody et al. 2001; van Nispen 
et al. 2009b).  Less clear is the relationship between visual impairment and the number (and 
type) of co-morbidities on QoL.   
The inclusion of a generic health status questionnaire in QoL studies of elderly visually 
impaired patients is hypothesised to reveal important non-vision-specific information.  The 
EQ-5D was developed for use in clinical studies to provide a supplementary assessment of 
general health status and functional ability of patients (Rabin and de Charro, 2001).  The 
development of the five level EQ-5D questionnaire in 2005 arose after studies published by 
the EuroQol group found that the additional two levels significantly increased the 
questionnaires sensitivity and reliability (Janssen et al. 2013).  Its use has been extensively 
validated within populations of general and disease-specific states, and in a large number 
of geographical locations and languages (Janssen et al. 2013).  The EQ-5D is widely used 
in the UK, as recommended by NICE.   
The questionnaire consists of five items, representing five different health domains; three 
relate to function (mobility, self-care and usual activities) whilst two relate to feelings (pain / 
discomfort and anxiety / depression).  Each domain has three (EQ-5D-3L) or five (EQ-5L-
5D) levels to assess its severity.  For the EQ-5D-3L these are: ‘1’ (no problems), ‘2’ 
(moderate problems) and ‘3’ (severe problems).  With the five level version of the 
questionnaire, as proposed for the current study, the levels are: ‘1’ (no problems), ‘2’ (slight 
 64 
problems), ‘3’ (moderate problems), ‘4’ (severe problems) and ‘5’ (unable to / extreme 
problems) dependent upon the item.  This equates to a combination of potentially 243 (=35) 
and 3125 (=55) health states from the three and five level questionnaires respectively. 
Van Nispen et al. (2009b) used the EuroQol five-dimension, three-level (EQ-5D-3L) generic 
health status questionnaire with 296 visually impaired elderly patients.  They observed that 
the patients in this study who had self-reported co-morbidities at baseline demonstrated a 
lower QoL than those who did not.  Musculoskeletal conditions, chronic obstructive 
pulmonary disease / asthma, and stroke were the conditions that most predicted a 
subsequent decline in QoL, along with a higher logMAR visual acuity, although the exact 
value was not specified.  The same group also used the LVQOL questionnaire with this 
dataset (van Nispen et al. 2007).  The self-reported improvement in QoL scores for reading 
small print after five months led the authors to hypothesise that LVS improved aspects of 
functional vision-related aspects of QoL, rather than health-related QoL.  Binns et al. (2012) 
also observed a trend of lack of sensitivity when general health-related QoL questionnaires 
are applied to the assessment of LVS. 
Malkin et al. (2013) reported that the EQ-5D-3L was not a suitable outcome measure for 
LVS, stating that it was unresponsive as a measure of rehabilitation, and struggled to 
discriminate amongst patients exhibiting varying levels of visual impairment.  However as it 
was a late addition to their study and only administered to 77 of 764 participants further 
work would be required to validate the results. 
The current study aims to use both the LVQOL questionnaire and the extended five level 
EQ-5D-5L on all patients to examine whether the increased sensitivity of the five level 
response (c.f. Malkin et al. 2013) means that the EQ-5D general health questionnaire is 
more applicable to the assessment of LV related QoL.  This is a combination that has not 
been used previously. 
The EQ-5D questionnaire also contains a visual analogue scale (VAS) with which the 
patient rates their general health status on a scale from 0 (worst imaginable health state) to 
100 (best imaginable health state; EuroQol, 2014).  De Boer et al. (2006) evaluated 
outcomes between two different types of LVS (optometric and multidisciplinary) with both 
the LVQOL and VCM1.  The authors also used the VAS component of the EQ-5D to assess 
general health status, and corrected their analyses for this and other confounders.  The 
current study will also use the VAS in combination with the EQ-5D-5L to allow greater insight 
into the additional health-related requirements of patients attending LVS.   
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1.5 Summary 
Although LVS have been shown to improve clinical and functional outcomes for patients, 
evidence of their effect on vision and health-related QoL remains unclear.  Access to a valid, 
reliable and reproducible questionnaire to aid the audit process for the benefit of future 
planning and provision is important when considering the potential impact of ARMD on LVS 
in years to come.  This is of particularly relevance in Milton Keynes, where the elderly 
population is predicted to be the fastest increasing in the UK. 
 
1.6 Aims  
This study will use the established and validated LVQOL and EQ-5D-5L questionnaires in 
parallel to provide quantifiable assessment of LVS QoL outcomes for patients with ARMD 
attending the LV Clinic at MKUH.  The aims of the study are to: 
1. Evaluate LVS at MKUH and inform improvement of service delivery and efficiency. 
2. Examine which patients suffering from ARMD are most likely to benefit from LVS in 
the future.   
3. Determine whether or not the five level general health status EQ-5D questionnaire 
provides sufficient sensitivity to be used in isolation to evaluate LVS at MKUH and 
inform improvement in service delivery and efficiency. 
 
1.7 Research Hypotheses 
Hypothesis A for this study is: 
H0(A): LVS at MKUH have no effect on the QoL of patients with ARMD. 
Two alternative hypotheses are proposed:  
H1(A): LVS at MKUH improve the QoL of patients with ARMD. 
H2(A): LVS at MKUH decrease the QoL of patients with ARMD. 
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Hypothesis B for this study is: 
H0(B): All patients with ARMD benefit equally from LVS. 
One alternative hypothesis is proposed: 
H1(B): It is possible to identify a subgroup of ARMD patients that benefit more from LVS 
than others. 
Hypothesis C for this study is: 
H0(C): The EQ-5D-5L general health status questionnaire has insufficient sensitivity to 
determine whether or not LVS at MKUH improves QoL in patients with ARMD. 
One alternative hypothesis is proposed: 
H1(C): The EQ-5D-5L general health status questionnaire has sufficient sensitivity to 
determine whether or not LVS at MKUH improves QoL in patients with ARMD. 
 
1.8 Objectives 
1. To design and conduct an experiment based on the LVQOL and EQ-5D-5L 
questionnaires to test hypotheses A, B and C in the LV Clinic at MKUH over a six 
month period. 
2. To perform analysis using robust statistical techniques to test hypotheses A, B and 
C and to determine mechanisms by which LVS improve QoL where appropriate. 
3. To provide recommendations to the hospital and wider audiences based on the 
findings of this study to improve the efficiency and effectiveness of LVS. 
4. To make recommendations on the improvement of LVS at MKUH and in the wider 
NHS. 
5. To evaluate the methodology and approach taken to provide recommendations for 
future work in this subject. 
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2 METHODOLOGY 
2.1 Introduction 
In order to achieve the objectives a questionnaire-based study was designed and carried 
out in the LV clinic at MKUH.  The study was conducted on 40 patients diagnosed with 
ARMD in one or both eyes and attending the LV Clinic for assessment over a six month 
period.  A six month period was selected to allow for two follow-up visits after the initial 
consultation. 
 
2.2 Study Participants 
2.2.1 Inclusion and exclusion criteria 
Eligibility requirements for inclusion in the study were as follows: 
1. Recent referral to, or current attendance at, the Optometrist-led LV clinic, MKUH. 
2. Following the initial LV assessment, the patient was deemed to require three and 
six-month follow-up LV clinic reviews. 
3. A diagnosis of ARMD (affecting at least one eye, regardless of subtype 
classification) had been made previously by an ophthalmologist. 
4. Participants were aged 18 years or over. 
5. Irreversible vision loss. 
 
Exclusion criteria: 
1. Patients that lacked the capacity to provide informed consent for themselves. 
2. Participants had no other ocular co-morbidities, with the exception of lenticular 
opacities. 
 
2.2.2 Recruitment 
For all patients attending the LV clinic at MKUH on that particular day, the Chief Investigator 
(Louise James) read through any previous relevant eye clinic documentation in the hospital 
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records to determine patient suitability for participation in the study.  Original / new referral 
letters to the LV clinic for each patient from local GPs (via community based optometrists), 
hospital ophthalmologists and the ECLO were also reviewed where available.  Patients that 
had previously attended the clinic or another hospital LV clinic / provider (existing patients) 
were considered for the study, along with those who had never previously received LVS 
input (new patients).   
Using the inclusion and exclusion criteria for the study, a decision was made as to whether 
any patients were suitable to participate, and these were noted by the Chief Investigator.   
Following attendance at the LV clinic and on completion of an LV assessment (see Section 
2.3.1), the Chief Investigator made a further assessment as to whether the patient would 
require both three and six-month follow-up LV clinic reviews.  If these were considered 
necessary, the patient was deemed suitable for inclusion in the study. 
Participants were then recruited through verbal invitation and presented with a verbal 
overview of the research and what participation in the study would involve (e.g. future 
attendance at LV clinics and questionnaire procedures).  The Chief Investigator discussed 
the Patient Information Sheet (v2) and Consent Form (v2) (see Appendix 2.1) with the 
patient, who was then given a minimum 30 minute period for reflection.  All invited patients 
decided that they would like to participate. 
The minimum number of patients was determined using an a priori power analysis in 
G*Power (version 3.1.9.2, University of Düsseldorf) for a two-tailed paired Student t-test 
with a power of 80%, α=0.05 and a medium effect size (Prajapati et al. 2010).  The selection 
of the Student t-test was based on the normal distribution of LVQOL data in Wolffsohn and 
Cochrane (2000).  This determined a minimum sample size of 34 patients.  In total, 40 
patients were recruited for the study between 5th March 2013 and 18th February 2014. 
 
2.2.3 Informed consent 
Prior to commencement of the study, and by way of a written consent form, patients were 
asked for their consent to use data collected from questionnaires.  One copy of this consent 
form was given to the patient, and a second copy was kept securely by the Chief 
Investigator. 
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The Chief Investigator made it clear that: 
1. Participation in the study was not necessary in order for the patient to continue to 
receive LVS at MKUH. 
2. Consent to take part in the study was not compulsory. 
3. There were to be no adverse consequences should consent not be granted. 
4. Consent given at the beginning of the study was implied throughout the six month 
period that data was to be collected; however the participant was free to withdraw 
from the study at any stage without penalty. 
5. The research involved collecting data by questionnaire, and included some 
questions of a sensitive nature as they related to QoL. 
6. The research involved collecting data by questionnaire a maximum of three times 
over a six month period.   
7. The Chief Investigator would be responsible for maintaining privacy and 
confidentiality throughout (and following) the study. 
8. Only anonymous data would be published. 
 
2.2.4 Privacy, confidentiality and data security 
The Chief Investigator was responsible for maintaining privacy and confidentiality.  All 
collected data from questionnaires were stored on a database, and information collected 
over the study period was added to this database.  To maintain anonymity in the study, 
each participant was assigned a unique identification number between 001 and 040 on a 
consecutive basis.  Patient names and / or hospital numbers were not included in the 
database. 
Privacy and confidentiality was protected vigorously to the extent permissible by law.  
However, patients were made aware that privacy and / or confidentiality could not be 
guaranteed.  All personal and collected data were stored securely and destroyed on study 
completion.  Whilst participant identification numbers remained with the study data, there 
was no remaining link between identification numbers and personal details.   
Published data do not require identification of patients or pseudonymisation - aggregated 
(statistical) anonymised data were used.  Anonymised data were made available to 
Professor Stephen J. Anderson (Supervisor, Aston University) but non-anonymised data 
were not transferred externally from the Eye Clinic at MKUH. 
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2.2.5 Characteristics of study participants 
Table 2.1 Demographic characteristics of study participants at baseline (n=40) 
 All Female Male 
Gender  n = 26 (65%) n = 14 (35%) 
    
Mean1 Age (years) 81.4 ± 1.36 81.3 ± 1.75 81.4 ± 2.18 
    
New Patients n = 20 n =14 n = 6 
Existing Patients n = 20 n = 12 n = 8 
    
ARMD Sub-type2    
Geographic atrophy (GA) n = 22 n = 14 n = 8 
Exudative (Ex) n = 10 n = 7 n = 3 
Mixed n = 8 n = 5 n = 3 
    
ARMD Sub-type by eye   
GA both eyes n = 19 n = 13 n = 6 
Ex both eyes n = 9 n = 6 n = 3 
R/L: GA/Ex or Ex/GA n = 8 n = 5 n = 3 
Monocular GA n = 3 n = 1 n = 2 
Monocular Ex n = 1 n = 1 n = 0 
    
Living Status    
Lives alone n = 20 n = 16 n = 4 
Lives with spouse n = 16 n = 7 n = 9 
Lives with family (no spouse) n = 4 n = 3 n = 1 
    
Registration Status3   
Registered as SI n = 13 n = 7 n = 6 
Registered as SSI n = 5 n = 3 n = 2 
Not Registered n = 22 n = 16 n = 6 
Notes:   
1. Mean ± standard error of the mean.  
2. Where diagnosis was previously made by an ophthalmologist at MKUH and this information was obtained 
from the patient’s hospital records.   
3. Where registration as Severely Sight I (SSI) indicates: Group 1 – VA below 3/60; Group 2 – VA of 6/60 but 
below 3/60 with a very contracted field of vision; Group 3 – VA of 6/60 or above with a contracted field of 
vision, especially in the lower part of the field.  Registration as Sight Impaired (SI) indicates: VA 3/60 to 6/60 
with full field; or up to 6/24 with moderate contraction of the field, opacities in media or aphakia; or, 6/18 or 
even better if they have a gross defect, for example hemianopia, or if there is a marked contraction of the 
visual field.  Adapted from the Certificate of Vision Impairment, Department of Health (2013). 
 71 
2.3 Procedure 
2.3.1 Low vision clinic assessment 
Each participant received a 30 minute clinical LV assessment, carried out by the Chief 
Investigator.  All techniques fell within the scope of normal professional practice and 
included the following (see also Appendix 1.1): 
Comprehensive case history – to determine any general and / or specific problems that the 
patient was having with their vision, and the effect that these had upon their ability to perform 
everyday tasks.  The patient’s social situation, general health status and current level of 
support were identified, along with the level of adaptation to vision loss and expectations of 
the LV clinic.  The date of the last full eye examination was noted, along with the type and 
age of any spectacle correction currently worn. 
Assessment of distance visual acuity – an assessment of both monocular (OD and OS) and 
binocular distance visual acuities were obtained using the ‘Bailey-Lovie Logarithmic Visual 
Acuity Chart 2000’ (Sussex Vision, Rustington, UK).  A standard chart illumination of 1206 
± 63.7 lux, and room illumination of 273 ± 17.5 lux (mean ± standard error of five 
measurements using the Whitegoods LightMeter app on an iPhone 5S, 
www.whitegoods.com) was consistent throughout all initial and follow-up assessments, for 
all 40 study participants.   
Due to the constraints of the clinic room, a 2 m (rather than the standard 4 m specified by 
the manufacturer) testing distance was used.  To allow for this enforced alteration in testing 
distance, the addition of 0.3 log units was applied to each recorded measurement of both 
unaided and corrected distance visual acuities to ensure that the measured logMAR was 
accurately documented.  By using this method, a range of acuity levels between logMAR 
1.30 to 0.00 were obtained, equivalent to Snellen visual acuities of 3/60 and 6/6 
respectively.  This was extended to logMAR values of 1.80 for a Snellen visual acuity of 
1/60 by movement of relative chart position.   
If appropriate, standard notation of count fingers (CF), hand movements (HM; both at 
0.6 m), perception of light (LP) and, no perception of light (NPL) were recorded; logMAR 
values of 2.00 and 3.00 were assigned to CF and HM respectively (Holladay, 2004).  
Monocular pinhole acuity was also recorded where visual acuity was found to be at a level 
equal to (or below) 0.20 logMAR. 
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Assessment of near visual acuity – assessment of monocular (OD and OS) and binocular 
near visual acuity (NVA) using the non-illuminated Times New Roman ‘N’ point notation 
chart (range between N5 to N48) with the patient wearing their current near correction (e.g. 
single vision, bifocal, multifocal).  Working distance(s) were recorded for each patient, and 
a conversion to logMAR values made using the following formula: 
ݕ ൌ logଵ଴ ݔ8ݓ 
Where: 
 y is the near visual acuity in logMAR 
 x is the near visual acuity in N notation 
 w is the working distance in metres 
 
Distance Refraction – retinoscopy and monocular subjective refraction were carried out for 
each patient. 
Assessment of contrast sensitivity – was conducted with the optimum distance refractive 
correction in place at a testing distance of one metre, using the non-illuminated ‘Pelli-
Robson Contrast Sensitivity Chart 2L’, copyright © 1988 by Denis G. Pelli (serial number: 
KB084). 
Near refraction – where appropriate, a high reading addition (≥+4.00 DS) was demonstrated 
at this stage, with any advantages (e.g. hands-free viewing) and disadvantages (e.g. close 
working distances) of this method of magnification explained to the patient. 
To ensure that the patient was wearing the optimum correction for both their distance and 
near requirements, a verbal explanation of the best form(s) of spectacle correction was 
given.  A new spectacle prescription was issued (where deemed appropriate) for the patient 
to present to their community dispensing optician.  However, the limitation of visual 
improvement with the new spectacles was also discussed, where necessary, to manage 
the patient’s current and future expectations. 
Optical low vision aid demonstration and training –trial LVAs were initially chosen based on 
the patient’s specific task requirements (e.g. size and contrast of print), level of visual acuity, 
patient motivation and handling ability.  LVAs of different types (as appropriate for each 
task) were demonstrated, however the number of LVAs issued was limited to a maximum 
of three per patient as per clinic protocol (e.g. a stand magnifier for reading newsprint, a 
hand magnifier for reading packets in the kitchen and a foldaway magnifier for shopping).  
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A record was made of the LVAs trialled (and issued), the acuity level achieved, fluency of 
reading, type of spectacle correction worn (where relevant), and any other patient 
comments. 
Distance optical LVAs (e.g. monoculars and binoculars) were demonstrated (and issued) 
as required.  Note that no distance LVAs were issued in this study, so there were no data 
to analyse. 
Guidance on how to achieve the optimum results with each magnifier was given verbally to 
the patient (and any family / carers present), and was also issued in large print written 
format.  Explanation of the maintenance of LVAs was provided along with telephone details 
of the LV clinic in the event of any future problems.  Patients were made aware that LVAs 
were loaned without cost on a long-term basis. 
Lighting and non-optical low vision aids – limited advice on the most appropriate general 
and task lighting was issued as required.  Techniques were discussed for improvement of 
contrast within the home, particularly if a reduced level of contrast sensitivity had been 
measured.  For further help and advice with both improved lighting and contrast, a written 
referral was sent to the ECLO (see below). 
Glare shields in various tints were demonstrated if the patient had previously indicated a 
problem with glare.  One pair was loaned (if necessary) and the advantage of peaked hats / 
caps was discussed.   
Demonstration of a limited range of large print items was carried out, along with both written 
and verbal information on how to purchase these and other items privately.  If the patient 
was receptive to the concept of audio books and talking newspapers, written information 
was provided on both local and national schemes. 
Other non-optical equipment (e.g. liquid level indicators and talking watches) were 
discussed, and details of where to trial / purchase these were issued.  Reference was made 
to the advantages of eccentric viewing and steady eye strategy and if deemed appropriate, 
a referral made to the ECLO to arrange further training in these techniques. 
Discussion of electronic LVAs (including e-readers, and portable / non-portable CCTVs) 
was provided along with information including estimates of the costs involved to purchase 
privately.  Referral for demonstration of a range of CCTVs at the local resource centre was 
made via the ECLO.   
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Onward referral – if required, and with the patient’s consent, further referral was made to 
the ECLO within MKUH eye clinic through the completion of an RVI (Appendix 2.2).  On 
receiving the RVI, the ECLO telephoned the patient to conduct an assessment of their 
needs and discuss further support processes.  If deemed necessary, onward referral was 
made by the ECLO to the local Sensory Advice Resource Centre (SARC) allowing access 
to a wider range of rehabilitative services, advice and support.  In cases whereby no further 
in-person support was needed, patients were provided with contact details for SARC (and / 
or other local and national support groups) in case of any future difficulties. 
During the study, three (/40) patients were referred to the ECLO at the initial study visit (T0) 
and 14/40 patients had contact with the ECLO prior to the study.  Five were awaiting home 
visits and 18 did not want to use the service during the study. 
 
2.3.2 Questionnaires 
On completion of the LV assessment and after informed consent had been given, the Chief 
Investigator conducted the two questionnaires (LVQOL and EQ-5D-5L) with the patient.  For 
all participants, both questionnaires were interviewer-administered, with verbal responses 
recorded on paper forms.  During this process, no feedback was given to the patient on 
their responses. 
Low Vision Quality of Life (LVQOL) questionnaire:  
The Low Vision Quality of Life (LVQOL) questionnaire (Wolffsohn and Cochrane, 2000) was 
used in this study (Appendix 2.3).  Twenty-five consecutive questions on vision-specific QoL 
were asked within sections on ‘Distance Vision Mobility and Lighting’ (12 questions); 
‘Adjustment’ (4 questions); ‘Reading and Fine Work’ (5 questions); and ‘Activities of Daily 
Living’ (4 questions).  For each question, the patient was asked to provide a graded 
response on a numerical Likert scale related to the difficulty / problem with the specific task 
being assessed between ‘5’ (no problem due to their vision) and ‘1’ (great problem due to 
their vision).  A response of ‘X’ was marked if the patient could no longer complete the task 
due to their visual impairment, and ‘N/A’ was recorded if they did not perform the task for 
non-visual reasons.  If the patient made specific comments on any of the questions, these 
were recorded separately (see Patient Testimonials, Appendix 2.4).  
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The scores for each of the 25 questions were combined to provide a summed total 
questionnaire score for each patient with a minimum score of 0 and a maximum score of 
125.  It is assumed that the higher the total score, the higher the patient’s QoL (Wolffsohn 
and Cochrane, 2000).  Questions scored ‘N/A’ were given a midpoint score of 3, as 
recommended by Wolffsohn and Cochrane (2000), to prevent bias towards an artificially 
reduced QoL for those patients scoring multiple questions as not relevant to themselves.  
Questions scored as ‘X’ were given a score of zero. 
EuroQol five-dimension, five-level (EQ-5D-5L) questionnaire: 
The five-level version of the EuroQol five-dimension (EQ-5D-5L) generic health status 
questionnaire (Herdman et al. 2011) was used in this study (Appendix 2.5).  For questions 
one ‘Mobility’, two ‘Self-Care’, and three ‘Usual Activities’, participants were asked to 
provide a graded response from five levels between ‘1’ (no problem performing task) and 
‘5’ (unable to complete task).  For questions four and five relating to level of ‘Pain / 
Discomfort’ and ‘Anxiety and Depression’ respectively, the response was scored between 
‘1’ (no pain or discomfort / not anxious or depressed) and ‘5’ (extreme pain or discomfort / 
extremely anxious or depressed).  Again, if the patient made any specific comments on any 
question, these were recorded separately (Patient Testimonials, Appendix 2.6). 
For analysis, the summed score of the five questions was calculated with results between 
a lowest possible score of 5 and the highest of 25.  Lower scores indicated a better health-
related QoL. 
Finally, a score was recorded for the patient’s subjective assessment of their health at that 
particular time using the EuroQol visual analogue scale (EQ-VAS).  This was given a value 
between ‘0’ (worst health they could imagine) and ‘100’ (best health they could imagine). 
Follow-up appointment - the patient was given an appointment for a three month follow-up 
LV clinic review, and provided with details to enable them to contact the clinic by telephone 
if required in the meantime. 
 
2.3.3 Three-month follow-up assessment 
At the three-month follow-up visit, the Chief Investigator conducted an LV clinic review, this 
included: 
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History and symptoms – any new symptoms were noted, along with any new difficulties 
experienced with daily tasks.  Patients were questioned as to how useful they had found 
the loaned LVAs, the tasks that they were used for, and any difficulties they faced with using 
them.  If the patient had been referred to the ECLO following the first visit, the outcome of 
this was discussed and any new equipment provided / purchased was noted. 
Distance / near visual acuity and contrast sensitivity – was reassessed. 
Refraction – was not carried out at the three-month follow-up visit unless required. 
Assessment of distance and near visual acuity with current low vision aids – assessment of 
the patients near acuity, fluency and handling technique with the current near optical LVAs.  
Demonstration of stronger / weaker or alternative types of aid was provided if necessary, 
along with further training and advice on handling techniques. 
Further information on non-optical aids was issued if required.  For those patients who had 
not previously been assessed by the ECLO but now needed this service, a referral was 
made.  
Questionnaires: – the two questionnaires (LVQOL and EQ-5D-5L) were administered as 
before (see Section 2.3.2). 
Follow-up appointment – the patient was given an appointment for the six-month follow-up 
low vision clinic review. 
 
2.3.4 Six-month follow-up assessment 
At the six-month follow-up visit, the Chief Investigator provided an LV clinic review as per 
the three-month follow-up described in Section 2.3.3.  After completing both questionnaires 
at the six-month review, the patient was informed that they had completed all requirements 
for the study.   
If no further appointments were required in the LV clinic, participants were then discharged 
from the clinic and given advice regarding the need for regular eye examination with their 
community optometrist.  Patients were also advised to contact their own optometrist or GP 
should they develop any new symptoms, and on how to access LV clinic services in the 
future. 
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For those patients where a further routine appointment was required for the LVA and / or 
ophthalmology clinics, this was arranged. 
 
2.3.5 Drop outs 
One patient (023) was discharged from the LV clinic following the three-month follow-up 
assessment as they did not require a six-month assessment.  In this case, the patient 
consented to the chief investigator collecting questionnaire data by telephone at the six-
month time point. 
Four other participants (009, 010, 011 and 020) attended for six-month LV clinic follow-up 
as planned but were seen by an optometrist other than the Chief Investigator as 
appointments had been rearranged previously.  In these cases, the Chief Investigator 
obtained all questionnaire data by telephone. 
Participant 036 completed the initial and three-month clinic visits and questionnaires but 
was unable to attend the six-month review, necessitating completion of the questionnaires 
by telephone.   
Participant 038 attended the initial and six-month visit, but was unable to attend the three-
month visit due to poor health and was unable to answer questionnaires by telephone during 
this period. 
 
2.4 Ethics 
The primary ethical issues raised by the scientific design of this protocol were 
randomization, psychological risks, testing vulnerable patients, statistical validity and data 
protection. 
 
Although QoL questionnaires do not involve any physical risk to the patient, they do involve 
a risk of psychological harm due to the sensitive nature of some questions.  This risk was 
minimised wherever possible and patients were able to leave the study at any time if they 
were experiencing any negative psychological reaction.  There was also a risk of breaching 
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patient privacy and confidentiality in relation to the information contained within the 
questionnaires.  This risk was minimised by seeking patient consent prior to participation to 
allow data to be analysed, along with the secure storage of collected data and 
anonymisation. 
Patients were informed when consent was taken to expect no benefit from participating in 
this study.  The results of this study may therefore only be beneficial to future patients 
attending for LVS. 
To manage appropriately the ethical complexities inherent in this study, it was necessary to 
put the following additional protections of the research participants in place: informed 
continued consent, anonymisation and data security.  By instituting these additional 
protections, the risks were appropriately minimised and a reasonable and ethically 
acceptable balance between risks and benefits was established.   
Prior to the commencement of the study, ethical approval was obtained from Aston 
University Audiology / Optometry Research Ethics Committee on 13th January 2010.  
Approval was also gained from the NHS Cambridgeshire 3 Research Ethics Committee 
(now known as NRES Committee East of England - Norfolk) on 24th May 2011 (reference 
11/H0306/1), along with the local ethics committee of MKUH on 24th June 2011 (Appendix 
2.7). 
 
2.5 Statistical Analysis 
2.5.1 Testing for normal distribution of data 
The first stage of the statistical analysis was to examine the frequency distribution of the 
sample data at each visit.  Visits were designated as: the initial visit (T0), the three-month 
visit (T3) and the six-month visit (T6).  The frequency distributions of the data were 
compared with the normal distribution using the Shapiro-Wilk Test (p<0.05), appropriate for 
small sample sizes (n = 40). 
Where data were normally distributed, parametric statistical methods were used.  Where 
data were not normally distributed, attempts were made to transform the data using the 
square-root and logarithmic methods to enable a multifactorial analysis.  Where these did 
not produce normal distributions through transformation, non-parametric statistical methods 
were used. 
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2.5.2 Determination of differences in visual acuity and questionnaire score among visits 
Two types of omnibus test were used to determine whether statistically significant 
differences existed among sample visual acuity measures and questionnaire scores for 
each visit.  For normally distributed data a repeated-measures analysis of variance 
(RMANOVA) test was used.  RMANOVA considers the error variation of the comparisons 
among results for the same patients over the three time intervals simultaneously (i.e. it takes 
into account the error at T3 when comparing T0 to T6). 
There are five assumptions of this test: 
1. One dependent variable measured at the continuous (interval or ratio) level. 
2. One within-patients factor (independent-variable) that comprises three or more 
categorical levels. 
3. There should be no significant outliers in the within-patient factors. 
4. The distribution of the dependent variable in the within-patient factors should be 
approximately normally distributed. 
5. The variances of the differences between all combinations of levels of the within-
patients factor must be equal (sphericity). 
The questionnaires in this study use Likert-scales of one to five.  The assumption is made 
that a score of four on this scale is twice as good (or bad) as a score of two.  With this 
assumption, the aggregated score across a number of questions is routinely considered to 
be continuous in psychometric testing (Streiner et al. 2014).  Therefore Assumption 1 is 
valid.  It should be noted however that there is a maximum possible questionnaire score 
and therefore if ‘improvement’ is measured over time, the data will become skewed because 
patients cannot score more than the maximum (e.g. 125 for the LVQOL questionnaire). 
Where significant differences among visits or interactions with patient categorisation effects 
existed (p<0.05), post-hoc testing to determine differences between visit pairs (or patient 
categorisation effects) was carried out using the paired-sample Student t-test. 
Where data were non-normal and it was not possible to transform the data to normal 
distributions by the square-root or logarithmic methods, the non-parametric Friedman’s two-
way analysis of variance by ranks test was used to detect differences in sample visual acuity 
or questionnaire score across the three visits. 
Where significant differences were observed (p<0.05), post-hoc comparison of samples 
between visit pairs was conducted using the Wilcoxon Signed Rank Test or the Paired-
Samples Sign Test.  The Wilcoxon Signed Rank Test is the non-parametric equivalent of 
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the Paired-sample Student t-Test for the determination of median difference between paired 
observations.  This test does not require normal distribution of the data but has three 
assumptions: 
1. One dependent variable measured at the continuous (interval or ratio) level. 
2. One independent variable that comprises two categorical, related groups or 
matched pairs. 
3. The distributions of difference between the two related groups should be 
symmetrical in shape. 
The Paired-Samples Sign Test is a less statistically powerful test than the Wilcoxon Signed 
Rank Test and was used when the distribution of difference between the two related groups 
was not symmetrical (see Assumption 3 of the Wilcoxon Signed Rank Test above).  This 
test has four assumptions: 
1. One dependent variable measured at the continuous (interval or ratio) or ordinal 
level. 
2. One independent variable that comprises two categorical, related groups or 
matched pairs. 
3. The paired observations for each participant need to be independent, i.e. one 
patient cannot influence another patient’s score. 
4. The difference scores are from a continuous distribution. 
A modification of the standard Paired-Samples Sign Test was necessary because there 
were a large number of neutral pairs in the analysis.  These are patients whose visual acuity 
or questionnaire score does not increase (positive difference for LVQOL, negative 
difference for acuity and EQ-5D-5L) from visit to visit (particularly T3 to T6).  The standard 
related-samples Sign Test ignores these neutral pairs and considers only the binomial 
positive or negative probability.  Randles (2001) recommended the use of the more 
conservative Intermediate Preference Sign Test that weights the effect of neutrals using a 
factor of 1/3.  This method was used where the proportion of neutrals was more than 10%. 
2.5.3 Correlation analysis 
Where data were normally distributed, the Pearson Correlation Test (r) was used to 
examine whether correlative relationships existed among different datasets.  For data with 
a non-normal distribution, the Spearman Rank Correlation (rs) was used. 
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2.5.4 Software used 
Statistical analyses were conducted using SPSS version 21 (SPSS Inc, Chicago, Illinois), 
with the exception of the Intermediate Sign Test which was conducted using Microsoft Excel 
2013 (Microsoft Corporation, Redmond, Washington). 
 
  
 82 
3 RESULTS 
3.1 Low Vision Assessments 
3.1.1 Data characterisation 
Patient habitual distance binocular visual acuity (DVA) was normally distributed at each visit 
(Figure 3.1; Shapiro-Wilk, p=0.248 to p=0.287, Table 3.1).  Patient habitual monocular DVA 
was also normally distributed for the right and left eyes (Shapiro-Wilk, p=0.389 to p=0.718 
for all visits). 
 
Figure 3.1 Frequency distribution of binocular distance visual acuity (DVA, logMAR) at the initial (T0, 
n=39), three-month (T3, n=39) and six-month (T6, n=38) visits. 
The frequency distribution of binocular near visual acuity (NVA) was positively skewed and 
non-normal at each visit (Figure 3.2; Shapiro-Wilk, p<0.05, Table 3.1).  A simple square-
root transform rendered the data normally distributed for each visit.  Patient monocular NVA 
was normally distributed for the right and left eyes (Shapiro-Wilk, p=0.151 to p=0.980 for all 
visits). 
Optimum NVA in low vision patients is typically achieved using an LVA.  The maximum NVA 
was determined for each patient using the LVA or LVAs with which they attended the 
appointment; this is referred to as NVA-LVA throughout this thesis.  IN the situation where 
patients attended with multiple LVAs, the best acuity (lowest NVA-LVA) measurement was 
used for analysis.  The NVA-LVA data were strongly positively skewed and non-normal 
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(Figure 3.3; Shapiro-Wilk, p<0.001, Table 3.1).  Neither a square-root or log transform of 
the data resulted in a normal distribution at any visit, principally because the majority of 
patients were achieving an optimum NVA-LVA of 0.19 logMAR when using their LVA.  
Monocular data were not recorded as LVAs tend to be used binocularly or with the patient’s 
best eye. 
 
Figure 3.2 Frequency distribution of binocular near visual acuity (NVA, logMAR) at the initial (T0, 
n=39), three-month (T3, n=34) and six-month (T6, n=33) visits. 
 
Figure 3.3 Frequency distribution of binocular near visual acuity with the patient’s low vision aid 
(NVA-LVA, logMAR) at the initial (T0, n=39), three-month (T3, n=38) and six-month (T6, n=37) visits.
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Table 3.1 Comparison of near visual acuity (logMAR) distribution to the normal distribution. 
Visit As measured Square-Root Transform1 Logarithmic Transform2 
 Skewness Normal3 Skewness Normal3 Skewness Normal3 
Distance Visual Acuity 
T0 0.757 p=0.287 
n/a n/a T3 0.715 p=0.248 
T6 0.577 p=0.273 
Near Visual Acuity 
T0 1.046 p=0.019 0.420 p=0.202 
n/a T3 0.609 p=0.048 0.057 p=0.079 
T6 0.897 p=0.015 0.387 p=0.080 
Near Visual Acuity with Low Vision Aid 
T0 2.210 p<0.001 1.656 p<0.001 1.114 p<0.001 
T3 4.777 p<0.001 4.376 p<0.001 3.826 p<0.001 
T6 4.611 p<0.001 4.302 p<0.001 3.996 p<0.001 
Notes: 
1. Square root transformation for positively skewed data. 
2. Log10 transformation for positively skewed data. 
3. The Shapiro-Wilk test was used to determine whether the distribution of measured data was significantly different from 
the normal distribution (p<0.05). 
 
3.1.2 Analysis of distance visual acuity 
Mean presenting binocular distance visual acuity (DVA) is shown in Figure 3.4.  A repeated-
measures analysis of variance revealed that there was no significant change in DVA among 
the three visits (Greenhouse-Geisser correction, p=0.335).  Monocularly, the same no 
significant change over time was observed (Greenhouse-Geisser correction, RE p=0.505, 
LE p=0.190). 
Within the patient sample (n=40) there were 20 patients who were attending an LV clinic for 
the first time (‘new patients’) and 20 patients who had previously attended an LV clinic 
(‘existing patients’).  This sub categorisation of patients was included as a factor in a two-
way RMANOVA.  There was no significant interaction between the visit term and the 
classification of the patient as ‘new’ or ‘existing’ (p=0.388).  This means that irrespective of 
whether or not the patient was new to the clinic, their binocular DVA did not improve or 
worsen significantly during the six-month experimental period.  There was no significant 
interaction between the new and existing patient term for monocular DVA (either eye) in a 
two-way RMANOVA (RE p=0.877, LE p=0.749). 
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3.1.3 Analysis of near visual acuity 
Mean presenting binocular near visual acuity is shown in Figure 3.4.  RMANOVA of the 
square-root transformed data determined that there was no significant change in NVA 
among the three visits (Greenhouse-Geisser correction, p=0.701).  As with distance acuity, 
there was no significant interaction between the visit term and the classification of the 
patient as ‘new’ or ‘existing’ (p=0.116). 
 
Figure 3.4 Mean presenting binocular visual acuity (for distance and near) at the initial (T0), three-
month (T3) and six-month (T6) visits. Error bars represent the standard error of the mean. 
 
Monocularly, the same no significant change over time was observed (Greenhouse-Geisser 
correction, RE p=0.728, LE p=0.732).  There was no significant interaction between the new 
and existing patient term for either eye in a two-way RMANOVA (RE p=0.798, LE p=0.263). 
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Figure 3.5 Comparison of binocular near visual acuity with a low vision aid (NVA-LVA, logMAR) for 
each patient, between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and the six-
month (T6) visits. The marker area is proportional to the number of patients with visual acuities at 
the centre of the marker, which are also labelled (markers with no label represent single-patient 
acuity measurements). The dashed line represents the line of equal acuity measurements at each 
visit (i.e. the 'line of no effect'). 
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3.1.4 Analysis of near visual acuity using a low vision aid 
Figure 3.5a shows that just under half of the 37 patients had the same NVA-LVA at T0 and 
T3 (18/37 patients on the line of no effect), a few deteriorated slightly (three patients above 
the line) but some improved dramatically (16 patients below the line).  Figure 3.5b shows 
that between T0 and T6 more patients were below the line of no effect (18/36) than on 
(16/36), or above (2/36); this indicates a greater improvement between T0 and T6 than 
between T0 and T3.  Measurement of NVA-LVA at T0 was prior to any improvements made 
during the clinic and therefore represents the best NVA-LVA influencing the patient’s QoL 
prior to assessment by questionnaire.  These data were not normally distributed (Shapiro-
Wilk p<0.001, Table 3.1) and therefore non-parametric statistical methods were used for 
analysis.  Median (± interquartile range) NVA-LVA increased from 0.27 ± 0.20 logMAR at 
T0 to 0.19 ± 0.00 logMAR at T3 and T6.  The Friedman’s two-way ANOVA by ranks test 
demonstrated that there was a significant difference in NVA-LVA among visits (p<0.001).   
The related-samples Sign Test was used post-hoc to determine whether there was a 
significant difference in the median differences in NVA-LVA between sample pairs at T0, 
T3 and T6 (i.e. T0-T3, T3-T6 and T0-T6).  Table 3.2 shows that the number of neutral pairs 
(NVA-LVA acuities that do not change from T0 to T3, or from T0 to T6, or T3 to T6) is a high 
proportion of the data for all three comparisons.  The Intermediate Sign Test showed that 
there was a statistically significant median decrease of 0.08 logMAR between T0 and T6 
(p=0.011), but no significant difference in T0-T3 or T3-T6. 
Table 3.2 Number of positive, negative and neutral differences in near visual acuity with low vision 
aid, between visit pairs.  Positive differences are an increase in logMAR (i.e. a decline in acuity) 
between two visits; negative differences are a decrease in logMAR (i.e. an improvement in acuity) 
between two visits; and neutral differences are ties (i.e zero change in acuity). 
 Comparison between visit pairs 
Difference T0-T3 T3-T6 T0-T6 
Positive 3 2 2 
Negative 16 6 18 
Neutral (ties) 18 27 16 
Total 37 35 36 
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Table 3.3 Number of positive, negative and neutral differences in near visual acuity with low vision 
aid, between visit pairs for existing and new patients. Positive differences are an increase in logMAR 
(i.e. a decline in acuity) between two visits; negative differences are a decrease in logMAR (i.e. an 
improvement in acuity) between two visits; and neutral differences are ties (i.e zero change in acuity). 
 Comparison between visit pairs 
Difference T0-T3 T3-T6 T0-T6 
 Existing Patients 
Positive 2 2 2 
Negative 3 3 5 
Neutral (ties) 12 13 12 
Total 17 18 19 
 New Patients 
Positive 1 0 0 
Negative 13 3 13 
Neutral (ties) 6 14 4 
Total 20 17 17 
The analysis was repeated using subsets of the data based on whether the patient was new 
or existing (Table 3.3; Figure 3.6).  Median (± interquartile range) NVA-LVA for existing 
patients was 0.19 logMAR at T0 (± 0.08 logMAR), T3 (± 0.00 logMAR) and T6 (± 0.02 
logMAR).  Figure 3.6 shows that the range in NVA-LVA was smaller for existing patients 
than new patients, reflecting the increased use of magnifiers among the existing patient 
group prior to T0.  For new patients, median NVA-LVA increased from 0.40 ± 0.32 logMAR 
at T0 to 0.19 logMAR at T3 (±0.02 logMAR) and T6 (±0.00 logMAR).  A Friedman’s two-
way ANOVA by ranks test revealed that there were no significant differences among the 
NVA-LVA results for existing patients at the three visits (T0 to T6; p=0.368).  For new 
patients, there was a significant (Intermediate Sign Test) median decrease of 0.10 logMAR 
between T0 and T3 (p=0.005) and 0.20 logMAR between T0 and T6 (p=0.001).  Intervention 
by LVS between T0 and T3 resulted in an improvement in NVA-LVA in new patients.   
 
 89 
 
Figure 3.6 Comparison of binocular near visual acuity with a low vision aid (NVA-LVA) in logMAR for 
each payient, between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and the six-
month (T6) visits.  The marker colour differentiates between existing patients (black, solid) and new 
patients (red, dashed). The marker area is proportional to the number of patients with visual acuities 
at the centre of the marker, which are also labelled (markers with no label represent single-patient 
acuity measurements). The black dashed line represents the line of equal acuity measurements at 
each visit (i.e. the 'line of no effect'). 
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Figure 3.7 Comparison of binocular log contrast sensitivity for each patient, between: (a) the initial 
(T0) and three-month (T3) visits; (b) the initial (T0) and the six-month (T6) visits. The marker area is 
proportional to the number of patients with contrast sensitivity at the centre of the marker, which are 
also labelled (markers with no label represent single-patient measurements). The dashed line 
represents the line of equal measurements at each visit (i.e. the 'line of no effect'). 
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3.1.5 Contrast sensitivity 
Binocular distance contrast sensitivity was negatively skewed and not normally distributed 
for any visit (Shapiro-Wilk, p=0.004 to p=0.014).  Figure 3.7 shows that the majority of 
patients are close to the line of no effect, i.e. patients with a high contrast sensitivity at T0, 
maintain a high contrast sensitivity at T3 and T6 (and vice-versa).  Median (± interquartile 
range) log contrast sensitivity was 1.20 ± 0.30 at T0 and T3, and reduced to 1.05 ± 0.45 at 
T6.  A related-samples Friedman’s two-way ANOVA by ranks test revealed that there were 
no significant differences among the contrast sensitivity results for all three visits (T0 to T6; 
p=0.216). 
There was no correlation between contrast sensitivity and DVA, NVA, or NVA-LVA visual 
acuity at the first (T0) and second (T3) visits (Spearman Rank Correlation, p>0.05 in all 
cases).  At the six-month visit (T6), however, there were small but significant negative 
correlations between contrast sensitivity and both DVA (rs=-0.437, p=0.011) and NVA-LVA 
(rs=-0.444, p=0.012).  The negative correlations observed at T6 are intuitive: as contrast 
sensitivity increases the visual acuity improves (logMAR decreases).  Lord et al. (1991) 
found that in patients with a mean age of 83 years (similar to the 81.4 mean age for this 
study), both high and low contrast measures of visual acuity were correlated to Melbourne 
Edge Test contrast sensitivity measurements. 
 
3.2 Low Vision Quality of Life Questionnaire 
3.2.1 Data characterisation 
At the initial visit (T0), the total LVQOL questionnaire score was normally distributed (Figure 
3.8; Shapiro-Wilk, p=0.102, Table 3.4).  At subsequent visits (T3 & T6), the total LVQOL 
score was not normally distributed (Shapiro-Wilk, p>0.05) and was negatively skewed 
(Figure 3.8, Table 3.4), which is indicative of an improvement in QoL.  As it was not possible 
to transform the data (Table 3.4) non-parametric testing methods were employed. 
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Figure 3.8 Frequency distribution of total Low Vision Quality of Life (LVQOL) score at the initial (T0), 
three-month (T3) and six-month (T6) visits. 
Table 3.4 Comparison of total Low Vision Quality of Life (LVQOL) questionnaire score distribution to 
the normal distribution. 
Visit As measured Square-Root Transform1 Logarithmic Transform2 
 Skewness Normal3 Skewness Normal3 Skewness Normal3 
T0 -0.121 p=0.102 -0.558 p=0.045 -1.542 p<0.0005 
T3 -0.405 p=0.013 -0.185 p=0.024 -0.381 p<0.0005 
T6 -0.417 p=0.018 -0.261 p=0.018 -0.952 p<0.0005 
Notes: 
1. Reflect and square root transformation for negatively skewed data. 
2. Reflect and log10 transformation for negatively skewed data. 
3. The Shapiro-Wilk test was used to determine whether the distribution of measured data was significantly different from 
the normal distribution (p<0.05). 
 
3.2.2 Analysis of total (overall) score 
There was an increase in total (/125) LVQOL score for 26 of the 39 study patients between 
T0 and T3 (Figure 3.9a), with a reduced score for 10 patients and no change in score for 
three patients.  This increased to 31 out of 40 patients with an increased total LVQOL score 
between T0 and T6 (Figure 3.9b), with a reduced score for eight patients and no change for 
one patient. 
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Figure 3.9 Comparison of total Low Vision Quality of Life (LVQOL) questionnaire scores for each 
patient between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and the six-month 
(T6) visits. The marker area is proportional to the number of patients with total LVQOL score at the 
centre of the marker, which are also labelled (markers with no label represent single-patient 
measurements). The dashed line represents the line of equal scores at each visit (i.e. the ‘line of no 
effect’).  
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The individual data points in each panel show the results for individual participants, while 
the diagonal line in each panel is the ‘line of no effect’ (i.e. equal score for both visits).  Note 
that the data lie predominantly above the diagonal in Figure 3.9a and Figure 3.9b, indicating 
that individual patient scores increase from T0 to T3 and from T0 to T6. 
Friedman’s two-way ANOVA by ranks revealed a significant difference in the distribution of 
LVQOL data among visits T0, T3 and T6 (p<0.001).  Initially, the Related-Samples Wilcoxon 
Signed Rank Test was used to determine whether the median total LVQOL score was 
significantly different between paired samples at T0-T3, T3-T6 and T0-T6.  Post-hoc 
examination of the differences between pairs revealed that these differences were not 
symmetrical and therefore Assumption 3 of the Wilcoxon Signed Rank Test (see Section 
2.5.2) was not valid and the Paired-Samples Sign Test was used. 
Median (± interquartile range) total LVQOL score increased from T0 (87.0 ± 39.0) to T3 
(96.0 ± 44.0), a significant median increase of 6.0 (p=0.012).  Between T3 and T6, median 
(± interquartile range) total LVQOL score increased from 96.0 ± 44.0 to 99.5 ± 34.0, with a 
significant median increase of 2.0 (p=0.007).  There was an increase in total LVQOL score 
for 26 patients, a decrease for nine patients and no change for four patients.  There was no 
significant change in distance and near visual acuity (either with or without LVAs) during 
this same period. 
The cumulative effect of interventions at T0 and other factors between T0 and T6 caused 
median (± interquartile range) total LVQOL score to increase from T0 (87.0 ± 39.0) to T6 
(99.5 ± 34.0), a significant median increase of 8.0 (p<0.001). 
 
3.2.3 Comparison of existing and new patient scores 
An effect of whether or not the patient is new to the clinic has already been observed in the 
visual acuity data (Section 3.1.4), and this factor was explored further in the LVQOL data.  
A mixed RMANOVA model was used to examine whether or not LVQOL scores for new 
patients were significantly different from those for existing patients.  The assumptions of the 
two-way RMANOVA model were tested and were valid in all but one case (existing patients 
at T3; Shapiro-Wilk, p=0.041). 
While there was a significant interaction between the new / existing patient grouping and 
time (T0, T3, T6) on total LVQOL score (p=0.001; Table 3.5), post-hoc analyses using the 
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Student t-test determined that there was no statistically significant difference in total LVQOL 
score between new and existing patients at T0 (p=0.103), T3 (p=0.363) and T6 (p=0.923). 
For existing patients, there was a significant difference in total LVQOL scores between T0 
and T3 (p=0.031) and between T0 and T6 (p=0.006), but not between T3 and T6 (p=0.251).  
For new patients, a significant difference was observed between T0 and T3 (p=0.003), T3 
and T6 (p=0.048) and T0 and T6 (p<0.001).   
There was a significant increase in mean total LVQOL score (6.8) for existing patients over 
the first three months but no significant difference after that.  In new patients, a significant 
increase in mean total LVQOL score (13.9) occurred after three months, followed by a 
further significant increase of 8.2 between T3 and T6 (Table 3.5). 
Table 3.5 Summary of mean (± standard deviation) total Low Vision Quality of Life (LVQOL) 
questionnaire score for existing and new patients at each visit (T0, T3, T6). 
LVQOL 
score 
Maximum 
Possible 
Score 
Initial visit 
(T0) 
Three-month visit 
(T3) 
Six-month visit 
(T6) 
Existing New Existing New Existing New 
n  20 20 19 20 20 20 
Total 125 90.3 ± 22.96a 
75.4 ± 
26.16α 
97.1 ± 
23.29b 
89.9 ± 
25.78β 
99.4 ± 
21.50b 
98.1 ± 
19.34γ 
Note: superscript letters indicate significantly different sample means as determined by the Student t-test 
(p<0.05). Because there was no significant difference in total LVQOL score between new and existing patients 
at T0, T3 or T6 (p≥0.05), comparisons should not be made between groups with Latin and Greek alphabets. 
 
3.2.4 The impact of living alone 
Mean total LVQOL score at any particular visit (T0, T3, T6) for patients living alone (n=20) 
was normally distributed (Shapiro-Wilk, p>0.05) and was not significantly different from 
patients living with a partner / family (n=19; RMANOVA p=0.999, Table 3.6).  The 
distributions of both the T3 and T6 LVQOL scores for patients not living alone were non-
normal (Shapiro-Wilk, p=0.010 and p=0.043 respectively).  The reflect and square-root 
transform was applied but the outcome of the RMANOVA was similar; there was no 
significant interaction between patients living alone or patients living with a partner / family 
(p=0.571).  In brief, whether or not the patient lived alone was not significant in determining 
total LVQOL score at any visit. 
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Table 3.6 Summary of mean (± standard error) total Low Vision Quality of Life (LVQOL) questionnaire 
score for patients that live alone and not alone at each visit (T0, T3, T6). 
LVQOL 
score 
Maximum 
Possible 
Score 
Initial visit 
(T0) 
Three-month visit 
(T3) 
Six-month visit 
(T6) 
Alone Not Alone Alone Not Alone Alone Not Alone 
n  20 20 19 20 20 20 
Total 125 82.5 ± 5.86 
85.4 ± 
6.01 
92.9 ± 
5.59 
95.8 ± 
5.73 
98.1 ± 
4.60 
100.8 ± 
4.72 
 
3.2.5 Analysis of scores by questionnaire section 
The LVQOL questionnaire can be split into four sections which relate to different aspects of 
a patient’s life as follows: 
 Section A – Distance Vision, Mobility and Lighting (12 questions, maximum score 
60) 
 Section B – Adjustment (4 questions, maximum score 20) 
 Section C – Reading and Fine Work (5 questions, maximum score 25) 
 Section D – Activities of Daily Living (4 questions, maximum score 20) 
Table 3.7 and Figure 3.10 to Figure 3.13 show that as per the total LVQOL score, the 
distribution of scores in each section, at each visit, was non-normal (Shapiro-Wilk, p<0.05; 
except for Section A at T0, p=0.112) and negatively skewed (except for Section C at T0).   
Table 3.7 Comparison of Low Vision Quality of Life (LVQOL) section score distribution to the normal 
distribution. 
Visit Section Shapiro-Wilk Skewness 
T0 A p=0.112 -0.286 
 B p=0.002 -0.577 
 C p=0.019 0.118 
 D p=0.004 -0.237 
T3 A p=0.006 -0.256 
 B p<0.001 -1.290 
 C p=0.001 -0.706 
 D p=0.003 -0.424 
T6 A p=0.006 -0.405 
 B p<0.001 -1.261 
 C p<0.001 -1.166 
 D p=0.001 -0.681 
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Figure 3.10 Frequency distribution of Low Vision Quality of Life (LVQOL) score for Section A at the 
initial (T0), three-month (T3) and six-month (T6) visits. 
 
 
Figure 3.11 Frequency distribution of Low Vision Quality of Life (LVQOL) score for Section B at the 
initial (T0), three-month (T3) and six-month (T6) visits. 
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Figure 3.12 Frequency distribution of Low Vision Quality of Life (LVQOL) score for Section C at the 
initial (T0), three-month (T3) and six-month (T6) visits. 
 
 
Figure 3.13 Frequency distribution of Low Vision Quality of Life (LVQOL) score for Section D at the 
initial (T0), three-month (T3) and six-month (T6) visits. 
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Table 3.8 shows the median (± interquartile range) LVQOL score for each section (A to D) 
and the total score at T0, T3 and T6.  A Friedman’s two-way ANOVA by ranks test 
determined that there were significant differences in LVQOL scores among the three visits 
in each section (A-C: p<0.001, D: p=0.049).  The Intermediate Sign Test was used post-
hoc to determine significant median differences in LVQOL score between visit pairs within 
each section (Table 3.9).   
Table 3.8 Summary of median (± interquartile range) Low Vision Quality of Life (LVQOL) 
questionnaire score for each section (A – distance vision, mobility and lighting, B – adjustment, C – 
reading and fine work and D – activities of daily living) and in total at each visit (T0, T3, T6). 
Section Maximum 
Possible Score 
Initial visit 
(T0) 
Three-month visit 
(T3) 
Six-month visit 
(T6) 
n  40 39 40 
A 60 42.0 ± 21.0a 45.0 ± 23.0b 48.0 ± 19.0c 
B 20 16.0 ± 7.0a 18.0 ± 4.0b 19.0 ± 2.0c 
C 25 14.0 ± 12.0a 19.0 ± 10.0b 19.0 ± 7.0b 
D 20 14.0 ± 10.0a 15.0 ± 8.0a 16.0 ± 8.0a 
Total 125 85.0 ± 39.0a 96.0 ± 44.0b 99.0 ± 34.0c 
Note: superscript letters indicate where there is a significant (p<0.05) median increase or decrease between 
LVQOL score among visits (T0, T3, T6) within each category as determined by the Intermediate Sign Test 
(Randles, 2001).  Comparisons among section scores are not valid in this analysis, i.e. a median denoted a, in 
Section A should not be compared with a median denoted b in Section C. 
 
Table 3.9 Intermediate Sign Test probability values when comparing between the initial visit (T0), the 
three-month visit (T3) and the six-month visit (T6). 
Section All Patients Existing Patients New Patients 
T0-T3 T3-T6 T0-T6 T0-T3 T3-T6 T0-T6 T0-T3 T3-T6 T0-T6 
A 0.002 0.008 <0.001 0.194 0.048 0.008 0.001 0.043 <0.001 
B 0.062 0.038 0.001 0.537 0.153 0.059 0.016 0.069 0.004 
C 0.006 0.568 <0.001 0.128 0.402 0.043 0.008 0.685 0.001 
D 0.094 0.851 0.116 0.270 0.856 0.500 0.104 0.655 0.050 
Figure 3.14 shows individual patient LVQOL section A scores at T0 plotted against LVQOL 
section A scores at T3 (a) and T6 (b).  Note that in panel (a) results are clustered around 
the line of no effect, while in panel (b) the data are predominantly above the line of no effect 
indicating that there is a greater improvement in Section A scores between T0 and T6 than 
between T0 and T3.  A similar pattern is observed in Section B (Figure 3.15).  In both 
sections A and B (Table 3.8), median scores increased significantly at each visit 
(Intermediate Sign Test, p<0.05).   
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Figure 3.14 Comparison of Low Vision Quality of Life (LVQOL) score in Section A (distance vision, 
mobility and lighting) for each patient, between: (a) the initial (T0) and three-month (T3) visits; (b) the 
initial (T0) and the six-month (T6) visits. The marker area is proportional to the number of patients 
with scores at the centre of the marker, which are also labelled (markers with no label represent 
single-patient measurements). The dashed line represents the line of equal score at each visit (i.e. 
the 'line of no effect'). 
 
Figure 3.15 Comparison of Low Vision Quality of Life (LVQOL) score in Section B (adjustment) for 
each patient, between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and the six-
month (T6) visits. The marker area is proportional to the number of patients with scores at the centre 
of the marker, which are also labelled (markers with no label represent single-patient 
measurements). The dashed line represents the line of equal score at each visit (i.e. the 'line of no 
effect'). 
Figure 3.16 shows that in Section C, individual patient LVQOL scores are greater at T3 than 
T0 (panel a) but that scores do not appear to move further above the line of no effect at T6 
(panel b).  In Section C (Figure 3.16, Table 3.8, Table 3.9), there was a significant increase 
in median LVQOL score between T0 and T3 (p=0.006) but no further significant difference 
between visit T3 and T6 (p=0.568).  In Section D (Figure 3.17, Table 3.8, Table 3.9), there 
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was no significant difference in median score among the three visits (p≥0.05) and this is 
shown in Figure 3.17 where data are distributed either side of the line of no effect. 
 
 
Figure 3.16 Comparison of Low Vision Quality of Life (LVQOL) score in Section C (reading and fine 
work) for each patient, between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and 
the six-month (T6) visits. The marker area is proportional to the number of patients with scores at 
the centre of the marker, which are also labelled (markers with no label represent single-patient 
measurements). The dashed line represents the line of equal score at each visit (i.e. the 'line of no 
effect'). 
 
Figure 3.17 Comparison of Low Vision Quality of Life (LVQOL) score in Section D (activities of daily 
living) for each patient, between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and 
the six-month (T6) visits. The marker area is proportional to the number of patients with scores at 
the centre of the marker, which are also labelled (markers with no label represent single-patient 
measurements). The dashed line represents the line of equal score at each visit (i.e. the 'line of no 
effect'). 
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3.3 EuroQol Five-Dimension, Five-Level (EQ-5D-5L) Questionnaire 
3.3.1 Data characterisation 
Figure 3.18 shows that the total EuroQol five-dimension, five-level (EQ-5D-5L) score was 
positively skewed and non-normally distributed at T0, T3 and T6 (Figure 3.18, Table 3.10), 
indicating a bias towards lower scores (greater general-health related QoL). 
 
Figure 3.18 Frequency distribution of total EuroQol five-dimension, five-level (EQ-5D-5L) score at 
the initial (T0), three-month (T3) and six-month (T6) visits. 
Table 3.10 Comparison of total EuroQol five-dimension, five-level (EQ-5D-5L) score distribution to 
the normal distribution. 
Visit As measured Square-Root Transform1 Logarithmic Transform2 
 Skewness Normal3 Skewness Normal3 Skewness Normal3 
T0 0.346 p=0.013 0.103 p=0.015 -0.120 p=0.009 
T3 0.722 p<0.001 0.526 p=0.001 0.343 p=0.001 
T6 0.711 p<0.001 0.508 p=0.001 0.319 p=0.001 
Notes: 
1. Square root transformation for positively skewed data. 
2. Log10 transformation for positively skewed data. 
3. The Shapiro-Wilk test was used to determine whether the distribution of measured data was significantly different from 
the normal distribution (p<0.05). 
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3.3.2 Analysis of total (overall) score 
There was a decrease (improvement) in total (minimum 5 to maximum 25) EQ-5D-5L score 
for 18 of the 40 study patients between T0 and T3 (Figure 3.19a), and for 23 of the 40 
patients between T0 and T6 (Figure 3.19b). 
Median (± interquartile range) total EQ-5D-5L score decreased from T0 (9 ± 6) to T3 (7 ± 
5).  Of the 39 patients analysed, there was a decrease in EQ-5D-5L score at T3 for 18 
patients, an increase for six patients, however 15 (37.5%) patients showed no change in 
score.  The Intermediate Sign Test revealed that the median difference between scores at 
T0 and T3 was zero and not significant (p=0.084).  A similar effect was observed between 
T3 and T6 where median EQ-5D-5L score increased from 7 ± 5 to 8 ± 4 (15 patients reduced 
their score, 8 patients increased their score and there were 16 ties), but there was not a 
significant median difference (p=0.369).  Median EQ-5D-5L score decreased from T0 (9 ± 
6) to T6 (8 ± 4), (23 decreased score, 5 increased score and 12 tied), a median difference 
that was significant (Intermediate Sign Test, p=0.005). 
Analysis investigated whether there was a correlation between total LVQOL score and total 
EQ-5D-5L score.  Figure 3.20 shows that generally as LVQOL score increased, EQ-5D-5L 
score decreased but there was significant variation about this trend.  Over all three visits 
the Spearman’s Rank Correlation coefficient between total LVQOL score and total EQ-5D-
5L score (Figure 3.20) was rs=-0.476, p<0.001.  Correlation coefficients at each visit were: 
rs=-0.563, p<0.001 (T0); rs=-0.496, p=0.001 (T3); and rs = -0.312, p=0.050 (T6). 
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Figure 3.19 Comparison of total EuroQol five-dimension, five-level (EQ-5D-5L)score for each patient, 
between: (a) the initial (T0) and three-month (T3) visits; (b) the initial (T0) and the six-month (T6) 
visits. The marker area is proportional to the number of patients with scores at the centre of the 
marker, which are also labelled (markers with no label represent single-patient measurements). The 
dashed line represents the line of equal score at each visit (i.e. the 'line of no effect'). 
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Figure 3.20 Plot of total Low Vision Quality of Life (LVQOL) score (/125) against total EuroQol five-
dimension, five-level (EQ-5D-5L) general health-related quality of life score (/25) at the (a) initial (T0), 
(b) three-month (T3) and (c) six-month (T6) visits. 
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3.3.3 EuroQol visual analogue scale (EQ-VAS) 
The distributions of the EQ-VAS scores (Figure 3.21) were non-normal (Shapiro-Wilk, 
p<0.05), negatively skewed at each visit and were not significantly different among visits 
(Friedman’s two-way ANOVA by ranks, p=0.662). 
 
Figure 3.21 Frequency distribution of the EuroQol visual analogue scale (EQ-VAS) score at the initial 
(T0), three-month (T3) and six-month (T6) visits. 
 
3.4 Relationship Between Visual Acuity and Quality of Life Questionnaire Scores 
Examination of the Spearman Correlation coefficients in Table 3.11 reveals that there was 
no significant correlation between total EQ-5D-5L score and any measure of visual acuity 
using the Spearman Rank Correlation method, whether overall or at a particular visit.  This 
is evident in the wide spread of data shown in the various panels in the right-hand column 
of Figure 3.22 which shows the relationship between each of the three measurements of 
acuity (DVA, NVA, NVA-LVA) and the QoL questionnaire scores (LVQOL, EQ-5D-5L). 
Total LVQOL score was negatively correlated with measures of visual acuity (Table 3.11).  
Correlation coefficients increased from NVA-LVA (rs=-0.456, p<0.01), to NVA (rs=-0.549, 
p<0.01), to DVA (rs=-0.599, p<0.01).  For each measure of acuity, correlation coefficients 
increased with each visit, except for NVA-LVA where there was no significant correlation at 
T6 (Table 3.11).   
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Table 3.11 Spearman’s rank correlation coefficients (rs) for total Low Vision Quality of Life (LVQOL) 
and total EuroQol five-dimension five-level (EQ-5D-5L) scores against distance visual acuity (DVA), 
near visual acuity (NVA) and near visual acuity with low vision aid (NVA-LVA).  Significant 
correlations are denoted as significant at the p<0.01 level (**) and at the p<0.05 level (*). 
 Spearman’s Rank Correlation Coefficient (rs) 
Visit DVA NVA NVA-LVA 
 LVQOL 
T0    -0.571**(1) -0.500** -0.487** 
T3 -0.608** -0.522** -0.381* 
T6 -0.743** -0.643** -0.298 
All -0.599** -0.549** -0.456** 
 EQ-5D-5L 
T0 0.113 <0.001 0.187 
T3 0.154 0.046 0.007 
T6 0.156 -0.059 -0.004 
All 0.133 -0.001 0.130 
Notes: 
1. Pearson correlation coefficient as these two datasets are normally distributed (Shapiro-Wilk test, p>0.05). 
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Figure 3.22 Total Low Vision Quality of Life (LVQOL) score (left) and total EuroQol five-dimension, 
five-level (EQ-5D-5L) score (right) in relation to distance visual acuity (DVA, top), near visual acuity 
(NVA, middle) and near visual acuity with low vision aid (NVA-LVA bottom). 
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4 DISCUSSION 
4.1 Discussion of Results 
4.1.1 Low vision services and quality of life 
Over a six-month study period, intervention by LVS through the LV Clinic at MKUH had a 
significant positive impact upon patient reported quality of life (QoL).  The median 
(± interquartile range) total LVQOL score increased from 87.0 ± 39.0 at the initial (T0) visit 
to 96.0 ± 44.0 at the three-month (T3) visit (p=0.012), and again to 99.5 ± 34.0 at the six-
month (T6) visit (p=0.007).  On this basis the null hypothesis {H0(A): LVS at MKUH have no 
effect on the QoL of patients with ARMD} is rejected and the alternative hypothesis {H1(A): 
LVS at MKUH improve the QoL of patients with ARMD} is accepted. 
Potential mechanisms for this improvement in QoL are an improvement in visual acuity and / 
or the impact of rehabilitation, as these are the two principal outcomes from LVS.  A third 
mechanism is an improvement in wider general health QoL that is related to improvement 
in co-morbidities, and this is discussed further in Section 4.2.  The use of LVAs provided by 
the LV clinic significantly improved NVA, although for the complete dataset (n=40) this 
improvement was only significant over the six month period (T0 to T6, p=0.011).  
Differences between the initial and three-month visits (T0 to T3), and three and six-month 
visits (T3 to T6) were not significant due to the large numbers of neutral pairs where visual 
acuity remained stable.   
Whilst there was a significant increase in median LVQOL score between T3 and T6 
(p=0.007), there was no significant change in DVA, NVA or NVA-LVA during the same 
period.  Therefore the improvement in LVQOL score between T3 and T6 could be a function 
of the rehabilitation mechanism, providing that an improvement in general health-related 
QoL can be excluded. 
The increase in LVQOL score between T0 and T3 is in contrast to Wolffsohn et al. (2000), 
who assessed patients with a range of conditions causing LV and found a reduction 
(although not significant) in QoL scores after three months.  Note that Wolffsohn and 
Cochrane (2000) reported a mean (± SD) total LVQOL score of 60.8 ± 27.8 prior to 
attendance at an LV clinic for the first time and 68.5 ± 28.0 post-attendance (time period not 
reported, n=278).  These scores are significantly lower than those obtained here.  ARMD-
specific mean totals in Wolffsohn et al. (2000) were 65.1 (± 23.1) pre- and 71.7 ± 22.8 post-
rehabilitation.  De Boer et al. (2006) also published LVQOL scores comparing pre- and post-
attendance at LV clinics. However their data were transformed and they did not provide 
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sufficient information to enable conversion back to the 0-125 total score range used in this 
study. 
The current study comprised patients exhibiting different classifications and stages (early 
or late) of ARMD, in either one or both eyes.  These different forms of the disease did not 
impact significantly upon visual acuity (DVA / NVA, binocularly or monocularly) or contrast 
sensitivity measurements over the six-month period.  This may be a reflection of the greater 
number of study patients with geographic atrophy (GA), the slower progressing form of the 
disease (Sunness, 1999).  Binocularly or monocularly, there were 22 patients with GA only 
and 10 patients with exudative ARMD only (Table 2.1).  It was not possible to determine a 
significant difference in QoL scores between patients with GA and exudative ARMD 
because of this imbalance in sub-sample size.  As highlighted by Bennion et al. (2012), 
research that separated the QoL of patients with different types, stages and treatability of 
ARMD would be beneficial.  This also applies to the length of time that a patient has been 
living with ARMD prior to intervention and the rate of vision loss.  To analyse these factors 
fully would require a larger study(ies), with an equal number of patients recruited to each 
sub-type, time to intervention and rate of vision loss. 
Analysis of scores within each of the four sections of the LVQOL questionnaire revealed 
that there were significant differences in median score among the three visits in Section A 
(distance vision, mobility and lighting), Section B (adjustment), and Section C (reading and 
fine work).  The median total LVQOL questionnaire scores for Section A increased 
significantly between T0 and T3 (p=0.002), and between T3 and T6 (p=0.008; Table 3.9).  
As the 12 questions within this section refer to issues surrounding glare, mobility and 
distance vision, rather than near vision, they are less likely to be influenced by LVA provision 
and more likely to be influenced by advice and / or equipment given during the LV clinic 
assessment (e.g. provision of glare shields, advice on repositioning the television).  The 
impact of rehabilitation from external services such as SARC would also be expected to 
improve patient QoL in these areas, particularly if a patient was to receive mobility training 
and therefore regain greater independence outside of the home.  This is illustrated by 
patient testimonials, see Appendix 2.4, but for example: 
 ‘I’ve not been out on my own since October 2013’ (reported April 2014). 
 ‘I go out with my husband – always’. 
 ‘I never go out alone’. 
It is difficult to attribute the continued increase in score for Section A purely to LV 
assessment or rehabilitative services; it is likely to be due to a combination of both. 
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Section B of the LVQOL questionnaire considered the impact of a patient’s adjustment to 
their visual loss.  The median total LVQOL questionnaire scores for this section increased 
significantly between T0 and T6 (p=0.001) and between T3 and T6 (p=0.038), but not 
between T0 and T3 (p=0.062; Table 3.9).  As three of the four questions relate to patient 
frustration, unhappiness and restriction in visiting friends and family, a number of factors 
could be involved in the observed increase in score.  LV clinic assessment allows patients 
the chance to discuss (for perhaps the first time) with a professional, their feelings towards 
the loss of vision though ARMD.  Although patients will have received the diagnosis in a 
previous visit to the consultant or specialist doctor, this may have been unexpected and by 
the time the patient attends for LV assessment they may have many (as yet unanswered) 
questions.  Discussion of the eye condition, reassurance, and referral to the ECLO for 
further emotional support may therefore help the patient adapt to living with their sight loss 
but this adaptation could take longer than three months for some patients.  Furthermore, 
the time between diagnosis and initial LV clinic assessment is of importance, particularly for 
new patients.  This could not be evaluated in the current study as new patients attended for 
the initial visit at various time points following diagnosis, and may have previously attended 
multiple doctor’s clinics beforehand.  Other factors such as poor general health or loss of a 
partner may also impact on the patient’s ability to adapt to their loss of vision, for example 
see patient testimonials in Appendix 2.4, such as: 
 ‘Hearing impairment makes it harder’. 
 ‘My hearing is also an issue’. 
The five questions in Section C (reading and fine work) related to areas that require good 
near visual acuity (e.g. reading letters and mail, reading labels).  Therefore the observation 
that the median total Section C score increased significantly between T0 (14) to T3 (19) 
(p=0.006; Table 3.9) is likely to reflect the issuing of LVA(s) at the initial visit to assist these 
tasks and the significant improvement in NVA-LVA observed during the same period.  This 
increase in acuity between T0 and T3 was the largest proportional increase (20%) between 
two visits over three months for any section.  Wolffsohn and Cochrane (2000) also observed 
the most improved scores within this section of the LVQOL questionnaire.  Together, the 
results from both studies indicate that reading skills / fine work is one area whereby 
significant improvements can be made to patient QoL and daily living skills (e.g. reading 
prices when shopping and maintaining correspondence), from attendance at the LV clinic.  
For example see patient testimonials in Appendix 2.4, such as: 
 ‘’I have no problems if I use a magnifier’. 
 ‘With magnifier it is better’. 
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 ‘The magnifier has made a huge impact on my vision’. 
There was no change in score between the three (19) and six-month (19) visits (p=0.568; 
Table 3.9).  By visit two (T3), the majority of patients had adapted well to the use of LVA(s), 
achieving their maximum possible NVA-LVA and therefore no further impact could be made 
on QoL scores at the third visit (T6). 
Section D (activities of daily living) scores did not change significantly over time (p≥0.05; 
Table 3.9) and questions in this section do not appear to be sensitive to the effects of LV 
clinic input.  There is a greater variation in Section D scores among patients: interquartile 
range among visits is between 8 and 10, c.f. Section B (which also has four questions) with 
interquartile ranges of 2 to 7 (Table 3.8, Figure 3.15 & Figure 3.17).  One reason for these 
observations is that only one of the four questions (reading your own hand writing) is 
assisted by the provision of LVA(s).  While advice is issued to make the remaining three 
tasks easier (finding out the time, writing, and everyday activities), no specific equipment is 
provided by the clinic to complete these activities.  In the author’s experience, although 
advice may be issued on where to purchase large numeric / digital talking watches and 
clocks to assist with determining the time, this has often not been followed when questioned 
at the next clinic visit.  The question relating to household chores is broad and covers a 
wide range of tasks.  When asked this question, some patients reported that family came in 
to do specific tasks (e.g. ironing), whilst others employed a cleaner / gardener.  Within the 
LV clinic, limited advice is given to address any particular problem mentioned by the patient, 
however access to rehabilitation services is an important factor in improving QoL in this 
area.  A rehabilitation assessment within the patient’s home is more likely to focus on 
specific problems, whilst equipment can also be provided or recommended.   
 
4.1.2 Is it possible to identify a subgroup or subgroups of patients with age-related 
macular degeneration that benefit more from low vision services than others? 
Analysis of the total sample of patients is potentially misleading.  New patients had a greater 
increase in mean quality of life score between T0 and T3 (14.5, p=0.003) than existing 
patients (6.8, p=0.031; Table 3.5).  Mean total LVQOL scores for new patients are 12.7 and 
23.3 greater than those in the Wolffsohn and Cochrane (2000) study at T0 and T3, 
respectively.  The difference between new and existing patient scores in this study was 
related to a significant improvement in QoL from the initial prescription of LVAs to new 
patients, which resulted in an improvement in NVA from 0.40 ± 0.32 logMAR at T0 to 0.19 
± 0.02 logMAR at T3 (p=0.005).  In the author’s experience, most new patients attend for 
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the first time with either no form of LVA, or an LVA that is sub-optimal (e.g. one that had 
been inherited from a family member).  Existing patients were already benefitting from 
optimised LVA provision and this was illustrated with no significant change in NVA-LVA 
among T0, T3 and T6 for this subgroup. 
New patients had a significant increase in total LVQOL score from T0 to T3 and from T3 to 
T6.  Existing patients did exhibit significant increases in LVQOL score between T0 and T3 
(p=0.031), and T0 and T6 (p=0.006) but not between T3 and T6 (p=0.251).  The initial (T0-
T3) increase in QoL score for existing patients cannot be attributed to the improvement in 
NVA-LVA mechanism discussed above; i.e. significant increases in LVQOL score between 
T0 and T3 are likely explained by different mechanisms for new patients than for existing 
patients.  Of the 20 existing patients, for 15 patients T0 was only their second visit to the LV 
Clinic.  Therefore for 15/20 existing patients, the increase between T0 and T3 is equivalent 
to the increase observed between T3 and T6 for new patients.  Patients are exhibiting an 
increase in QoL for the first six months but at periods greater than this, there is no statistical 
evidence for an improvement in QoL in this study.  On an individual patient basis however, 
this will depend on the rate of disease progression.  The implications of these findings on 
clinic follow-up times are discussed further in Section 4.1.3. 
Patient recruitment in this study was not specifically designed to achieve an equal 
distribution of new and existing patients.  Further studies could standardise for the length of 
time a patient has spent within LVS, particularly if these studies were carried out over a 
longer period and / or multiple hospitals. 
Although existing patients presented with a higher QoL score at T0 compared with new 
patients, there was no statistically significant difference in LVQOL score between the two 
groups.  Patients who have already attended clinic should have optimised LVAs but are 
living with a debilitating untreatable disease and might have been doing so for a long time.  
Existing patients might not be achieving optimal use from LVAs provided previously, which 
requires correction of technique, a change in LVA type or strength, or motivational support.  
Other factors could be a change in emotional support (e.g. from the death of a partner, and / 
or changes in living circumstances and support networks since the previous LVS 
intervention). 
Whether or not the patient lived alone did not have an impact on total LVQOL score at any 
of the three visits.  This was unexpected based on the author’s subjective experience of 
working within the LV clinic.  Prior to the study it would have been expected that patients 
living alone would have a lower QoL in comparison to those living with somebody else who 
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could support them.  It could be that although a patient lives alone, they may have excellent 
support from friends, family and neighbours.  At each clinic visit, clarification of the level of 
current support is obtained, along with any changes to previous visits.  This is important as 
it allows the clinician to be aware of occasions when signposting to other support services 
may be beneficial.   
The null hypothesis B for this study was:   
H0(B):  All patients with ARMD benefit equally from LVS. 
This hypothesis can be rejected and two alternative hypotheses are proposed:   
H1(B):  New patients’ quality of life improves as the result of the prescription of 
optimised LVAs (or the optimisation of LVA prescription) over the initial six 
months.   
H2(B):  Patients that live alone do not have a reduced quality of life compared with 
patients living with a partner or wider family because of the support received 
in LVS and / or the wider community / friendship circle. 
 
4.1.3 Does inclusion of the EuroQol five-dimension five-level questionnaire improve the 
assessment of quality of life in low vision patients? 
It is well documented that patients who access LVS (particularly the elderly) are often living 
with health-related co-morbidities (van Nispen et al. 2009b) that can affect QoL (Parrish, 
1996).  The EQ-5D-5L questionnaire was included in this study to assess whether patient 
co-morbidities confound low vision-specific assessment of QoL in patients with ARMD.  The 
direct link between improvement in near visual acuity with LVAs and the initial improvement 
in LVQOL between T0 and T3 has been established above.  Change in EQ-5D-5L score 
did not follow this pattern and only decreased significantly between T0 and T6 (p=0.005).  
This longer term decrease indicates a significant improvement in general health-related QoL 
over the period of the study.  The question is whether the improvement in EQ-5D-5L 
assessment of general health-related QoL is a function of the improvement in low vision 
QoL determined by the LVQOL, whether this is coincidental, or whether the EQ-5D-5L is 
insensitive to changes in general health-related quality of life.  It was not possible to test the 
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latter within the scope of this study but the validation work reported in the literature (Janssen 
et al. 2013) would rule this out.   
Table 4.1 Number (and percentage of number of patients questioned) of ties in each time comparison 
for the Low Vision Quality of Life (LVQOL) and the EuroQol five-dimension, five-level (EQ-5D-5L) 
questionnaires. 
Questionnaire T0-T3 (/39) T3-T6 (/39) T0-T6 (/40) 
LVQOL 3 (8%) 4 (10%) 1 (3%) 
EQ-5D-5L 15 (38%) 16 (41%) 12 (30%) 
There is a larger proportion of ties observed in comparisons of the EQ-5D-5L score over 
time than with the LVQOL score (Table 4.1).  This is in part because the EQ-5D-5L score 
only ranges from five to 25, giving 20 possible total scores, compared to the 125 with the 
LVQOL.  It could be assumed that co-morbidities are deteriorating / improving to a lesser 
extent over the same time period; whereas there are direct, measureable improvements in 
visual acuity and vision-related QoL.  It should be noted that to test this assumption would 
require specialist assessment of change in co-morbidities across a range of specialities and 
hospital departments.   
It is unlikely that the improvement in LV related QoL is being damped by a deterioration in 
general health QoL, but it is not possible to determine whether or not improvement in vision-
related QoL is causing any improvement in general health QoL.  Results from this study 
demonstrated a significant (but weak) correlation between the two questionnaires when all 
the data from the three visits are considered (p<0.001).  This weak correlation is observed 
at the initial (p<0.001) and three-month (p=0.001) visits, but is not evident after six months 
(p=0.050).  The weak correlation between the two questionnaires used in this study also 
indicates that general health-related QoL has only a limited effect on total LVQOL score 
and vice-versa.  In previous studies, Wolffsohn et al. (2014) included the EQ-5D (level not 
stated) in the development of their functional ability Quality of Vision (faVIQ) questionnaire 
and found no correlation (p=0.476).   
It is not possible to determine a causal relationship between vision-specific QoL and general 
health-related QoL in this study.  The mean age of patients was 81.4 years, and therefore 
these patients will be at increased risk of other chronic conditions (e.g. diabetes, stroke and 
arthritis which may all cumulatively influence QoL).  This may occur through changes in 
motivation, memory and handling of LVAs (Wolffsohn and Karas, 2004).  At the same time 
intervention by LVS, although shown to improve LVQOL score, will not simultaneously 
improve these conditions.  For example, attendance at the LV clinic will not improve a 
patient’s arthritis or diabetes but will hopefully - from the provision of LVAs - improve vision 
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and a general feeling of well-being.  In the case of arthritis, handling of the LVA may also 
be an issue and exacerbate the condition if an unsuitable aid is prescribed, and so on an 
individual patient basis the assessment and understanding of patient specific co-morbidities 
and their impact on QoL is important for individual QoL outcomes.  It is not possible to 
isolate the effect of these co-morbidities using the EQ-5D-5L questionnaire alone.  Other 
specific questionnaires such as the Stroke-Specific Quality of Life Scale (Williams et al. 
1999) would need to be used, however due to the complex nature of co-morbidities in the 
elderly, many different questionnaires would be required and therefore this would not be 
practical in the LV clinic setting.  The EQ-5D-5L questionnaire does include a question on 
depression and the levels of depression in visually impaired patients has been reported as 
comparable to those of patients with other chronic conditions such as stroke, cancer and 
diabetes (Tabrett and Latham, 2009).  Depression is not addressed directly in the LVQOL 
and so there is a particular role for a depression-specific questionnaire. 
The questionnaire assessment method could also be a confounding factor.  It is not known 
how well patients with low vision can discriminate vision- and health-related QoL when 
being asked questions in the LV clinic setting.  In other words, does discussion of the impact 
of their low vision at the same time as administering the EQ-5D-5L have a bearing on their 
perception of their health-related QoL? 
This study demonstrates that the EQ-5D-5L is not sensitive enough to be used as a 
standalone questionnaire within the LV clinic in the assessment of patient QoL over a six 
month period, and therefore would not be useful (on its own) in the process of planning 
future LVS.  For this reason, the null hypothesis H0(C) is not rejected. 
H0(C): The EQ-5D-5L general-health questionnaire has insufficient sensitivity to 
determine whether or not LVS at MKUH improves QoL in ARMD patients. 
Furthermore, this study has shown that, without a detailed analysis of the complex co-
morbidities of a patient sample with a mean age of 81.4 years, the inclusion of the EQ-5D-
5L questionnaire does not contribute to the assessment of QoL in the LVS context over a 
six-month period.  This is in agreement with Binns et al. (2012), who concluded that in a 
high proportion of studies undergoing review, rehabilitation by LVS had no impact on health-
related QoL.  Whether or not the EQ-5D-5L would contribute to a longer term study (e.g. 
over five years) has not been assessed. 
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4.2 The Improvement of Low Vision Services within the Hospital Eye Service 
4.2.1 Direct implications for the optimisation of low vision service delivery at Milton 
Keynes University Hospital and the wider Hospital Eye Service 
Milton Keynes has the fastest growing and fastest ageing population in the country 
(Snelson, 2012).  Because ARMD is a function of ageing, the predicted 45% increase of the 
over 65 years age group between 2012 and 2020 living within Milton Keynes (Snelson, 
2012) is set to burden ophthalmology services within the hospital.  Therefore efficient and 
effective delivery of LVS at MKUH is essential. 
This following findings of this study have implications for the delivery of LVS at MKUH:  
 Evidence that provision of LVAs improves NVA and that this in turn improves patient 
QoL in the first three months provides justification for LVS delivery and support for 
the methods used, but also highlights the importance of dispensing LVAs correctly. 
 
 Improvement in QoL is greatest three months after prescription of LVAs but QoL 
increases significantly up to six months and this appears to be a function of 
rehabilitation and adaptation.  This has the potential to optimise the timing of patient 
appointments. 
The LVS service is improving patient quality of life but currently patient attendance following 
the initial visit can be on a three monthly frequency, although this is dependent upon the 
clinician and requirements of the patient.  This study shows that this ‘three monthly visit’ 
approach is valid for the first two follow-up visits at three and six months but there is an 
indication that the follow-up frequency could be reduced to six months following this (i.e. 
patients are seen at 0, 3, 6, 12, 18, 24 months and so on).  This would create additional 
capacity within the LV clinic, which will be essential for seeing greater patient numbers in 
the future. 
 
4.2.2 Using the questionnaires in routine clinical decision making 
The LVQOL questionnaire was used to evaluate specific research hypotheses, and detailed 
analysis of the data by section indicates that the questionnaire could be used as a pre-
screening tool to help tailor LV services.  Whether or not this would provide information that 
cannot be obtained through standard optometric discussions with patients is questionable, 
but it would provide systematic collection of information and a decision making process 
could be built based on patient response to questions.  For example, if a patient gave a 
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score of 1 (great problem) on question number 17 (reading large print) an LVA could be 
issued to help, whereas a score of 5 (no problem) would indicate that such input would not 
be needed. 
Use of the LVQOL in clinical decision making is particularly valuable in the assessment of 
whether or not a patient would benefit from additional rehabilitation services such as 
consultation with an Eye Clinic Liaison Officer (ECLO).  Specific examples of this can be 
found in each section (e.g. a number of questions from Section A relate to mobility - the 
ability to see steps or curbs, getting around safely outdoors, and crossing a road with traffic).  
Patients who respond with concerns in these areas could then be referred for further mobility 
training.  In these examples (and others) the LVQOL would serve to highlight specific patient 
concerns that require further referral / intervention, concerns that might otherwise not have 
been evident.  However, the LVQOL does not include questions which would routinely be 
asked as part of the LV clinic assessment at MKUH.  For example, although in Section D 
there is a question relating to everyday activities (household chores), this is non-specific 
and would not elicit information such as the patient’s ability to safely prepare hot food and 
drinks, one aspect which is routinely questioned by the author.  Although the LVQOL does 
not (and cannot) comprehensively cover a full range of patient abilities and concerns, its 
use (or that of an alternative questionnaire) may help to standardise LV clinic protocols 
among colleagues working within MKUH.   
The LVQOL questionnaire is 25 questions long and takes approximately five to seven 
minutes to answer in the clinic context.  With clinic time under increasing pressure, the 
questionnaire could be provided to the patient for completion prior to the LV clinic 
appointment.  Another strategy would be to reduce the number of questions for use in a 
pre-screening context.  Van Nispen et al. (2007) carried out analysis of the psychometric 
properties of the LVQOL using item response theory analysis to assess QoL prior to and 
following LVS.  They concluded that the ‘reading and fine work’ subsection should be split 
into ‘reading small print’ and ‘visual (motor) skills’, reducing the number of items overall to 
23.  Items number 5 (‘problems reading street signs’) and 25 (‘problems in performing 
everyday activities’) were removed due to low factor pattern coefficients and confusing 
interpretation of factors.  A later study (van Nispen et al. 2011) concluded that a further 
reduction to 21 questions was appropriate to remove differential item functioning and further 
improve the validity of results.  In this study the authors omitted items ‘1’ (“your vision in 
general”) and ‘24’ (problems using tools).  
The reduction of the 25-item questionnaire to a 21-item version was achieved in this study 
by deletion of questions 1, 5, 24 and 25.  Table 4.2 shows that the headline comparison of 
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total LVQOL score for all patients between visits was similar using the 25 and 21 questions 
versions.  This indicates that the 21 question version would have provided similar results 
and could be used in future studies. 
Table 4.2 Comparison of related-samples Sign Test results for the full 25 question Low Vision Quality 
of Life questionnaire and the reduced 21 question version (van Nispen et al. 2011). 
 T0 vs T3 T3 vs T6 T0 vs T6 
Number of 
questions 25 21 25 21 25 21 
Positive 26 30 26 24 31 30 
Negative 10 9 9 11 8 8 
Ties 3 0 4 4 1 2 
p 0.012 0.001 0.007 0.043 <0.001 0.001 
4.2.3 Audit and evaluation 
As well as testing hypotheses in a controlled research context, the study is effectively a six 
month audit of the performance of LV services for ARMD patients at MKUH.  The LVQOL 
has been shown to be a useful tool for audit of LV services in the context of ARMD, and a 
similar methodology could be used for assessing it as an audit tool for other diseases 
causing low vision such as glaucoma and diabetes.  This audit could be extended over a 
longer time period and it would be of value to compare data with other causes of low vision 
to see whether LVS could be optimised further. 
Nationally, low vision is an expanding problem due to the ageing population and the 
increased prevalence of untreatable sight loss (Binns et al. 2012).  Through the provision 
of LVS, patients are supported to enable them to live as independently as possible. 
However there is obviously a financial cost involved.  Binns et al. (2012) concluded that 
there was a lack of evidence to clarify what constitutes an effective (and cost-effective) 
service.  Evidence-based information regarding both the effectiveness and efficiency of 
services is fundamental in a time of financial constraint for continued allocation of resources 
within the NHS.  Ongoing evaluation of LVS is therefore essential to enable future service 
provision. 
Although the current study was carried out in only one hospital clinic, it would be beneficial 
to be able to recommend a method of service evaluation utilising QoL questionnaires that 
could be used nationally.  Naturally, the different locations of hospital LV clinics in the UK 
would be subject to the effects of different demographics (e.g. eye conditions, age, gender 
and race).  Regardless, consistency of evaluation methods among different service 
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providers (hospitals) is important.  This would ensure that any different measures of 
outcome among providers related to the differences between the various approaches to 
LVS, rather than differences due to the method of evaluation.   
Binns et al. (2012) proposed that the use of such a broad range of QoL questionnaires in 
the evaluation of LVS was a disadvantage because variation among questionnaires can 
mask treatment effects (such as QoL outcomes from different LVS models).  It would 
therefore be beneficial to reach a conclusion on the most suitable vision-related QoL 
questionnaire to use, and whether or not this should be supplemented by a health-related 
QoL measure.  The current study does not provide the answers to this question, however, 
it does contribute new data to the knowledge base on the LVQOL to support this 
assessment. 
The benefit of an NHS-wide evaluation of services would be the identification of best 
practice in a range of contexts, allowing identification of the most effective (and cost-
effective) model of LVS.  This could then be shared amongst service providers to improve 
knowledge and understanding of these services for the future.  The wider optometric 
community would also benefit as optometrists would be able to use this knowledge to make 
clinical decisions, particularly when deciding which patients to refer into the service.  Once 
it is evident which method or approach to LVS provision is most effective, wider questions 
could be asked such as how to optimise the service for use in different circumstances.  
Ultimately this evaluation would need to determine how the service needs to adapt going 
forward to ensure provision for a greatly increased number of service users in the future. 
A centrally funded study would be required with data collected at multiple LV clinic providers 
(hospitals).  The use of a QoL questionnaire(s) such as the LVQOL for this multi-centre 
study would be critical to ensure that quantifiable results are obtained, rather than purely 
subjective assessment.  Questionnaire(s) and implementation methods would need to be 
standardised throughout to reduce bias.  The broad number of current approaches to low 
vision within hospital optometry in the UK includes a range of different rehabilitation services 
and multidisciplinary approaches comprising a wide range of health care professionals and 
levels of attachment to social services (CO-RCO, 2013; Ryan, 2014).  The proposed study 
would be designed to include a representation from as many of these systems as possible, 
to inform debate as to the effectiveness of these different approaches.  Of course, there 
may not be one single approach that is suited to all areas of the UK. However, evaluation 
will lead to knowledge of what works well, where, and how services (and resources) can be 
tailored and integrated to meet the specific requirements of patients served by hospitals 
based in different demographic areas. 
 121 
Results could then be disseminated through the Hospital Optometrists Annual Conference 
and Head of Department meetings to ensure that all practitioners working within LV clinics 
are following the same guidelines.  From study results, a number of key questions for UK 
hospital departments offering LVS would then need consideration.  For example, does the 
current approach to LVS offered meet best practice to ensure effectiveness?  If not, how 
could each provider improve their service based on recommendations from the study?  
Once any changes were implicated, further evaluation of the new model of provision would 
be required to ensure these changes had improved outcomes.  Ultimately, an assessment 
would need to be made of the benefit of investment in this research. 
The College of Optometrists together with the Royal College of Ophthalmologists have 
provided recommendations on the evaluation of LVS (CO-RCO, 2013).  One of the 
objectives contained within this report focuses on the use of QoL questionnaires to assess 
the role of LVS.  Suggested QoL questionnaires include the Manchester Low Vision 
Questionnaire (MLVQ), the Vision-Related Quality of Life Questionnaire, the Mass of 
Activity Inventory (MAI; modified version) and the National Eye Institute Visual Function 
Questionnaire (NEI-VFQ). 
 
4.2.4 Provision of rehabilitation services within low vision services 
It has been demonstrated above that improvement in QoL is not simply a function of 
improvement in NVA, and that rehabilitation provided within LVS may also contribute to 
improved QoL.  For those patients attending the LV clinic, the ability to refer to the ECLO 
on the same day for rehabilitation advice enables a greater proportion of optometric time to 
be spent on clinical assessment and demonstrating LVAs, with the ECLO focussing on 
adaptations at home and emotional support.  The ECLO was not present in the clinic on 
any of the days that this study took place.  However three (/40) patients were referred to 
the ECLO at Visit 1 (T0) whilst 14 patients had contact with the ECLO prior to the study.  In 
this study several patients had no rehabilitative support, others received telephone ECLO 
support only, while a small number had access to a home visit and telephone support.  To 
determine the impact of ECLO services objectively would require a study designed with an 
LVS + ECLO, vs LVS - ECLO factor as per Reeves et al. (2004) and de Boer et al. (2006).  
However, to withhold rehabilitative support could be considered unethical. 
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4.3 Evaluation and Further Development of This Study 
Research hypotheses regarding the impact of LVS on QoL in ARMD patients was assessed 
at MKUH.   
Limitations of the study, largely dictated by the time and recourses available, include: 
1. Sample size. 
2. Variable history within the LV Clinic before T0. 
3. Time limited to six months. 
4. No control group (as a result of ethical constraints), and no randomisation. 
5. Impact of direct implementation method. 
6. Limited to ARMD. 
7. Limited to one vision-specific and one general health questionnaire. 
8. Limited to one hospital / LV clinic model. 
Sample size and variable prior history in the LV clinic before T0 
A total of 40 patients were recruited, resulting in an 18 month study period.  This sample 
size exceeded the minimum required for the experimental protocol (34 patients; see Section 
2.2.2).  A larger sample, however, may have allowed subdividing the participant group into 
new and existing patients.  This may be beneficial because it would add more power to the 
analysis of the difference in QoL outcomes between new and existing patients. 
Stage (of disease) and time since diagnosis are also important factors that should be 
included in the selection of patients for future studies.  This is because it is hypothesised 
that the stage and rate of disease progression will be significant factors in determining the 
QoL benefit of LVS. 
Time limitations 
Results indicated that the QoL benefit of attendance at LV clinic appointments appears to 
decrease over time, but over a greater time period than six months (indicated by examining 
existing patients).  This needs to be tested over a 24 or even 36 month period.  This is 
because the rate of disease progression in ARMD patients occurs on a longer time 
frequency than six months. 
Other confounders include co-morbidities and ARMD subtype and these should be explored 
further in future studies. 
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No control group and no randomisation 
To have had a control group that did not receive LVS despite their ARMD and the problems 
with visual acuity that this causes was not done for ethical reasons.  De Boer et al. (2006) 
recommended the use of a ‘waiting list group’ as a control; this would not have been 
practical at MKUH due to the management of waiting lists, although it may be an option for 
a future study. 
Limited to ARMD 
ARMD is one of many conditions that cause low vision.  It would be of interest to determine 
whether patients attending the LV clinic with other ocular diseases benefit equally from the 
LV clinic.  For example, a comparison between patients with glaucoma and patients with 
ARMD would test the hypothesis that loss of peripheral vision has less impact on QoL than 
the loss of central vision, and that LVS (provision of LVAs and rehabilitation) has different 
impacts on the QoL of the two groups.  This was explored by Evans et al. (2009) who 
reported that although QoL was affected to a similar level in patients with either glaucoma 
or ARMD, general and mental health were a greater problem for those with glaucoma, whilst 
physical function was more restricted for those with ARMD. 
Questionnaire selection and implementation method 
Further evaluation of LVS within MKUH could include a comparison of two vision-related 
QoL questionnaires e.g. the LVQOL and the functional ability Quality of Vision (faVIQ) 
questionnaire (Wolffsohn et al. 2014).  The latter has recently been shown to be a sensitive 
tool for the measurement of QoL in patients with visual impairment and employs more 
recently developed statistical techniques, thought to be more robust.  In a future study, 
patients could be randomly assigned to one of two groups – one receiving the LVQOL (as 
per the current study), and the other receiving the faVIQ.  Providing each group received 
the same method of administration, over the same time period, with the same controls on 
disease and patient history in the LVS, the effect of bias from these factors should be 
minimised. 
Some of the differences observed between the Wolffsohn and Cochrane (2000) study and 
this study could be due to implementation method.  This study used in-person 
implementation, while Wolffsohn and Cochrane (2000) used postal implementation for self-
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completion.  Wolffsohn et al. (2000) observed that postal implementation resulted in a lower 
QoL score compared with in-person interviews due to a lack of interaction with the 
ophthalmic practitioner.  This is one explanation for the larger LVQOL scores observed in 
the present study.  Patients completing the questionnaire with the optometrist may give a 
better impression of how they are managing, therefore artificially increasing QoL scores.  
The large differences in total LVQOL scores observed between the current study and those 
of Wolffsohn and Cochrane (2000) may not be attributable to implementation method alone.  
A further study is required to test the effect of implementation method on QoL scores, 
whereby low vision patients would be randomised into two groups – one group receiving 
the questionnaire in large print format by post for self-completion, the other attending the 
LV clinic to complete the questionnaire with the optometrist. 
Study was limited to one hospital / LV clinic model 
The study was conducted in one hospital using a single model of LVS delivery.  It is 
reasonable to extend the findings of this study to similar LVS models at similarly sized 
hospitals.  However other models of LVS delivery exist and these would need to be 
examined in further studies to determine whether the findings of this study are applicable to 
other LV clinics.  
  
 125 
5 MAJOR FINDINGS AND CONCLUSIONS 
1. Over a six month period, low vision aids significantly improved near visual acuity 
(p=0.011).  Over this same period, no significant difference was recorded in binocular 
distance visual acuity (p=0.335), near visual acuity without low vision aids (p=0.701) or, 
binocular distance contrast sensitivity (p=0.216). 
2. There was no significant change in near visual acuity with low vision aids over the six-
month study period for patients who had previously attended a low vision clinic (existing 
patients; p=0.368).  For patients who were new to the clinic, the maximum improvement in 
near acuity with low vision aids occurred within the first three months following 
intervention (p=0.005).   
3. Median total Low Vision Quality of Life (LVQOL) score increased between the initial (T0) 
and the three-month (T3) visits (p=0.012), and again between the three and six-month (T6) 
visits (p=0.007).  Because there was no significant change in visual acuity measures 
(including near acuity with low vision aids) between the second and third visits, the 
improvement in LVQOL score within this period is likely related to factors other than vision 
(e.g. rehabilitation / adaptation). 
4. There was no significant difference in the mean total LVQOL questionnaire score 
between new and existing patients at all three visits: T0 (p=0.103), T3 (p=0.363) and T6 
(p=0.923).  In existing patients, there was a significant increase in mean total LVQOL score 
(8.6) between T0 and T3 (p=0.031), but no further increase between T3 and T6 (p=0.251).  
In new patients, a significant increase in score (13.9) occurred between T0 and T3 
(p=0.003) and between T3 and T6 (p=0.048).  These results provide evidence to suggest 
that intervention by low vision services for new patients increases their quality of life 
following the initial appointment. 
5. Mean total LVQOL questionnaire scores at any of the three visits was not significantly 
different for patients living alone compared with those living with a partner / family (p=0.571). 
6. Analysis of scores within each of the four sections of the LVQOL questionnaire revealed 
that there were significant differences in median score between the three visits for Sections 
A (distance vision, mobility and lighting), B (adjustment) and C (reading and fine work).  In 
Section A, the median total LVQOL score increased significantly between T0 and T3 
(p=0.002), and between T3 and T6 (p=0.008).  It is difficult to attribute the continued 
increase in score for this section purely to low vision clinic assessment or rehabilitative 
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services: the increased score is likely to be due to a combination of both.  The significant 
increase in Section C score between T0 and T3 (p=0.006) is assumed to reflect the 
significant improvement in near acuity with low vision aids during that period.  Adaptation to 
the use of low vision aids by the second visit is a likely explanation for no change in score 
between the three and six-month visits (p=0.568).  Section D (activities of daily living) scores 
did not change significantly over the three visits (p≥0.05), and these questions do not appear 
to be sensitive to the effects of low vision clinic input.   
7. The EuroQol five-dimension, five-level (EQ-5D-5L) questionnaire scores decreased 
significantly between T0 and T6 (p=0.005) indicating a significant improvement in general 
health-related quality of life over the period of the study.  A further multi-disciplinary 
assessment of co-morbidities would be needed to determine whether or not the 
improvement in vision-related quality of life was linked to these findings. 
8. The EQ-5D-5L questionnaire is not sensitive enough to be used as a standalone 
questionnaire within the low vision clinic in the assessment of patient quality of life over a 
six month period. 
9. The findings of this study can be used to improve the efficiency of low vision service 
delivery at Milton Keynes University Hospital by initially seeing new patients on a three-
month frequency but increasing this to a six-month frequency after the first three visits (i.e. 
after the initial, three-month and six-month visits).  This is a more resource efficient 
approach. 
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APPENDICES 
Appendix 1.1 
Protocol for low vision assessment for a new patient attending Milton Keynes 
University Hospital low vision clinic 
1. Comprehensive case history – to determine any general and / or specific problems 
that the patient is having with their vision, and the effect that this has upon their ability to 
perform everyday tasks.  The patient’s social situation and current level of support should 
be identified. 
2. Assessment of visual function – measurement of distance and near visual acuity for 
each eye (including pinhole) and binocularly, providing an initial assessment of the 
limitations of vision.  Assessment of contrast sensitivity to indicate whether further advice 
on contrast and lighting is required. 
3. Refraction – to ensure that the patient is wearing the optimum spectacle correction 
for both distance and near.  Discussion on the best form(s) of spectacle correction.  
Demonstration of high reading addition spectacle prescription (where appropriate). 
4. Optical LVA demonstration and training – choice of LVA based on the specific task 
(e.g. size and contrast of print), patient’s level of visual acuity, patient motivation and 
handling ability.  Demonstration of more than one type of LVA for separate tasks, and 
guidance on how to achieve the optimum results from each.  Explanation of the provision 
of LVAs on free-of-charge loan, how to change batteries, and LV clinic contact details in 
case of any problems.   
5. Lighting and non-optical low vision aids – advice on appropriate lighting and 
improvement of contrast, provision of glare shields.   Discussion of electronic LVAs, how to 
obtain a demonstration, and estimates of the costs involved to purchase privately.  
Demonstration of large print, advice on audio books and talking newspapers, along with 
other products that can be purchased privately.  Eccentric viewing and steady eye strategy 
training. 
6. Referral to other services – with informed consent from the patient, a ‘Referral of 
Vision Impairment’ (RVI) is completed to enable access to social services for assessment 
and support.  Provision of information on other local and national (voluntary) support groups. 
7. Arrangements for follow-up LV assessment or discharge. 
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Appendix 2.1 
Patient Information Sheet v2 
PATIENT INFORMATION SHEET 
We would like to invite you to take part in our research study. Before 
you decide we would like you to understand why the research is being 
done and what it would involve for you.  One of our team will go 
through the information sheet with you and answer any questions you 
have.  We‘d suggest this should take about 30 minutes. 
 
Talk to others about the study if you wish. 
 
Research workers, school and subject area responsible: 
Mrs Louise James 
Milton Keynes Hospital NHS Foundation Trust  
and School of Life & Health Sciences, Vision Sciences, Aston 
University 
 
Professor Stephen J. Anderson 
School of Life & Health Sciences, Vision Sciences, Aston University 
 
Project Title: 
Evaluation of Low Vision Services on Quality of Life 
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Invitation: 
You are being invited to take part in a research study.  Before you decide 
whether to take part, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read 
the following information carefully. 
 
What is the purpose of the study? 
The purpose of this study is to determine the impact of low vision 
rehabilitation on the quality of life of patients with macular disease.  The 
results of this study will be analysed to determine which patients benefit 
from the rehabilitation process, thereby providing useful information as 
to which patients are most likely to benefit from visual rehabilitation in 
the future. 
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with macular 
disease and are currently attending the Low Vision clinic at Milton 
Keynes General Hospital.  A minimum of 34 participants will be asked 
to take part. 
 
What will happen to me if I take part? 
By volunteering to participate in this study you will be required to answer 
questions on your experiences of living with macular disease and how 
this impacts upon your quality of life.  This will involve completing two 
short questionnaires after your initial Low Vision Assessment in the Low 
Vision clinic at Milton Keynes General Hospital. 
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When you return for your 3 and 6 month Low Vision Review 
appointments you will be asked to complete the questionnaires again.  
You will be asked to complete the questionnaires up to three times in a 
period of six months. 
 
It will be necessary for NHS staff in the Low Vision Clinic to access your 
medical records as part of this research. 
 
Are there any potential risks in taking part in the study? 
There are no physical risks from taking part in this study. Any risk of 
breaching privacy and confidentiality in relation to data collected from 
the questionnaire will be minimised by seeking your consent prior to 
participation to allow data to be analysed.  It may be necessary to 
breach your confidentiality if your health and safety or that of another is 
at risk. 
 
Questions about your lifestyle will be asked, and you may consider 
these to be an intrusion.  We shall take every step to ensure that the risk 
of causing offence will be minimised. 
 
  
 141 
Do I have to take part? 
It is up to you to decide to join the study.  We will describe the study and 
go through this information sheet. If you agree to take part, we will then 
ask you to sign a consent form. You are free to withdraw at any time, 
without giving a reason. This would not affect the standard of care you 
receive. 
 
Expenses and payment: 
There are no expenses or payments for participation in this study. 
 
Will my taking part in this study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about 
you will be handled in confidence.  All information which is collected 
about you during the course of the research will be kept strictly 
confidential, and any information about you which leaves the hospital 
will have your name and address removed so that you cannot be 
recognised (if it is applicable to your research). 
 
We shall collect your response to the questionnaires on paper records.  
These will not carry your name, hospital number, NHS number or any 
information that can be used to identify you, outside of the Low Vision 
Clinic at Milton Keynes Hospital.  Instead we shall mark each 
questionnaire response with a unique number. 
 
We shall keep a list of unique identification numbers securely in the 
clinic offices throughout the period of research.  On completion of the 
research we shall securely destroy this list and only anonymous data 
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will be used in our analysis and in our discussions with research staff at 
Aston University. 
 
All questionnaire responses will therefore be anonymised and will be 
stored securely.  Only staff in the Low Vision Clinic at Milton Keynes 
Hospital will have access to identifiable records. 
 
Data from the questionnaire responses will be used in statistical analysis 
that will help inform how we deliver Low Vision services in the NHS. 
 
Anonymised questionnaire responses will be retained for a minimum 
period of five years in the School of Health and Life Sciences at Aston 
University and will then be disposed of securely. 
Please note that privacy and confidentiality will be protected vigorously 
to the extent permissible by law.  We cannot, however, guarantee 
privacy or confidentiality. 
 
What will happen to the results of the research study? 
We aim to publish the results of this study in appropriate medical 
research journals.  However, there will be no reference to any 
individual’s results in any publication.  Published research will be 
available to all participants – to receive your copy, please contact Louise 
James at Milton Keynes General Hospital. 
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Who is organising and funding the research? 
The Chief Investigator is Mrs Louise James working under the 
supervision of Professor Stephen J. Anderson at The School of Life & 
Health Sciences, Aston University.  This research study is organised in 
conjunction with Aston University.  This research is not funded. 
 
Indemnity 
This research is covered by the Aston University Indemnity Insurance 
provided by Zurich Municipal under policy number NHE-02CA02-0013. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee, to protect your interests. This 
study has been reviewed and given favourable opinion by 
Cambridgeshire 3 Research Ethics Committee. 
 
The research has also been reviewed by the Aston University’s Ethics 
Committee. 
 
Who do I contact if something goes wrong or I need further 
information? 
Please feel free to contact Mrs Louise James (jameslc@aston.ac.uk, 
01908 660033 x 5403) 
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Who do I need to contact if I wish to make a complaint about the 
way in which the research is conducted? 
If you have any concerns about the way in which this study has been 
carried out, then you may contact the Secretary of the Aston University 
Research Ethics Committee by email j.g.walter@aston.ac.uk or 
telephone 0121 204 4665 
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Patient Consent Form v2 
PATIENT CONSENT FORM 
Evaluation of Low Vision Services on Quality of Life 
Name of Chief Investigator: Mrs Louise James 
Patient Identification number for this study:________________________ 
Please initial boxes 
   
1 I confirm that I have read and understand the 
information sheet dated 1 May 2011 (version 2) for the 
above study. I have had the opportunity to consider the 
information, ask questions and have had these 
answered satisfactorily. 
 
2 I understand that my participation is voluntary and that 
I am free to withdraw at any time without giving any 
reason, without my medical care or legal rights being 
affected. 
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3 I understand that relevant sections of my medical 
notes and data collected during the study may be 
looked at by individuals from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these 
individuals to have access to my records. 
 
4 I agree to take part in the above study. 
 
 
 
 
Name of Patient _____________ Date ________ Signature___________ 
 
Name of Person _____________ Date ________ Signature___________ 
taking consent 
 
When completed: 1 for participant; 1 for researcher site file. 
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Appendix 2.2 
Milton Keynes University Hospital Referral of Vision Impairment (RVI) Form 
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Appendix 2.3 
Low Vison Quality of Life Questionnaire 
THE LOW VISION QUALITY‐OF‐LIFE QUESTIONNAIRE 
Distance Vision, Mobility and Lighting 
How much of a problem do you have: 
  none            moderate          great    
With your vision in general  5           4            3            2            1  x  n/a 
With your eyes getting tired (e.g. only being able to do a 
task for a short period of time) 
5           4            3            2            1  x  n/a 
With your vision at night inside the house  5           4            3            2            1  x  n/a 
Getting the right amount of light to be able to see  5           4            3            2            1  x  n/a 
With glare (e.g. dazzled by car lights or the sun)  5           4            3            2            1  x  n/a 
Seeing street signs  5           4            3            2            1  x  n/a 
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Seeing the television (appreciating the pictures)  5           4            3            2            1  x  n/a 
Seeing moving objects (e.g. cars on the road)  5           4            3            2            1  x  n/a 
With judging depth or distance of items (e.g. reaching for a 
glass) 
5           4            3            2            1  x  n/a 
Seeing steps or curbs  5           4            3            2            1  x  n/a 
Getting around outdoors (e.g. on uneven pavements) 
because of your vision 
5           4            3            2            1  x  n/a 
Crossing a road with traffic because of your vision  5           4            3            2            1  x  n/a 
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Adjustment 
Because of your vision are you: 
  no           moderately         greatly     
Unhappy at your situation in life  5           4            3            2            1  x  n/a 
Frustrated at not being able to do certain tasks  5           4            3            2            1  x  n/a 
Restricted in visiting friends or family  5           4            3            2            1  x  n/a 
 
  well                                        poorly not 
explained 
How well has your eye condition been explained to you  5           4            3            2            1  x 
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Reading and Fine Work 
With your reading aids / glasses, if used, how much of a problem do you have: 
  none            moderate          great    
Reading large print (e.g. newspaper headlines)  5           4            3            2            1  x  n/a 
Reading newspaper text and books  5           4            3            2            1  x  n/a 
Reading labels (e.g. on medicine bottles)  5           4            3            2            1  x  n/a 
Reading your letters and mail  5           4            3            2            1  x  n/a 
Having problems using tools (e.g. threading a needle or 
cutting) 
5           4            3            2            1  x  n/a 
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Activities of Daily Living 
With your reading aids / glasses, if used, how much of a problem do you have: 
  none            moderate          great    
Finding out the time for yourself  5           4            3            2            1  x  n/a 
Writing (e.g. cheques or cards)  5           4            3            2            1  x  n/a 
Reading your own hand writing  5           4            3            2            1  x  n/a 
With your everyday activities (e.g. household chores)  5           4            3            2            1  x  n/a 
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Appendix 2.4 
Patient Testimonials (Low Vision Quality of Life Questionnaire) 
Underlined text represents interpretation by Chief Investigator. T0 is the initial visit, T3 is 
the three-month follow-up and T6 is the six-month follow-up.  Three digit number is patient 
identifier code.  Numbers in brackets indicate LVQOL response score (1-5, x, n/a). 
  
Section A: Distance Vision, Mobility and Lighting 
How much problem do you have: 
 
Q1: With your vision in general 
001 (T6) – “I can’t see faces now” (3) 
011 (T3) – “better with my new glasses” (4).  Gave a score of (2) at (T0) and issued 
prescription for new spectacles on this occasion. 
015 (T0) – “problems with bus numbers” (1) 
015 (T3) – “slightly improved” (3) 
020 (T6) – “I have large support from family” (5).  Patient lives with family 
021 (T3) – “seems worse” (1).  Patient scored (4) at (T0) 
023 (T6) – “people need to be closer before I recognise them now” (3).  Scored (4) at (T3). 
025 (T6) – “It goes dark sometimes” (3) 
029 (T0) – “In a crowd I find faces a problem” (4) 
 
Q2: With your eyes getting tired (e.g. only being able to do a task for a short period of 
time) 
007 (T3) – “my magnifier has helped with this” (3).  Gave a score of (1) at (T0). 
009 (T0) – “with television especially” (2) 
022 (T0) – “at the end of the day they feel gritty” (1) 
024 (T6) – “evenings mainly” (4)  
025 (T0) – “after 20 to 30 minutes reading” (3) 
028 (T0) – “in the evenings” (4) 
035 (T3) – “I am aware of it – moderately” (3) 
038 (T0) – “depends upon the task” (4)  
038 (T6) – “evenings with television – but otherwise no” (4)  
 
 
Q3: With your vision at night inside the house 
012 (T3) – “I have a torch to help” (3) 
015 (T0) – “a change in light levels is especially a problem” (1) 
015 (T3) – “I use glare shields” (4) 
015 (T6) – “dusk outside is more of a problem” (5) 
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024 (T0) – “I’m better in the dark” (5) 
024 (T3) – “I see better in the dark” (5) 
034 (T6) – “I can’t see the clock on my microwave” (2) 
039 (T0) – “I use a torch” (2) 
 
Q4: Getting the right amount of light to be able to see 
016 (T0) – “I need a new lamp” (3) 
017 (T3) – “especially in winter” (1) 
 
Q5: With glare (e.g. dazzled by car lights or the sun) 
003 (T6) – “eyes watery” 
007 (T6) – “even when I wear my own dark sunglasses” (1) 
035 (T3) – “especially going from dark to light” (2) 
 
Q6: Seeing street signs 
027 (T0) – “I don’t need to” (1) 
035 (T0) – “I need to be close” (2) 
 
Q7: Seeing the television (appreciating the pictures) 
001 (T6) – “not faces” (3) 
006 (T6) – “I can watch for a maximum of 2 hours only” (3) 
007 (T6) – “but I wear tinted glasses” (5) 
012 (T3) – “ok if a big screen” (4) 
015 (T0) – “I can only listen” (1) 
015 (T6) – “better” (4).  Patient had new spectacles made after (T3), scored (3) at (T3). 
018 (T3) – “they are hazy” (3) 
019 (T6) – “it’s worse on HD [high definition]” (5) 
023 (T6) – “I can’t see faces and recognise actors that I know” (1) 
024 (T6) – “I sit close to it” (2) 
025 (T6) – “I need to get very close” (2) 
026 (T6) – “It irritates me due to the distortion” (1) 
029 (T0) – “I have gone a bit nearer” (5) 
033 (T3) – “slight problem with text on the television, yellow on black is better” (4)  
034 (T6) – “I have a large screen” (3)  
035 (T6) – “I am sitting closer” (4) 
037 (T0) – “It’s foggy” (3)  
038 (T0) – “I have a large screen but text is a problem” (4) 
039 (T0) – “faces difficult” (3) 
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Q8: Seeing moving objects (e.g. cars on the road) 
003 (T6) – “I listen” (3) 
018 (T3) – “I’m careful” (2) 
024 (T6) – “daylight is worse than evenings” (2) 
027 (T0) – “especially dark cars” (1) 
 
Q9: With judging depth or distance of items (e.g. reaching for a glass) 
016 (T0) – “pouring liquids a problem” (4) 
017 (T6) – “reaching tablets from the side in the kitchen” (4) 
023 (T6) – “I have broken a glass before as I’ve misjudged” (4) 
024 (T3) – “I feel for things” (1) 
024 (T6) – “I smashed a glass – I feel for things” (1) 
025 (T0) – “problems with pouring and miss the cup when I pour tea” (1) 
026 (T0) – “I miss when pouring water” (1) 
 
Q10: Seeing steps or curbs 
006 (T6) – “I use my stick to help me feel” (3) 
008 (T6) – “steps particularly” (3) 
015 (T0) – “recently” (3) 
017 (T0) – “I don’t go out alone” (1) 
018 (T3) – “I use my scooter generally” (2) 
025 (T0) – “I do fall down curbs” (1) 
025 (T6) – “I tripped down the curb two to three weeks ago” (1) 
035 (T3) – “I am very careful” (5)  
 
Q11: Getting around outdoors (e.g. on uneven pavements) because of your vision 
006 (T0) – “I need my trolley to help me” (3) 
024 (T6) – “I stagger now” (1) 
034 (T0) – “I have a white cane now” (2) 
038 (T0) – “I go out with my husband – always” (5) 
 
Q12: Crossing a road with traffic because of your vision 
001 (T6) – “I almost stepped out in front of a car last week” (1) 
002 (T6) – “getting worse” (1) 
006 (T6) – “I can manage on my own” (3)  
012 (T3) – “only if I know where I am” (3) 
012 (T6) – “I choose quiet times to cross” (4) 
014 (T3) – “I never go out alone” (4) 
014 (T6) – “I choose not to cross on my own” (3). 
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015 (T3) – “Ok if cars are coming from the left, not from the right” (2) 
017 (T6) – “I only cross side streets” (2) 
019 (T0) – “but my mobility is poor” (5) 
023 (T6) – “I need to be extremely careful now” (1) 
024 (T6) – “Usually I would hold onto my wife’s wheelchair, I would not cross on my own” 
(1) 
025 (T6) – “I need to be careful crossing the road, I get blank patches as cars are coming 
towards me” (1) 
026 (T0) – “I’m always accompanied” (1) 
026 (T6) – “I’ve not been out on my own since October 2013” (x).  Reported April 2014. 
027 (T0) – “I wouldn’t go out on my own” (1)  
035 (T0) – “I am becoming more careful” (3) 
038 (T0) – “I am always with my husband” (5) 
 
Section B: Adjustment 
Because of your vision are you: 
Q13: Unhappy at your situation in life 
031 (T6) – “I have to get on with it as I live alone – that’s the way it is” (5) 
034 (T6) – “I try not to get depressed – I don’t want to go on tablets” (4) 
 
Q14: Frustrated at not being able to do certain tasks 
004 (T6) – “my hearing is also an issue” (4) 
007 (T3) – “sewing - my eyes get sore if I try to sew for any length of time” (4) 
015 (T0) – “driving” (1) 
016 (T0) – “reading especially” (4) 
017 (T6) – “knitting – I have bags of wool upstairs I can’t use” (3) 
021 (T0) – “hearing impairment makes it harder” (3) 
023 (T6) – “Yes, I am, but I don’t let it get at me” (5) 
025 (T0) – “I don’t get frustrated, there’s no point” (5)   
025 (T6) – “I feel it is what I expect at my age, there’s no point getting frustrated or angry” 
(5) 
036 (T3) – “frustration over not being able to drive – my wife drives” (4) 
 
Q15: Restricted in visiting friends or family 
014 (T3) – “I have people visit now” (5) 
015 (T3) – “by not driving” (2) 
016 (T0) – “my daughter lives five minutes away but I don’t like to rely on her too much 
and try to manage on my own as much as I can” (5) 
020 (T0) – “live with family” (5) 
025 (T0) – “I live with my son” (5) 
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034 (T6) – “I need to have a taxi door to door so I tend to phone friends rather than visit” 
(3) 
036 (T3) – “my wife drives” (5) 
 
Q16: How well has your eye condition been explained to you 
 
Section C: Reading and Fine Work 
With your reading aids / glasses, if used, how much of a problem do you have: 
Q17: Reading large print (e.g. newspaper headlines) 
026 (T3) – “for a short time it’s ok” (5) 
 
Q18: Reading newspaper text and books 
003 (T3) – “I just don’t bother to read” (n/a) 
005 (T0) – “I don’t read the newspaper anymore” (x) 
018 (T3) – “I know I can read this (N6 - with bifocals and no magnifier) but I still feel this is 
very poor near vision” (3) 
021 (T0) – “I have no problems if I use a magnifier” (5) 
024 (T3) – “My wife reads the newspaper to me” (1) 
025 (T6) – “but not reading for very long” (5) 
029 (T3) – “my Kindle is great” (5)  
033 (T0) – “I hold them closer if need be” (5) 
034 (T6) – “I have Sound News” 
039 (T3) – “I dislike using magnifiers” 
 
Q19: Reading labels (e.g. on medicine bottles) 
013 (T6) – “even with the magnifier I struggle” (3) 
016 (T0) – “I can’t shop on my own, my daughter has to be there” (1) 
016 (T6) – “with magnifier it’s better” (4).  Patient attended at (T0) with her own magnifier 
(reading N12) and was loaned new LVAs (reading N5). 
018 (T6) - “with good light” (5) 
019 (T6) – “when they are very small print” (4) 
029 (T0) – “slight problems” (4) 
035 (T0) – “cooking instructions are difficult” (3) 
 
Q20: Reading your letters and mail 
004 (T0) – “I’ve stopped because of my vision” (x) 
006 (T6) – “my son reads them for me due to my vision” (x) 
008 (T3) – “I have a lot of large print” (3) 
012 (T3) – “it depends how complex they are” (4) 
014 (T0) – “I have large print” (4) 
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014 (T6) – “I don’t bother though” (x) 
020 (T0) – “family help” (3) 
024 (T6) – “I’m doing less reading than I was three months ago.  My wife reads everything 
to me now – even my letters” (x).  Scored (1) at (T3) and (T0). 
025 (T6) – “small print is difficult, my son reads it to me” (4) 
026 (T6) – “I have large print bank statements” (3)  
028 (T3) – “my wife generally does it” (5) 
030 (T3) – “the magnifier has made a huge impact on my vision” (5).  Scored (4) at (T0). 
032 (T0) – “my husband reads them” (1) 
 
Q21: Having problems using tools (e.g. threading a needle or cutting) 
006 (T0) – “I’ve stopped sewing due to my vision” (x) 
007 (T3) – “my magnifier helps” (5) 
012 (T6) – “needles – I can’t manage to thread them now” (1) 
018 (T6) – “I need good lighting” (5) 
021 (T3) – “missing cross stitch – I can’t do it and can’t thread a needle” (2) 
021 (T6) – “needles” (x) 
023 (T0) – “hands free magnifier helps” (1) 
023 (T6) – “I still do a little bit of sewing but it’s much more difficult – I have tries a needle 
threader but it didn’t help much” (2)  
025 (T3) – “needles – son does it” (1) 
025 (T6) – “I love sewing, it’s a shame – I do small bits of sewing but my son threads all 
the needles now, he leaves two or three already threaded for me before he goes to work” 
(x) 
026 (T3) – “scissors” (4)  
026 (T6) – “I can’t thread needles” (1) 
027 (T0) – “I can knit with light wool, not coloured.  I attend a (knitting) group in the 
sheltered accommodation” (1) 
029 (T0) – “I’m managing to use my sewing machine – I get there in the end” (5) 
031 (T3) – “I cannot find the hole when threading needles” (3)  
038 (T0) – “threading needles” (1)  
 
Section D: Activities of Daily Living 
With your reading aids / glasses, if used, how much of a problem do you have: 
 
Q22: Finding out the time for yourself 
016 (T0) – “I guess” (3) 
017 (T6) – “but I’m guessing” (3) 
018 (T0) – “my mobile has yellow on blue – large print” (5) 
034 (T6) – “I am just about seeing my watch” (2) 
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Q23: Writing (e.g. cheques or cards) 
005 (T3) – “I don’t write due to my vision” (x) 
006 (T6) – “I write very little” (2) 
008 (T3) – “I have stopped sending cards etc due to problems writing addresses, I’ve told 
people I will phone them instead” (3) 
012 (T6) – “I only write my shopping list - I have a pad with lines” (3) 
013 (T6) – “I have help with writing” (x) 
017 (T6) – “my husband does all my writing” (x) 
023 (T6) – “I forget to write big” (1) 
024 (T3) – “I manage signing forms only” (2) 
024 (T6) – “I can’t even sign a cheque” (x) 
025 (T3) – “Letters – I don’t write anymore as I’m untidy” (4)  
025 (T6) – “all wavy” (3) 
026 (T6) – “I am managing what I need to” (3)  
028 (T3) – “little bits” (5)  
037 (T0) – “It’s guesswork” (1) 
 
Q24: Reading your own hand writing 
002 (T6) – “I don’t check what I write anymore” (3) 
006 (T6) – “I write large” (5) 
025 (T0) – “It’s terrible” (1) 
025 (T6) – “I don’t read any letters/cards that I’ve written anymore” (3) 
 
Q25: With your everyday activities (e.g. household chores) 
006 (T6) - “I have a cleaner every two weeks” (3) 
012 (T6) – “I do break glasses and lose things” (3) 
013 (T6) – “my daughter helps” (3) 
015 (T0) – “I have a son (aged 10), my wife may have to move back in?” (1) 
015 (T6) – “cooking ok and washing ok” (3).  Patient had a home visit from ECLO 
following (T0).  Scored (3) at (T3). 
016 (T0) – “My daughter helps as I live alone.  My housework is not as good as it used to 
be and this matters to me a lot, I am independent and stubborn and I like to manage on 
my own” (3) 
017 (T6) – “I help with the cooking, but it’s mainly done by my husband.  My daughter 
does the cleaning” (3) 
018 (T0) – “I have a cleaner” (3) 
020 (T0) – “cooking is very difficult” (1) 
024 (T3) – “I can only do little bits” (2) 
024 (T6) – “I still hoover and make the bed” (5) 
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025 (T0) – “I love baking but can’t see the numbers on the scales anymore – but I still do 
it” (3) 
026 (T3) – “shopping a problem” (1)  
026 (T6) – “managing – I have a cleaner” 
027 (T0) – “I have a cleaner” (3)  
028 (T3) – “but limited due to a back problem” (5)  
034 (T0) – “I have a shopper to help me” (1) 
034 (T6) – “I cannot take my blood every morning as I can’t see, I am waiting for help with 
this” (2) 
036 (T0) – “packet instructions difficult” (4) 
039 (T0) – “my husband cooks, I hoover” (2)  
039 (T3) – “my husband is disabled but has to do all the cooking, the only way I know if 
the stove is on is if I wave my hand over it” (1) 
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Appendix 2.5 
EuroQol Five-Dimension, Five-Level (EQ-5D-5L) Questionnaire 
 
EQ‐5D‐5L  HEALTH  QUESTIONNAIRE 
Under each heading, please tick the ONE box that best 
describes your health TODAY 
MOBILITY 
I have no problems in walking about          □ 
I have slight problems in walking about        □ 
I have moderate problems in walking about      □ 
I have severe problems in walking about        □ 
I am unable to walk about              □ 
 
SELF‐CARE 
I have no problems washing or dressing myself      □ 
I have slight problems washing or dressing myself    □ 
I have moderate problems washing or dressing myself   □ 
I have severe problems washing or dressing myself    □ 
I am unable to wash or dress myself          □ 
 
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities) 
I have no problems doing my usual activities      □ 
I have slight problems doing my usual activities      □ 
I have moderate problems doing my usual activities    □ 
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I have severe problems doing my usual activities     □ 
I am unable to do my usual activities          □ 
 
PAIN / DISCOMFORT 
I have no pain or discomfort            □ 
I have slight pain or discomfort            □ 
I have moderate pain or discomfort          □ 
I have severe pain or discomfort           □ 
I have extreme pain or discomfort          □ 
 
ANXIETY / DEPRESSION 
I am not anxious or depressed            □ 
I am slightly anxious or depressed          □ 
I am moderately anxious or depressed        □ 
I am severely anxious or depressed          □ 
I am extremely anxious or depressed          □ 
 
We would like to know how good your health is TODAY. 
Where ‘0’ describes the worst health you can imagine and ‘100’ 
describes the best health you can imagine. 
Write the number between 0 and 100 that describes your health 
today in the box below: 
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Appendix 2.6 
Patient Testimonials (EuroQol Five-Dimension Five-Level Questionnaire) 
Underlined text represents interpretation by Chief Investigator.  T0 is the initial visit, T3 is 
the three-month follow-up and T6 is the six-month follow-up.  Three digit number is patient 
identifier code.  Numbers in brackets indicate EQ-5D-5L response score (1-5). 
  
Patient Testimonials – EQ-5D-5L Questionnaire 
 
Mobility 
012 (T3) – “getting more unsure now” (3 – moderate problems in walking about) 
014 (T6) – “I have a stick and have somebody with me all the time – I would not go out 
alone” (2 – slight problems in walking about) 
015 (T3) – “dependent upon lighting” (2) 
020 (T0) – “I’m getting a scooter at the weekend” (4 – severe problems in walking about) 
020 (T3) – “now I have my scooter” (1 – no problems in walking about) 
025 (T0) – “main problem is vision” (2) 
 
Self-Care 
009 (T0) – “my husband helps me every day” (3 – moderate problems washing or 
dressing myself) 
012 (T3) – “mixing up colours is a problem – blues and blacks” (3) 
012 (T6) – “choosing colours is difficult, I have torches to help, and a carer” (3) 
013 (T3) – “I am having problems with the bath, occupational therapy are helping with this 
– they visit next week” (2 – slight problems washing or dressing myself) 
014 (T3) – “I have help with the bath” (2) 
015 (T0) – “If nobody is there I put on the wrong combinations of colours” (2) 
019 (T0) – “due to mobility” (4 – severe problems washing or dressing myself) 
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019 (T3) – “I have a carer to put my shoes and socks on” (3) 
019 (T6) – “carer helps” (3) 
039 (T3) – “I cannot do my hair and make-up” (3) 
 
Usual Activities (e.g. work, study, homework, family or leisure activities) 
015 (T3) – “my son (aged 10) helps” (2 – slight problems doing my usual activities) 
016 (T0) – “pouring liquid” (2) 
018 (T0) – “I have a cleaner” (3 – moderate problems) 
019 (T3) - “I have a cleaner” (3) 
019 (T6) – “I do little bits only in one go” (3) 
035 (T3) – “cooking – I use the magnifier for recipes” (2) 
039 (T6) – “my husband helps” (2) 
 
Pain / Discomfort 
001 (T6) – “Arthritis – can be severely painful sometimes” (4 – severe pain or discomfort) 
 
Anxiety / Depression 
010 (T0) – “my sister went into hospital yesterday” (2 – slightly anxious or depressed) 
012 (T3) – “getting worse” (3 – moderately anxious or depressed).  Scored (3) at (T0). 
 
EQ-VAS 
 
026 (T3) – “50 – depends upon my company.  Today ok as my daughter is present but 
would be lower if I were on my own”.  Patient scored 50 on all three visits. 
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